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Technological and methodological advances in the fields of medical and life-sciences
have, over the last 25 years, revolutionised the way in which cellular activity is measured
at the molecular level. Three such advances have provided a means of accurately
and rapidly quantifying mRNA, from the development of quantitative Polymerase
Chain Reaction (qPCR), to DNA microarrays, and second-generation RNA-sequencing
(RNA-seq). Despite consistent improvements in measurement precision and sample
throughput, the data generated continue to be affected by high levels of variability
due to the use of biologically distinct experimental subjects, practical restrictions
necessitating the use of small sample sizes, and technical noise introduced during
frequently complex sample preparation and analysis procedures. A series of experiments
were performed during this project to profile sources of technical noise in each of these
three techniques, with the aim of using the information to produce more accurate and
more reliable results.
The mechanisms for the introduction of confounding noise in these experiments
are highly unpredictable. The variance structure of a qPCR experiment, for example,
depends on the particular tissue-type and gene under assessment while expression data
obtained by microarray can be greatly influenced by the day on which each array was
processed and scanned. RNA-seq, on the other hand, produces data that appear very
consistent in terms of differences between technical replicates, however there exist large
differences when results are compared against those reported by microarray, which
require careful interpretation.
It is demonstrated in this thesis that by quantifying some of the major sources of
noise in an experiment and utilising compensation mechanisms, either pre- or post-hoc,
researchers are better equipped to perform experiments that are more robust, more
accurate, and more consistent.
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1.1 General Introduction - Approaches towards quantifi-
cation of gene expression
1.1.1 DNA, RNA, and gene expression
The human genome is composed of deoxyribonucleic acid (DNA) and contains tens of
thousands of individual sequences called genes. The DNA molecule is a double-stranded
helix and, at the smallest scale, each strand is an unbroken chain of molecular elements
called nucleotides. There exist four types of nucleotide, each containing a phosphate
group, a deoxyribose sugar, and one of four nitrogen bases. These bases are adenine,
guanine, cytosine, and thymine and are commonly abbreviated to the more familiar A,
G, C, and T. The two strands are bound by hydrogen bonds between complimentary
pairs of nitrogen bases; with pairing adhering to the rule that A bonds only with T,
and C with G. This binding is known formally as the principle of DNA base pairing.
Genetic information is ultimately expressed in the organism through the coding
of proteins specific to particular genes. Genetic information stored in the DNA is
expressed in two stages: first, the gene is transcribed into the form of messenger
ribonucleic acid (mRNA); second, this mRNA is translated into protein. This process of
expression is the central dogma of molecular biology in which DNA transcribes mRNA
that is translated into protein [1].
An mRNA molecule is unique to a particular gene and is a single-stranded, com-
plementary copy of the nucleotide sequence of that gene, with the slight complication
that each thymine (T) base is replaced by uracil (U). Proteins are sequences of twenty
different types of amino acids and the translation of nucleotide-triplets, called codons,
from a mRNA molecule into these amino acids is specified by the genetic code.
It is the expression of both mRNA and protein that is of interest to biology. Proteins
have a much wider range of functions than mRNA, creating molecular complexes
that are vital both at the very centre of the nucleus, where they bind to DNA to
enhance or suppress transcription, and at the surface of the cell, where they interact
with the extracellular environment. Unfortunately, for many genes, the relationship
between mRNA and protein expression has been found to be non-linear and this lack
of correlation has been the subject of a number of published studies including [2, 3, 4, 5].
Due mainly to technological limitations in protein-level analysis, expression at the RNA-
level has instead been a traditional proxy for both levels in analyses of genome-wide
gene-expression.
In the remainder of this thesis, only mRNA expression experiments will be discussed.
As such, any and all reference to terms such as RNA, expression, and abundance are
used interchangeably and in the context of mRNA expression.
2
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1.1.2 Genome-wide expression experiment techniques
“Genomics aims to provide biologists with the equivalent of
Chemistry’s periodic table” - Eric S. Lander [6].
Several techniques have been developed to allow scientists to detect mRNA
transcripts. Early methods, such as Northern blotting [7], required large amounts of
RNA and provided, at best, semi-quantitative estimates of expression because results
had to be interpreted visually. The past 30 years has seen a rapid development
of techniques and instrumentation for mRNA quantification allowing the number of
transcripts present in a sample to be measured with increasing accuracy.
Modern research into gene expression relies heavily on mRNA quantification.
Current thinking suggests that the expression of any given gene is usually proportional
to the number of complimentary mRNA molecules within the cell or tissue. Advances
in measurement techniques to allow quantification of transcripts make measuring gene
expression in this way an attractive prospect for researchers.
In this thesis, three contemporary techniques by which the abundances of mRNA
transcripts can be quantified will be discussed. Introduced in the following three
sections, these are quantitative Polymerase Chain Reaction (qPCR), gene-expression
microarray, and second-generation RNA-sequencing (RNA-seq). Both microarrays and
qPCR measure the amount of mRNA through the annealing of complementary strands
of DNA [8, 9], while RNA-seq produces millions of short sequence fragments through
a variety of methods that are platform dependent [10, 11].
The major differences between these three techniques are accuracy, specificity, and
capacity. Large numbers of genes are concurrently probed by microarrays and as a
result the research community has enthusiastically embraced such technologies as a
tool for generating data-driven hypotheses. Despite being restricted to analyses of only
a small number of genes in a single experiment, the greater accuracy and specificity
of qPCR has led to its adoption in smaller, hypothesis-driven, studies including those
validating gene-expression levels obtained by array-based experiments. However the
throughput of qPCR technologies is steadily increasing, blurring this distinction to
microarrays [11, 12]. Due to the higher dynamic range and the option of measuring
absolute, as well as relative, abundance of mRNA targets in a sample, if it were not for
the high financial cost of qPCR on a per-gene basis, they would threaten microarrays
as the researchers’ default hypothesis-generating experiment.
RNA-seq provides, for the first time, the capability to directly sequence almost
entire cDNA transcriptome(s) contained within a given sample in a high-throughput
and affordable manner. It is this ability to estimate expression across the entire length
of a target transcript, rather than just within small region targeted by a probe, that
3
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makes RNA-seq such an appealing prospect compared to existing technologies such as
microarrays and qPCR [13]. Due to the quantification along entire transcripts RNA-
seq has higher specificity than qPCR and number of transcripts concurrently assessed
is generally greater than that afforded by arrays, depending on the number of reads
obtained from the sequencer.
1.2 Experiment design and bio-statistics
Insight, in the context of gene-expression, into factors governing some biological trait
is commonly achieved by obtaining observations of randomly sampled sources/subjects
belonging to one or more populations that are representative of the trait under
investigation. Expression measurements of one or more genes are summarised in terms
of the similarity of all observations between sources/subjects within each population
and then assessed for bulk-effects between the populations. Genes that are found to
vary little between samples within each population compared to the variation between
the populations are thus correlated with the experimental factor(s) and are considered
interesting/relevant to the studied trait. There are myriad ways in which the variability
between observations of randomly selected subjects within a population can be affected.
Such variability is considered as either biological in origin, if it results from some
fundamental property of the populations from which samples are obtained, or technical
in origin, resulting from a lack of measurement precision in the collection of the
observations.
1.2.1 Biological variation
Legitimate variation between individual experimental subjects and samples. The top
level of biological variation is dependent on the purpose of the investigation and, at it’s
most extreme, could represent variability between individuals from a number of distinct
species. In most cases, however, biological variation is simply the variability between
RNA samples that cannot be explained by the experimental factors under investigation
or the technical noise inherent in the experiment.
In this regard, biological variation is entirely a product of the fact that it is
not possible to define a set of experimental factors that are capable of accurately
predicting the expression of any given gene within any given sample. It is not
expected or physically meaningful, of course, that it will ever be possible to make
such predictions, but this is only half of the story. Real-world problems arise when the
model defining experimental factors is inadequate, including either too few variables
or, worse, the wrong variables entirely. In this case the biological variation will be
4
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large and potentially sufficient to obscure the differences between populations defined
in the model. Poor experiment design is the cause of inadequate description and
implementation of the model designed to describe the differences between populations
of individuals or samples.
Of course, poor experiment design does not always equate to bad experiment design,
especially in hypothesis-generating experiments. For example, systems that are subject
to complex and previously undocumented epigenetic or post-transcriptional expression
regulation might exhibit sufficient biological variation to obscure legitimate differences
between populations. Indeed, the act of measuring gene expression in living tissue is far
from simple, as transcription and translation of genetic information is a highly dynamic
and complex process that reflects the biosynthetic needs of a cell’s environment, an
excellent review is provided in [14].
Therefore, an effective means of reducing the impact of this unmodelled (or
unmodellable) complexity is to deliberately obtain a large amount of RNA from a
diverse and large set of random samples from each population. This averaging restricts
the scope of the analysis to so-called steady-state differences between the chosen
populations, which are the least variable between individual cells and subjects, but
the most variable between the populations. Unfortunately, the collection of a large set
of random and diverse samples is not always possible and in such cases it is usually
only possible to reliably resolve large differences between the populations.
1.2.2 Technical variation
Technical variation, on the other hand, is introduced entirely as a result of the, often
complex, procedures involved in physically collecting, storing, extracting, and preparing
the RNA for analysis. This variability is easily defined, and measured, as that which
remains in expressions derived from the repeated measurement of a single biological
sample. Exactly as is the case for biological variability, it is not possible to account for
all possible sources of technical noise and abstractions must be made to model those
sources that account for the majority of the error.
For this abstraction we employ ‘surrogate’ variables, which may be influenced
by numerous measurable or un-measurable factors that are all introduced into the
experiment at the same time. For example, atmospheric ozone concentration has
previously been shown [15] to affect microarray-based expression measurements. Even
though it is possible to record the ozone concentration during an experiment, it is not
feasible to do so. It is not the only source of potentially confounding variation that one
would have to measure during an experiment, but if it is reasonable to assume that a
number of sources, including ozone concentration, ambient temperature, and humidity
5
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remain approximately constant over the course of a day then simply recording the date
on which the experiments took place is sufficient to compensate for the bulk variation,
caused by the individual contribution of each source, to the experimental measurements.
Another example is the definition of a surrogate for each of the different technicians
involved in performing the experiments. A great many factors differentiate people,
(including, for example, their skill with a pipette) but are too difficult and too numerous
to record individually. Therefore we compensate for the aggregate of all these individual
differences between people using the ‘person’ surrogate.
The difficulty is in the definition of surrogates and how much variation is not catered
for in making assumptions such as the consistency of ozone throughout the course of
a day. All depends on relative contributions to the total variance by the surrogates
that are easiest to measure. The investigation of the relative contribution of various
surrogates to the overall technical error is what is of interest in this thesis.
1.3 Reverse-transcription qPCR gene-expression analyses
In quantitative real-time PCR (qPCR) a target double-stranded DNA sequence is
exponentially amplified allowing the number of input molecules it to be estimated.
Reverse transcription qPCR (RT-qPCR) is an established adaptation of this technique
for measuring the quantity of mRNA in biological samples at high sensitivity [16]. Due
to this high sensitivity, it is possible to obtain a reliable measurement of genes for which
mRNA is in relatively low abundance, even as little as one-cell equivalent [17, 18]. In a
typical PCR reaction the cDNA, reverse-transcribed from mRNA in the sample, may be
amplified up to forty times, where each round of amplification results in an approximate
doubling of product. The ‘real-time’ aspect of qPCR differentiates the technique from
traditional methods that relied on gel-electrophoresis to quantify amplified DNA. Real-
time PCR allows monitoring of the amplification during the reaction through the use
of fluorescent dyes and is described below.
1.3.1 Targeted amplification of short sequences using primers
Prior to qPCR analysis, all mRNA extracted from a sample is reverse-transcribed
to cDNA and entered into the qPCR reaction tube. Primer sequences, designed to
complement a specific short region within the target cDNA, define the start and end
positions of the short probe/amplicon that will undergo amplification. It is important
that the design of these forward and reverse primers is sufficiently specific that only
the desired sequence is amplified. The thermodynamic properties of the primer must
also be taken into consideration such that hybridisation can occur efficiently during the
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reaction.
PCR amplification, first described in [19] occurs in several cycles. In the first
cycle, forward and reverse primers are annealed to the positive and negative strand,
respectively, of denatured cDNA, before DNA polymerase is used to extend each primer,
5’ to 3’, producing double stranded DNA starting from the primer location on each
strand. In the second cycle the DNA is again denatured and more primers annealed to
each of the four single strands, which are again extended using the polymerase. This
process of denaturation, primer annealing, and extension continues through subsequent
cycles and results in an approximate doubling of the target amplicon after each cycle
[19].
However this amplification is not a perfect doubling throughout the entire reaction.
At the start of the reaction there are a large number of cDNAs in the reaction
mixture that are not targeted by the primers and towards the end of the reaction
the primers themselves are depleted. Both of these mean that the reaction curve is,
in log-space, sigmoidal, in which the linear ‘sweet spot’ of almost perfect doubling in
the mid-range is where there are plenty of primers and an abundance of target cDNA
sequences compared to the other, non-target, molecules in the reaction tube. Different
primer sequences have also been found to have different amplification efficiencies,
necessitating post-hoc estimation and normalisation between samples/genes during
statistical analysis [20, 21].
This amplification is quantified through the use of dual-labeled fluorogenic hybridi-
sation probes [22, 23] in which one of the labels serves as an emitter (a.k.a. ‘reporter’)
and the other as a quencher. When the polymerase binds to and extends the primer,
the reporter is released leading to an increase in peak fluorescence at 518nm [18].
1.3.2 Quantification of amplified target-sequences
The most popular method of PCR analysis uses the number of cycles required in each
reaction for the fluorescent intensity in the PCR tube to rise above a predefined, and
somewhat arbitrary, threshold value, typically based on 10 standard deviations above
background in the preceding cycles [18]. This cycle count is referred to as the ‘cycle
threshold’ (Ct) and the smaller this value, the fewer amplification cycles are necessary
to attain the critical intensity and the larger the initial quantity of transcript in the
sample. Figure 1.1 illustrates the sigmoid fluorescence response curve throughout the
PCR amplification and the meaning of the Ct and the threshold.
In general, there exist two main methods for quantifying input mRNA using the Ct
data output from RT-qPCR experiments. Absolute quantification uses concurrent RT-
qPCR reactions, in different tubes, of known amounts of material at several dilutions
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Figure 1.1: An illustration of the qPCR amplification curve, taken from Heid et al.
(1996) [18]
to calculate a standard curve from which the amount of material in the unknown
sample can be extrapolated. Relative quantification uses Ct data from one or more
stable reference genes, against which to normalise expression estimates of the gene(s)
of interest, to calibrate for total mRNA input and global expression differences between
biological replicates [24].
Absolute quantification is more time consuming and costly, in that several dilutions
are required for the standard curve and one must have very high confidence in the
concentration of target cDNA in the original reference sample, and all its subsequent
dilutions for the method to accurately quantify the sample of unknown quantity [24].
In the case of relative quantification, obviously the choice of reference gene(s) with
which to relatively quantify the gene of interest is extremely important. An unstable
reference gene that co-varies with the treatment groups will lead to a mis-estimation of
the difference between groups in the gene of interest [25]. For this reason, a large number
of studies continue to be published exploring the most stable battery of reference genes
to use for in analyses of a given species or for a given application [26, 27].
1.3.3 Technical variation and efforts towards standardisation
Although technical variation between qPCR replicates is low, variable sample-preparation
procedures and conditions, poor experiment design, and poor data analysis have made
it difficult to interpret published methods and results from qPCR experiments [28].
Various technical facets of qPCR experiments, such as input cDNA quality, the lab
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technician’s experience, the efficiency of reverse-transcription and the subjectivity in
data analysis have been reported to affect the reliability of qPCR results [25]. To aid in
the design, execution, and analysis of such experiments, a standard set of guidelines was
recently created that proposes the publication of a minimum amount of information
about qPCR experiments (MIQE) [28, 29, 30, 31].
1.4 Microarray gene-expression analyses
Gene expression microarrays allow the analyses of large numbers of transcripts,
often thousands at a time, by exploiting the preferential binding of complementary
nucleic acids described earlier. This technique is extremely powerful for comparing
the expression ‘profile’ of several samples to detect genes/probes that demonstrate
relative changes in expression between sample phenotypes [9], providing insight into
gene/phenotype relationships. There are currently a variety of array platforms available
with different manufacturers offering different designs and manufacturing techniques,
although the basic underlying principal remains constant among them.
1.4.1 Targeted capture of short sequences using probes
Microarrays provide thousands of concurrent gene expression measurements through
the quantification of mRNA in each sample using thousands of probes made of single-
stranded DNA molecules to which mRNA molecules can attach. These probes can be
of variable length, but most modern commercial array technologies involve the use of
fixed-length oligonucleotides of 20 to 100 nucleotides [32, 33, 34]. Probes are attached
to a solid substrate in a regular pattern, the array, and the location of each probe is
recorded for later use [35].
The mRNA in the sample is extracted and labeled with a fluorescent dye before
being washed, in solution, over the microarray substrate. Finally, the microarray is
washed to remove unbound transcripts and is scanned using a laser causing the dye to
fluoresce. Fluorescence intensity is measured using a photo-multiplier tube (PMT) or
charge-coupled device (CCD) and a scan over the entire surface of the array produces an
image, from which fluorescence intensity values are obtained for each probe [36], usually
by means of image analysis software proprietary to the hardware vendor, although open-
source alternatives exist [37]. A detailed review of the fundamental considerations of
microarray image analyses and information extraction is provided in [38]. The reported




Probe and array manufacture
Microarray fabrication has improved markedly in the past 20 years, produced by
individual research groups to large commercial companies. Early manufacturing
procedures to attach probes to the array substrate involved spotting [9], inkjet synthesis
[39], and bubblejet synthesis [40]. Systematic variation in the fabrication of the array,
for example due to inconsistent amount of probe material deposited over the substrate,
was the often the cause of significant error in reported fluorescence values [41, 42].
Affymetrix, a widely popular array vendor, manufacture their 25nt probes through a
process of photolithographic synthesis [43]. The significant difference between this and
the other methods is that the probes are constructed bottom-up from the substrate, one
nucleotide at a time [33]. This overcomes the spatial variability inherent in printing,
and a far greater density of oligonucleotide probes can be achieved. However the probes
are always built at the same location on every array and are therefore vulnerable to
systematic variation in signal intensity over the surface of the array [44].
The probe manufacturing procedure used by Illumina (an array vendor who’s
technology has been used extensively to generate expression data throughout this
thesis), results in the random assembly of glass beads attached to fibre-optic wells
in the array substrate [34]. To the surface of each bead is attached around half
a million oligonucleotide replicates, comprised of a 50nt probe and a 25nt identifier
sequence, illustrated in Figure 1.2. Each bead-type corresponds to a different gene-
specific oligonucleotide probe with a unique bead- identifier sequence. Several thousand
beads are sampled from an extremely large pool of prefabricated beads and several
technical-replicate beads of each type are deposited randomly across the entire surface
of the array; with the identifier sequences allowing the eventual location of each probe-
type to be determined after deposition [35]. This manufacturing process results in
individual arrays that are effectively unique and the random deposition of the beads,
and the multiple copies of each bead-type, reduces the impact of spatial variation over
the substrate.
Many other microarray vendors exist, as well as bespoke arrays created for specific
purposes, however further discussion will be limited to the Illumina and, to some extent,
Affymetrix platforms as these are the both widely used and the only arrays used in
generation of data for this thesis.
Targeting of probes to the reference
The composition of probes, regardless of their means of manufacture, are the
determining factor of biological relevance to the transcriptomic features claimed to
be interrogated by the array vendor. Traditionally probes have been designed to
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Figure 1.2: Illumina BeadArray manufacturing schematic and illustration of probe
hybridisation. Image taken from Fan et al. [45]
target regions of genes close to their 3’ end, but several other design variants also
exist that provide different analysis options. Exon arrays, for example, contain probes
targeting every known exon in the transcriptome of an organism [46], others target
specific junctions between these exons [47], and so-called tiling arrays contain a large
number of probes that target regular intervals over the entire transcriptome [48]. Each
has their own specific uses and advantages but for the remainder of this section, and
this thesis, only 3’ arrays will be discussed.
In general, the longer the sequence of the probe on the array, the greater the
specificity to the target region as defined by the reference, however longer probes
are more vulnerable to mutations in the sample transcript. Illumina arrays contain
long probes and provide multiple observations of each bead-type, but typically contain
only around one or two probes per gene. Several negative control bead-types used to
compensate for effects such as non-specific binding of cRNA in the sample to random
probes on the array [49]. Affymetrix arrays on the other hand, contain many more
(shorter) probes and sacrifice multiple replicate copies of each probe-type for multiple
observations of each gene and also have deliberately mis-matched sequences. Like the
Illumina negative controls, these mis-match probes are designed to assess the specificity
of the binding of the probes to the target mRNA. As described in Lipshutz et al. [33],
for every ‘perfect-match’ probe on the array exists a mis-match probe whose sequence
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differs from the PM by a single base in the middle of the probe. Typically 11-20
Affymetrix probe pairs are used to interrogating a different location within the target
gene and, together, make up what is known as a probeset [50].
Quantification of abundance of captured sequences
Image processing is an important consideration for microarrays and involves calculating
foreground intensities using the pixels that make up each feature on the array and
estimating a local background intensity using the pixels surrounding each feature. This
estimated background is then subtracted from the foreground intensity in preliminary
attempt to correct for spatial variation in the brightness of the array [36]. However for
features with low foreground intensities, this method can result in negative corrected
intensities that must be filtered or adjusted before subsequent analysis. It has also been
shown that this background correction increases variability in inter-array measurements
and has a detrimental effect on the ability to detect differentially expressed genes [51].
An interesting outcome of the study described in [51] was that there is a correlation
between the composition of probes at the nucleotide level and the fluorescent intensity
reported by the scanner. Similar observations have also been made in Affymetrix arrays
[52]
1.4.2 Analysis considerations
Dual-dye vs. single-dye, sample preparation, and experiment design
Some array designs perform a direct comparison on the chip itself by hybridising a
sample from both ‘experiment’ and ‘control’ samples, labelled with differently coloured
dyes, to the same array. By using two different coloured dyes it is possible to directly
compare mRNA levels in two different samples by forcing the RNA from the two
samples to compete for the hybridisation to the array probes. Therefore if a gene
is more highly expressed in the experiment sample compared to control, the dye used
to label the ‘experiment’ sample will be brighter. The disadvantage of this design is
that all information about the absolute expressions of the genes is lost and, as a result,
information regarding the individual variation of either the ‘experiment’ or the ‘control’
samples is obscured. Furthermore, cDNAs in the sample have different hybridisation
efficiency depending on the choice of reporter-dye and a dye-swap is often performed
to normalise for this effect. The remainder of the manufacturers produce a single-dye
design in which only one sample is hybridised to each array, and the fluorescence of the
probes are relative only to the background intensity of the array substrate, therefore
preserving the absolute expression levels of each gene under observation. Dual-dye
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arrays have special implications for experiment design and the analyses of single-dye
arrays is usually simpler [53].
Prior to labelling and array hybridisation, it is important to first assess the quality
of the RNA to ensure that results obtained from subsequent expression analyses are due
to legitimate biological processes and not to experimental artefact such as, for example,
degraded RNA [54, 55]. The protocols for preparing mRNA prior to array scanning
is platform dependent, but generally it is the case that mRNA is reverse-transcribed,
amplified and labeled with biotin before hybridisation to the arrays.
Filtering, scaling, and normalisation
The removal of ‘undetected’ probes, which fluoresce only marginally above background,
or ‘uninteresting’ probes, which are not sufficiently variable across all samples to
be differentially expressed, is a common and generally beneficial procedure. Such
filtering reduces the dimensionality of the dataset, speeding up normalisation and, more
importantly, reduces the number of statistical tests performed on the data, lessening
the impact of multiple-testing corrections [56, 57, 58].
Despite the utility of filtering, it is very important that the statistic used to
determine whether to discard a probe from further analysis does not lead to pre-
testing for the downstream differential expression analyses between sample groups [59].
Therefore information used in filtering should not be the same as that used in the
downstream testing for differential expression; covered in the following sections on
statistical analysis. It is acceptable to use statistics such as the mean expression or the
variance of the probe over all arrays, but it is imperative that all are arrays treated
equally, making no distinction based on the phenotypes under investigation [59]. Most
image analysis software outputs a confidence in the intensity estimate of each feature
on the array, or the specificity of the probe hybridisation based on mis-match probes
or internal controls; these confidence estimates are a powerful means by which to filter
features that are unreliably detected across a number of arrays.
Probes with larger mean intensities have larger variances [60] and data are
commonly transformed to reduce this dependence of the variance on the mean. Such
transformations can be simply logarithmic and log2 is a common choice due to the
simplicity in interpreting differences between two sets of expressions. The variance
stabilising transformation, VST, is similar to the logarithm at high intensities but is a
less severe correction at low intensities [61]. VST has been more recently adapted
specifically for Illumina BeadArray analysis to make full use of the within-array
technical bead-replicates [62].
normalisation is the process of minimising technical variation in measured signal
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intensity levels so that biological differences in gene expression can be better resolved.
The type of normalisation strategy employed depends upon the expected nature of the
technical variation, heavily influenced by the type of arrays used. For example, arrays
with printed probes require normalisation for spatial effects, such as that introduced by
non-consistent pressure applied by the print head or the physical position of the probes
on the array [42]. In the analysis of dual-dye array data with or without a dye-swap,
the normalisation might compensate for bulk differences in the signal obtained at each
wavelength, for such data a ‘loess’ [63] regression normalisation has been recommended,
followed by location and scale normalisation [41]; see [64] for a comprehensive review
of the treatment of two-colour array normalisation.
In single-channel arrays the normalisation required is simpler as dye intensity or
spatial effects due to print head pressure, for example, and are not a concern. Bulk
differences in observed intensities between arrays are the major source of obscuring
variation for which compensation is required. Such sources include differences in sample
preparation (imprecise concentrations, labelling efficiency, etc.), slight differences in
the manufacture of the arrays, and the processing of the arrays (different hybridisation
time, ambient temperature, scanner differences, etc.) [65]. Several methods have been
developed, including fixed-distribution calibration such as quantile [65] (fastest and
most widely used); sliding-window based calibration such as loess [42] (slower, less
widely used); and methods designed specifically for array expression data such as VSN
[61].
Statistical analyses
Much effort has been expended developing algorithms, both open-source and propri-
etary, to extract valuable results from microarray-derived expression quantifications.
Arrays/samples grouped according to phenotype, then tested. A linear model is fitted to
each probe-type, within each sample group. Genes are selected based on the significance
of the fit of the regression within each sample-group compared to the difference in the
sample-group means. Usually this is quantified using a t-statistic, reporting a signal-
to-noise ratio of the two distributions of disease and control samples. The outcome
of these tests is a list of genes, each exhibiting a statistically significant difference in
observed expression between the sample-groups under investigation.
Variations on the basic t-test include limma [66], which moderates the variance of
each gene towards a common mean calculated using all genes in the dataset using an
‘Empirical Bayes’ method. This is designed to stabilise variance amongst samples
in genes that are very highly or very poorly expressing. Significance analysis of
microarrays (SAM ) [67] was developed to estimate the rate of false positive results
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in the output of the standard t-test; which is achieved by permuting samples [68].
1.4.3 Identification of source and scope of confounding variation
introduced in array experiments
An early discussion of probable sources of systematic variation included hardware
manufacturing issues such as variation in inter- and intra-array quality, lab issues
such as RNA sample preparation and hybridisation protocols, as well as array-scanner
issues including variation in optical measurements and software image-processing
eccentricities [69]. Variation in expression between arrays has been shown to be highly
correlated with the concentration of Ozone gas in the localised atmosphere at the
time of the experiment [15]. Illumina BeadChips are processed in batches (6, 8, or 12
arrays on a chip), introducing the possibility of systematic batch-effects, non-biological
variation in the measured expression undermining the ability to accurately compare
samples across different chips and different batches [70]. A comparison of Illumina
and Affymetrix platforms found that they yield highly comparable data, although the
strength of this relationship is strongest for highly expressing probes and probes that
are close to each other in the target gene [71].
A similar investigation attempted to quantify errors introduced at different stages
of the sample-preparation workflow on the resulting observations of expression levels
[72]. Three levels of variability were identified and corresponded to cell culture, reverse
transcription, and hybridisation. The outcome was negative, in that no significant effect
was observed as a result of these levels. A comparison of Affymetrix arrays following
an RNA amplification protocol designed for small amounts of starting material, to the
standard amplification protocol found that direct comparability of expressions was not
possible due to the systematic bias introduced by the different protocols [73].
Efforts towards standardisation
A movement towards the standardisation of these levels of data was proposed after it
was recognised that combining results across published studies was a highly unreliable
process. The ‘Minimum Information About a Microarray Experiment’, MIAME, [74]
aimed to facilitate the interpretation of microarray data and the independent validation
of results derived from its analysis. MIAME itself is a standard for recording and
reporting microarray data and the authors intend that enforcement of the standard
among public repositories of microarray data will enable the development of cross-
platform data analysis tools.
The MIAME standard is quite comprehensive; the specification includes detail
about the reporting of important elements at all stages of a microarray experiment,
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from sample preparation to the method and variables employed in the detection of
differential expression. However the standard is interpreted differently by various
repositories and journals, and does not mandate some crucial information that might
be of use to diagnose systematic batch effects in the submitted data such as date of
sample-preparation, hybridisation, and scan.
1.5 RNA-seq gene-expression analyses
The completion of the International Human Genome Project in 2004 [75] has had
an enormous impact on the field of biomedical research and has recently been the
subject of an excellent review [76]. The enormous investment of time and money in this
project were a result of the limitations of Sanger-based capillary sequencing [77, 78] and
rapid technological innovation in the years since allow much more ambitious sequencing
projects to be performed in a fraction of the time and at a fraction of the cost [79].
During this period of innovation, several competing methods were pioneered and
have been extensively reviewed [80, 81, 11, 82], but all essentially share a common
underlying approach in which many millions of short sequence fragments are sequenced
in parallel. This so-called ‘massively parallel’, ‘next-generation’, or ‘second-generation’
sequencing is achieved through the ligation of short adapter sequences to each end of
the fragmented input DNAs which are used to secure the sequences to a solid substrate
prior to amplification and sequencing [83].
As was the case with arrays previously, second-generation sequencing methods have
been adapted to serve a variety of applications including genome-wide association
studies [84], chromatin analysis [85], DNA methylation analysis [86], and RNA analysis
[87]. The integration and analysis of these various sources of data is a fantastic challenge
and a major area of interest, reviewed in [88]. However, of direct interest in this thesis
is the application of second-generation sequencing to the study of gene expression and
the quantification of mRNA.
Sequence-based analysis of mRNA has been a viable technique since the advent of
Sanger sequencing through the sequencing of cDNA or EST libraries [89]. However, for
all but the most ambitious initiatives the sequencing of entire transcripts was prohibitive
and, as a result, methods of sequencing a reduced set of much shorter mRNAs were more
widely used [45]. These methods included Serial Analysis of Gene Expression (SAGE)
method [90] and Massively Parallel Signature Sequencing (MPSS) [91], in which short
(10-22nt) tags are obtained from predefined locations in each mRNA molecule and
subsequently sequenced. Several studies have compared expression estimates and
results obtained from these sequencing methods to those gathered by hybridisation-
based microarray technologies, reporting moderate correlation in absolute expression
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[92] but that within-technology expression ratios between sample groups are more
consistent [93].
Sequence-tag-based and hybridisation-based approaches to gene-expression analysis
suffer from a fundamental reliance on an accurate and well-annotated reference with
which to make sense of the results. As discussed previously in this chapter, array probes
are designed to deliberately target specific mRNAs based on their reference sequence
and while MPSS and SAGE methods do not require the a-priori definition of target
sequences, the short tags output still require mapping back to the reference before
their abundances can be estimated. They also suffer similar biases due to probe/tag
position within the transcript [94] and are both liable to mis-interpretation due to
alternative-splicing [95].
Second-generation RNA-sequencing (RNA-seq) allows, for the first time, the
comprehensive full-transcript, high-specificity, sequencing previously afforded by the
Sanger method but with the high-throughput and low-cost of tag- and hybridisation-
based methods [87, 96].
1.5.1 Non-targeted fragmentation and sequencing of whole tran-
scripts
To be compatible with most second-generation sequencer technologies, typically large
mRNA molecules are selected, reverse transcribed, and randomly fragmented such that
the length of the cDNAs are <500nt [97]. These fragments are typically amplified by
PCR depending on input amount, however this has been reported to be a potentially
significant source of bias, especially in GC-rich genomes [98]. Certain methods of
reverse-transcription have also been shown to exhibit detectable bias in the set of reads
output from the sequencer [99], and methods of directly sequencing unamplified RNA
have recently been proposed to address these biases [100]. Furthermore, the use of
RNA, or single-stranded cDNA, are among several methods used to preserve strand-
information from the sequencing [101, 102]. Whatever method of library preparation
is used, platform-specific adapter sequences are ligated to the input fragments, which
are subsequently and immobilisation on a solid substrate. Finally, the fragments are
amplified on the substrate in clonal clusters such that a reliable signal can be detected.
The most basic output from second-generation sequencers are images corresponding
to each ‘cycle’ of the sequencer in reading a predefined number (30-200) of nucleotides,
concurrently, from the start of each cDNA fragment. For example in the Illumina
sequencing method, these cycles relate to the incorporation of fluorescently labelled
nucleotides that are chemically blocked such that only one nucleotide incorporation
event occurs per fragment population per sequencing cycle [10]. These images are
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analysed and the fluorescence signal for each base is quantified along with an estimated
confidence based on the detection of the signal above the local background. These
quantifications are used for base calling and the more meaningful output of the cDNA
‘read’ sequences is returned along with the detection quality for each nucleotide. The
challenge then exists in mapping these short reads, themselves a small subsequence of
the fragmented cDNA, back to the genome of transcriptome of the relevant organism
before counting mapped reads to estimate the abundance of the relevant transcript in
the original sample. For a schematic overview of these stages of cDNA preparation,
sequencing, and mapping see Figure 1.3.
Quantification of sequence-fragments (‘reads’)
There are a great many methods for aligning these short reads back to the organism
reference, which have been discussed in great detail [103, 104, 88], as well as emerging
methods of reference-agnostic de-novo assembly [105]. The advantage of RNA-seq
compared to hybridisation-based expression analysis methods is that the detection
quality of the output sequences is available at a per-nucleotide level, allowing for bulk
exclusion of reads failing a certain minimum threshold and advanced alignment with
weights allowing small insertions or deletions, ‘indels’, in regions where the read-quality
is reportedly poor [106]. Such tolerance of indels have been extended to the point where
full gapped alignments can be performed to identify reads spanning both known and
novel exon-junctions, aiding discovery of novel isoforms [107, 103, 108]. Accurate,
fast alignment of large numbers of short reads to the reference presents not only a
considerable computational challenge but, due to the complexity of the transcriptome,
can also have a dramatic effect on estimated expression levels.
Once reads have been assembled or mapped to the reference, the abundance of RNA
in the input sample corresponding to the ‘region of interest’, be it a gene, transcript,
or exon is approximately equivalent to the read-depth. This read-depth is the average,
over all bases in the given reference region, number of reads in which each base is
present. Depending on the choice of RNA/cDNA preparation, the distribution of reads
over the length of a gene, transcript, or even an exon is not consistent and exhibits
strong bias against the extremes of the region [87]. This presents further challenges
to the identification, assembly, and quantification of novel isoforms as most rely on
the assumption of consistent expression across the entire length of the transcript. An
illustration of the process of translating millions of short reads to expression estimates
and insight is provided in Figure 1.4.
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Figure 1.3: Illustration of an RNA-seq experiment workflow; illustration taken from
Wang et al. [87]
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Figure 1.4: Schematic RNA-seq analysis pipeline from Oshlack et al. [13]
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1.5.2 Analysis considerations
Quantification of this abundance is achieved simply through the counting of the reads
mapping to a given region/feature of the genome. Despite the inherent biases in
the technique the number of reads mapping to a region of the reference between
technical replicate sequencing-runs is assumed to be, and has been shown to be, Poisson
distributed [109, 110, 111].
Filtering and normalisation
One of the main advantages of RNA-seq over microarrays is the ability to detect genes
and exons of much lower abundance in the input sample. This lower detection limit
depends on the number of reads obtained from a sequencing run and the size of the
transcriptome of the organism under study. Based on the assumption of Poisson noise
between technical replicates, and therefore the minimum possible variability between
biological replicates, it is possible to define a filter to remove features for which the
observed number of reads in all sample-groups cannot result in a significant test-statistic
in analyses of differential expression. Such a filter can be achieved, in a two-group
test for differential analysis, by inputting the two total library sizes for all samples in
each group into a contingency table prior to a Fisher’s exact-test or a Chi-square test.
The remaining two values in the 2x2 contingency table are set to zero and iteratively
increased for one of the groups only until the test is significant to some predefined value.
The number of reads for which the test is significant is then the minimum number of
reads across all samples, independent of sample-group and any feature with fewer reads
is removed from further analysis.
The total number of reads output by RNA-seq between lanes and samples can be
highly variable. Therefore count data are routinely normalised by the total number of
reads obtained per sample, due to the obvious situation in which a sample with twice
the number of mapped reads is likely to have twice the number of reads mapped to any
given feature; in this situation the feature is not biologically differentially expressed, as
nave count differences would suggest.
Count data can also be normalised by feature length to account for the fact that
longer features will have mapped more reads, so read counts are divided by the number
of bases in each mRNA region as well as the total number of mapped reads; first
introduced in [107] as ‘Reads Per Kilobase of exon-model per Million mapped reads’
(RPKM). However this correction has been reported to introduce error in the variance
such that the problem of feature-length bias persists [112], their solution being to assess
only fixed length regions for expression analyses however this presents obvious issues
surrounding the selection of such regions as well as neglecting a potentially huge amount
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of expensive experiment data [110]. Also, the choice to perform analyses at the exon-,
rather than the gene-level do not overcome length-bias issues as the variation in feature
length is approximately the same at both levels [112]. Normalisation has been identified
as having a large impact on the detection of differentially expressed features, especially
in situations involving a small number of very highly-expressed features [110].
Statistics for resolving differential expression and sources of technical
variation
The first volley of articles publishing results of differential expression analyses from
RNA-seq count data assumed Poisson variance not only between technical replicates but
also between biological replicates [109, 113]. However the variance estimated by such
a model has been found to under-represent the variability between biological replicates
[114, 115]. Perhaps a better model for these replicates, that incorporates the over-
dispersion of the count data, is the negative binomial and this has been adopted by a
number of more recent analysis methods [116, 117]. However, determining the correct
model of variance in RNA-seq analysis is still an area of active research.
Given that RNA-seq is a nascent technology and that experiments are expensive,
there have been limited numbers of studies investigating technical aspects of the reli-
ability and reproducibility of the expressions obtained using this technique. However,
technical replicate samples have been assessed in a handful of studies, each finding
that the variability between multiple sequencing runs of the same library is very
low [109, 110, 111]. Bullard et al. noted in their analysis of fold-changes between
different tissues in the MAQC stage 3 RNA-seq dataset [118], that estimated variability
introduced in replicate library preparations is much smaller, on average, than biological
differential expression [110].
1.6 Batch-effects, bias, and systematic error
High-throughput experimental techniques in biology, such as those briefly introduced
in the previous sections commonly require a complex set of procedures to prepare
biological material for analysis. These procedures vary depending on the platform,
the manufacturer, and the current state-of-the-art approach based on the scientific
literature. Each stage of sample preparation increases the likelihood that conditions
vary during the course of the experiment, introducing systematic variation into the
experiment output. Such variation can be both biological and technical in nature and
effectively introduces new hidden variables to the model that explains the observed data
in addition to those variables that are known, corresponding to different populations
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of experimental subjects [119].
The consequences of such batch effects are that the ‘new variables’, which are
unrelated to the biological variables under study, serve to confound interpretation
of the experimental results and, depending on the design of the study, can lead to
incorrect conclusions being made pertaining to the biological variables. Such a situation
is obviously exacerbated if the hidden batch variables are completely confounded with
the biological variables. For example, if all observations of a condition are made in
such a way that the biological replicates within each condition are contained within
different batches. In this hypothetical example, if all samples from treatment group A
were processed in January and all samples from B processed in March then if there were
some hidden batch effect resulting from the time difference between the observations,
then it would be very difficult to differentiate the batch-variation from any interesting
biological variation between the treatments.
Near-complete confounding can occur in meta-analyses of a merged set of multiple
independent datasets where samples are likely to have been quantified at different times,
using different protocols, and on different platforms. Meta-analyses are often valuable
means of extracting new information from existing data, and are performed in the
hope of attaining increased statistical resolution for detecting differential expression,
provided by a large number of samples compiled from several complementary studies.
Such analyses often avoid issues surrounding interpretation of independent analyses
of differential expression over all constituent datasets, performing instead a single
analysis for differential expression following data integration at the expression-level
[120]. Effective strategies for normalising data between these sub-experiments are vital,
however, to minimise these batch effects and maximise the resolution of the analysis to
the effect of interest.
Individual studies, as well as meta-analyses, can be vulnerable to batch effects and
depend on the quality of the design of the experiment. Specific examples of published
studies have been reported in which batch effects have been found to be completely
confounded with the biological contrast [121, 122]. A re-analysis of a microarray dataset
published by Spielman et al. [122], revealed that the two human populations that were
the subject of a gene-expression comparison were completely confounded by processing
date and that the large number of genes originally found differentially expressed could
not be resolved after compensation for the processing batch [123].
1.6.1 Methods for the detection of systematic error
The task of detecting systematic error is made simpler with prior knowledge of
the likely sources of technical variation in an experiment. Analyses using technical
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replicate samples are important in providing a basis for assessing the relative impact of
confounding variation introduced during each of the stages that lie between the subjects
under study and the acquisition of quantified data. Such information can be used as
the basis for recommendations pertaining to the optimal design of the study such that
technical variation is minimised.
Batch effects not restricted to, but are easiest to identify and model in high-
dimensional datasets. Detection of outlying samples and large batch effects can often
be performed visually through assessment of the per-sample expression distributions or
their similarity via unsupervised dimensionality reduction such as principal components
analysis (PCA) [124, 125]. A recent article published by Leek et al. [119] attempt
to formalise the analysis workflow for diagnosing potential systematic variation using
diagnostic methods such as these.
1.6.2 Pre-hoc defense against batch effects
In self-contained experiments, sound experiment design is the most effective strategy to
protect against the introduction of confounding technical noise and batch effects. There
remains, therefore, the need to have a thorough understanding of the experimental
method in order to design it in such a way that the major sources of technical variation
are averaged-out in the downstream data analysis.
Such a design would benefit, wherever possible, from ‘blocking’ samples in a
balanced design such that there is the same number of samples from each phenotype-
group in each potential batch. For example, in an analysis of samples belonging to two
treatment groups using a given experimental technique, if there was good evidence
for the introduction of technical variation due to the different days on which the
experiments are run then a prudent blocking scheme would be to simply run equal
numbers of samples from each treatment group on each day. Clearly, more complicated
contrasts require more careful blocking and such experiments will always be vulnerable
to introduction of technical noise from unexpected sources.
In addition to unexpected sources of technical variation, there are experiments in
which deliberate blocking is not possible. For example, the analyst obviously has no
control over the design of existing datasets to be combined in a meta-analysis, nor is
it always possible to perform such blocking in clinical diagnostics, in which a training
set was generated long before individual samples being classified. In such situations it
is often necessary to identify and correct for sources of confounding technical variation
after the data have been generated.
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1.6.3 Post-hoc compensation for batch effects
Systematic variation often violates assumptions made by standard bulk-normalisation
methods. For example, normalising a set of microarray samples such that they all
share a common expression distribution assumes that all probes are affected equally
by whatever systematic effect caused the distributions to differ in the first instance.
This is not always the case, however, and the signal from different genes or probes are
frequently affected differently [119]. In such circumstances more invasive, gene-wise,
corrections are often required to remove confounding technical variation.
A number of computational methods have been developed for compensating for
batch-effects in both large and small datasets. For example, mean-centring batches,
for each gene, with or without within-batch variance normalisation, is the simplest and
fastest means of correcting for batch-effects [126]. The number of samples in each batch
should be fairly large to obtain reliable estimates of within-batch mean and variance;
also, care must obviously be taken to account for the biological sample-groups during
the correction and the use of within-batch variance scaling is not valid in unbalanced
designs [127]. ComBat computes an ‘Empirical Bayes’ shrinkage of the individual gene-
wise batch effect parameters, using all genes within each batch, prior to adjusting each
gene to compensate for the batch effects [127]. The use of this common shrinkage allows
more robust parameter estimation even when the number of samples per batch is small,
as is also the case in methods for estimating differential expression in microarray [66]
and RNA-seq analyses [117]. Surrogate Variable Analysis (SVA) [128] is a method
for estimating technical variation where the source is unknown or known sources do
not account for the majority of the experiment noise [119]. Other methods also exist,
such as singular-value decomposition [129] and distance weighted discrimination [130],
although these methods require a large number of samples per batch in order to obtain
reliable results [127].
1.7 Project aims
Before any advanced analysis or biological interpretation can be made from gene-
expression experiments, one must have confidence that the observations themselves
are faithful to the underlying biology and not a product of confounding variation
caused by the specific circumstances in which they were obtained. In many clinical
and experimental studies, replicate samples are often unavailable due to either cost
constraints, a lack of sufficient experimental subjects, or small starting amounts
of material [131]. It is therefore desirable that experiments investigating gene
expression subject to these restrictions are as well designed as possible. This requires
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reliable knowledge of potential sources of technical variation to better resolve true
biological variation in the data. Also, for meta-analyses it is critical to understand
the various factors influencing individual datasets being merged, how different the
platforms/sample preparation procedures can be before the technical differences
between individual datasets starts to negatively affect the power of the meta-analysis.
The previous sections have introduced three of the most common high-throughput
methods of assessing mRNA abundance and provided some insight into the means by
which these abundances are obtained and the various sample preparation requirements
for each. The analyses in the following chapters will focus on ascertaining, for each
technology, the reliability of such measurements based on evidence obtained from
bespoke experiments and publicly available datasets.
1.7.1 Specific aims
1. To identify and quantify sources of technical variation in three popular methods
for assessing mRNA expression; qPCR, microarray, and RNA-seq;
2. Explore the extent to which such technical variation affects results of differential
expression analyses;
3. To investigate methods of correcting for observed variation, either through
improved experiment design, better data quality control, or statistical corrections.
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Preface
The content of this chapter is exactly that presented in Kitchen et al. Methods 2010.
The presentation has been modified so as to conform to the formatting guidelines for
a Ph.D. thesis chapter. The original article, formatted as it appeared in Methods, can
be downloaded free of charge from the publisher’s website.
Both the original article and this chapter were drafted by myself and, bar a few
recommendations by my fellow authors and reviewers, the structure and content is
my own. As is covered in the text, the analysis method was previously introduced
in Tichopad et al. 2009 where the nested-Anova was applied to the stages of qPCR
experiment design jointly by myself and Ales Tichopad. The software introduced in
that article, and more fully described in this chapter, was entirely created entirely by
myself to implement the nested-Anova. The data presented in the Methods 2010 article
and in this chapter, concerning the effect of normalisation to a reference gene on the
measured variance components, was analysed by myself.
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Abstract
Experiments using quantitative real-time PCR to test hypotheses are
limited by technical and biological variability; we seek to minimise
sources of confounding variability through optimum use of biological and
technical replicates. The quality of an experiment design is commonly
assessed by calculating its prospective power. Such calculations rely on
knowledge of the expected variances of the measurements of each group
of samples and the magnitude of the treatment effect; the estimation
of which is often uninformed and unreliable. Here we introduce a
method that exploits a small pilot study to estimate the biological and
technical variances in order to improve the design of a subsequent large
experiment. We measure the variance contributions at several levels of
the experiment design and provide a means of using this information to
predict both the total variance and the prospective power of the assay.
A validation of the method is provided through a variance analysis of
representative genes in several bovine tissue-types. We also discuss the
effect of normalisation to a reference gene in terms of the measured
variance components of the gene of interest. Finally, we describe a
software implementation of these methods, powerNest, that gives the
user the opportunity to input data from a pilot study and interactively
modify the design of the assay. The software automatically calculates
expected variances, statistical power, and optimal design of the larger
experiment. powerNest enables the researcher to minimise the total
confounding variance and maximise prospective power for a specified
maximum cost for the large study.
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2.1 Introduction
2.1.1 The importance of experiment design
The typical quantitative real-time PCR (qPCR) experiment is designed to test the
hypothesis that there is no difference in the expression of a gene between two or more
subpopulations; this is based on experiments performed on representative groups of
biological subjects that, for example, exhibit different phenotypic traits or have been
exposed to different treatments [16, 132, 133, 134, 135]. If this hypothesis is unlikely
to be true, the alternative hypothesis is supported stating that there is a difference
between the subpopulations. The ability of the researcher to obtain a statistically
significant result from the testing of these hypotheses is governed by three factors:
1. the treatment effect, that is the magnitude of the mean differential expression
between the chosen subpopulations;
2. the inherent and expected biological variability in the expression of the gene
between subjects randomly selected from within each subpopulation;
3. the technical noise introduced through measurement error.
The larger the treatment effect, the easier it becomes to resolve from the confounding
noise. Biological variability is generally unavoidable, but one can seek to minimise
its impact by randomly selecting large numbers of subjects (biological replicates) from
each subpopulation. Technical noise can be minimised through careful lab practice, the
use of technical replicates, and the addition of appropriate controls [136].
The concept of treatment effect and measurement variability is the basis of
statistical power. The power of a statistical test is the probability of rejecting the
null hypothesis, given that the null is false and the alternative hypothesis is true [137].
In other words, the power is the biological resolution of the experiment; it quantifies the
likelihood of being able to resolve any differential expression between treatment groups
based on the variance of available measurements. Power increases with increasing
magnitude of the differential expression, increasing number of biological replicates,
increasing measurement precision, and decreasing biological variability. The objective
is to maximise the statistical resolution of the assay, by minimising the confounding
variance in the measured experiment data, such that a determination of the treatment
effect can be more confidently reported.
It may sometimes be the case that results collected with an assay appear more
reproducible where small numbers of biological and technical replicates are employed.
This apparent increase in precision and power is illusory, however, and significant results
may simply reflect the chance fluctuations in the particular subjects or measurement
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processes chosen for the experiment [53]. It is generally considered good experimental
practice to vary the conditions of the assay, by sampling multiple subjects and analysing
multiple technical replicates, to increase the chance that the statistical significance of
the results obtained is real and reproducible in different settings [138].
2.1.2 qPCR experiment design and error propagation
Between the selection of subjects from the subpopulations and the gathering of
expression data by qPCR there are several steps of sample-preprocessing that are
necessary to prepare the genetic material for analysis. These procedures, illustrated in
Figure 2.1, are typically:
1. the sampling of material from each subject and the extraction of the nucleic acid;
2. in the case of RNA analysis, the reverse-transcription (RT) of RNA to convert it
into cDNA;
3. the amplification of the cDNA by qPCR.
Some protocols may include additional steps such as fixation of the sample, trans-
portation, and storage. All of these procedures are susceptible to the introduction of
error [25] and, combined, they represent the technical noise in the obtained RT qPCR
measurement. In addition to the biological variability between subjects, these sources of
technical noise all contribute to the total variance of the measured expressions reported
by the qPCR. The minimisation of this variance can be achieved through effective,
informed experiment designs and sampling plans that employ replicates where they are
expected to have the greatest benefit. The challenge is therefore to design experiments
with the optimal number of biological and technical replicates such that the statistical
power is maximised and sufficient to test a biological hypothesis, while maintaining an
affordable and realistic sampling plan.
It is assumed that technical noise introduced into the experiment from each
subsequent stage in the sample-preprocessing procedure is independent and, as such,
the effect on the overall noise of the assay is additive. Namely, the magnitude of error
introduced due to pipetting, uncertainties in instrument readings, and chemical noise
in the different processing steps are not considered to be interdependent. There are,
however, a few exceptions where this assumption is invalid; for example interference due
to the presence of an inhibitor may not be independent if the same inhibitor impairs
the performance of several steps of the sample processing.
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Figure 2.1: Example 2x3x3x3 experiment design for 2 subjects belonging to a single
subpopulation. 3 qPCRs are performed for each of 3 RTs of 3 samples from each subject.
The result is 27 Cq measurements for each subject, 54 in total for the subpopulation.
From this design, variance components at each stage of sampling can be estimated.
Mouse image appears courtesy of the Wellcome Trust Sanger Institute.
2.1.3 Focus of the paper
Due to the large scope for the introduction of error into qPCR measurements and
results, it is not only essential that experiments are well conducted and validated, but
also that they are carefully designed and documented; this enables the researcher to
maximise the likelihood of accurately and reproducibly reporting interesting biological
phenomena [28]. Power analyses afford the researcher a valuable tool with which to
estimate the resolution of the assay, in terms of its ability to test a specified hypothesis
while the experiment is still in the design phase. The importance and utility of these
prospective power analyses is universally accepted, however the calculation of power is
often reduced to mere guesswork due to the fact that, by definition, the magnitude of
the effect to be studied and the measurement variation in the prospective assay cannot
be precisely known [139]. After the assay has been performed and data are available,
however, these variables are known (at least in terms of the set of samples analysed)
allowing a more accurate calculation of power. Such retrospective power calculations
have been shown to be useful, although the measured effect size is often less informative
than the variance estimated from the data [140].
In this paper we describe a method of estimating the components of biological
variation and technical noise directly from qPCR measurements. This is achieved
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through the exploitation of a small number of biological and technical replicates at
each stage of the sample processing procedure; these stages being the inter-subject,
inter-sample, inter-RT, and inter-qPCR. These biological replicates form a pilot study
to a larger, prospective investigation and, as such, should be drawn randomly from a
larger cohort of subjects that are to be used as the basis of the future investigation. The
variance components estimated from this small pilot study are used to determine the
optimal experiment design and sampling plan for the subsequent prospective study. We
further exploit these measured variances by including them in the prospective power
calculation for the future study, providing a more accurate, evidence-based, estimate
of the expected experiment error.
As a validation of the method, variance components are estimated for several
genes from a number of bovine tissue-types and contrasted with the components from
the same data following normalisation to a reference gene. We use these data to
qualitatively assess the utility of technical replication at only the qPCR level; a common
practice in qPCR assay design and one for which the rationale is unclear, except perhaps
as a low-cost insurance against a failed PCR.
Finally, we present powerNest ; a software implementation of these methods that
provides an intuitive and efficient means of optimising the sampling plan given the
data from such a pilot study.
2.2 Description of method
2.2.1 Model
We define the model for any given Cq measurement by qPCR based on four processing
steps that account for both the biological variability and the technical noise that
influence the measured value. These are the choice of subjects from the subpopulation,
the replicate samples extracted from each subject, the replicate RTs of mRNA from the
same sample, and the replicate qPCRs of cDNAs from the same RT tube. These effects
are all assumed to be independent and randomly drawn from normal distributions on
the logarithmic scale [141, 142].
Although the introduction of biological and technical noise at each of the sampling
levels is independent, the observed variances are not. The variation introduced at a
given level propagates additively throughout subsequent levels, allowing these variance
contributions to be modelled. All factors therefore meet in unique combinations and so
a nested, or hierarchical, model of additive noise is applied to the measured Cq values
[143] such that any given measured Cq can be expressed as
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Cqgijkl = µg + αgi + βgij + γgijk + δgijkl, (2.1)
where µg is the geometric-mean expression of the gene in the g
th subpopulation
(which is equivalent to the arithmetic average of the fold-change or expression of
the gene on the log-scale), αgi is the random effect of the i
th subject in the gth
subpopulation, βgij is the random effect of the j
th sample extracted from the ith subject
in the gth subpopulation, γgijk is the random effect of the k
th RT reaction from the
jth sample extracted from the ith subject in the gth subpopulation, and δgijkl is the
random effect of the lth qPCR from the kth RT of the jth sample extracted from the
ith subject in the gth subpopulation.
This model was previously justified in terms of its application to qPCR experiment
design in [144]. The total variance of any given Cq measurement follows directly from












In simpler terms, the expected variance of each measurement can be divided into two
categories; the first is the treatment variation between subpopulations that is expressed
by the σ2G term; the second is confounding biological variance and processing noise
that is encompassed by the sum of the remaining variance components corresponding
to inter-subject, inter-sample, inter-RT, and inter-qPCR variation. To maximise the
statistical power of the assay one should minimise the confounding variance to be able
to accurately resolve the treatment effect.
The variance model in Eq.(2.2) is used to define a nested analysis of variance (nested-
ANOVA) that produces estimates of each of the four modelled components of variance.
The calculation of these variance components is performed as described in [145], by a
procedure essentially based on the subtraction of the sum-squared variations of each
level from that of the respective immediate higher level.












where x = I, J , K, or L.
2.2.2 Experiment optimisation
In terms of the optimisation of the experimental design, it is the objective to minimise
the total expected technical and biological variation within each treatment group, g,
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L are the variances of the subject, sample, RT, and qPCR levels,
respectively, estimated from the pilot data. Additionally nI is the number of subjects,
nJ is the number of replicate samples from each subject, nK is the number of replicate
RTs from each sample, and nL is the number of replicate qPCRs from each RT. By
varying the n replicates at each level the σ̂2Cqg can be changed. The optimal design is
the one in which σ̂2Cqg is minimised.
The inclusion of a financial cost into the calculation of the optimal design is trivial;
the total cost of the experiment is
CT = cInI + cJnInJ + cKnInJnK + cLnInJnKnL, (2.5)
where cI , cJ , cK , and cL are the costs of producing a subject, sample, RT, and
qPCR.
2.2.3 Statistical power
The power of a statistical test is the probability of rejecting the null hypothesis,
given that the null is false and the alternative hypothesis is true. Power is simply
a restatement of the Type II error rate, β, of falsely accepting a null hypothesis; power
= (1− β).
The power depends on two factors; the significance criterion and the effect size. The
significance criterion, α, is the Type I error rate of falsely rejecting a null hypothesis
and must be specified before the power can be calculated. The α is often referred to
as the rate of false-positives and the β as the rate of false-negatives. The α and β
symbols used in terms of the significance criterion and power bear no relation to the
αgi and βgij introduced in Eq.(2.1). For the purposes of this method only two classes
of power calculation are considered; that used for the testing of the average expression
of a single subpopulation in terms of a difference from a pre-specified value, and that
used for the testing of the means of two subpopulations in terms of the difference from
each other.
The effect size, d1, in the case of a comparison of the mean expression of a single
subpopulation from some pre-determined value, c, is simply
d1 = (mA − c)/σA (2.6)
where mA and σA are the mean and standard deviation of the subpopulation,
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The effect size, d2, in the case of a comparison of two subpopulations with unequal
variances is defined as the difference between the means of the subpopulations divided








where mA and σ
2
A are the mean and variance of one subpopulation and mB and σ
2
B
are the mean and variance of the second subpopulation.
Given the number of samples in the subpopulation(s) and the desired significance
criterion the power can either be determined from a table, as found in [137] for example,
or calculated from the cumulative distribution function of the t-distribution. N.B. a
compensation is required when using a table to find the power of a test using a single
subpopulation such that the effect size, d1, should be multiplied by
√
2 to compensate
for the fact that the c is a hypothetical population parameter without any associated
sampling error.
2.2.4 Software implementation
Here we present a software implementation of this model. The software has been
designed specifically for use with small pilot datasets where the variance structure
of the experiment design is to be estimated. The software is written in Java and
standard Windows / Mac OS X installers have been provided for native operating-
system integration, while the ‘.jar’ executable is available for Linux users. The majority
of the software construction was performed using the Eclipse IDE, however most
graphical user interface design and implementation was undertaken in the NetBeans
IDE. At the user-level, powerNest has been designed to be lightweight and intuitive,
requiring minimal computational or human resources for installation and operation,
while at lower-levels the software employs efficient custom data structures that reflect
the hierarchical nature of the experiment data. Initially based on user-modifiable
default parameters, calculations of variances and power are performed in real-time while
the user modifies the pilot-experiment design and updates displayed results as required.
A detailed tutorial on the operation of the software, also discussed in the remainder of
this subsection, is available at www.powernest.net/PowerNest/Guide.html.
Cq data can be entered into the software as MS Excel spreadsheets or plain text
files. The Cq values must be allocated to the correct position in the experiment design
hierarchy so that the software can determine to which subject, sample, and RT replicate
each given data point belongs. This allocation can be performed manually in the
software or be pre-specified in the input data file. In the case of the latter, a template file
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is available; the use of which enables the software to automatically parse the experiment
design. The user-interface for data input, design specification, and results analysis is
shown in Figure 2.2.
Figure 2.2: The main interface of the powerNest software. Cq data for a number of
subject groups from a pilot study can be entered and grouped to provide estimates of
the variance components of the experiment. Subjects within each group are assumed
to be biological replicates; qPCRs from the same RT, RTs from the same sample, and
samples from the same subject are assumed to be technical replicates.
Once the data have been allocated to their position in the experimental hierarchy,
the nested-ANOVA automatically performs the analysis to determine estimates for the
variance components of each of the four levels. These components are reported in terms
of the relative, fractional contributions to the total variance in the data as detailed in
Eq.(2.3). In the situation where experiment data are unavailable, a facility to manually
input error estimates is also provided for each level. The results generated by using
this facility must be interpreted with caution, depending on the researchers confidence
about the quality of the input variance estimations.
Once the data are allocated to their correct position within the design of the pilot
experiment the user is provided the opportunity to modify the design and sampling
plan by adding and removing biological and technical replicates at each level of the
design. Using the measured variance structure, error estimates and statistical power
are automatically calculated and displayed for each of the modified designs. A facility
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is also provided for inputting the approximate financial cost of performing a single
replicate for each level. If this information is available, the software will display the
total cost of each design as well as the expected total error.
Given the variance and costing information, the software is capable of determining
an experiment design that minimises the total variance for a specified financial cost.
This is achieved through an implementation of Eqs.(2.4) and (2.5). The user can
choose from various designs such as those optimised for cost-performance, for the
overall minimisation of biological and technical error, or for the maximisation of
statistical power. Calculations involved in producing these suggested designs are
deliberately limited, so as to remain computationally tractable, by a mandatory
maximum experiment budget and can optionally be further constrained by limiting
the maximum number of subjects, samples, RTs, or qPCRs to allow in the final design.
These options are made available as simple user-interface elements and provide the user
a rapid means of creating effective experiment designs.
2.2.5 Power calculation
For a single dataset from a single treatment group, the power of different experiment
designs can be estimated in terms of the difference of the mean of the given data
compared to a pre-specified value. The population variance is estimated either from
the variance of the input data, or by manual estimate.
Data can be entered for multiple treatment groups such that the entire experiment
design can be optimised based on the observed variances. Given this information, the
software provides an automatic power calculation such that the statistical resolution of
the assay for the desired contrast can be maximised before the experiment is performed.
The automatic optimisation of the entire experiment design is capable of producing
designs where the replicate structure of each treatment group is unique, enabling the
overall error of the entire experiment to be minimised (i.e. different designs for each
subject group depending on the result of the nested ANOVA).
The power is calculated based on the measured variance structure of the input
data for the treatment group(s) using the effect size formulae defined in Eq.(2.6) or
Eq.(2.7). For each design, the power is calculated using the number of biologically
distinct observations (usually subjects, sometimes samples), the difference between the
means of the treatment groups, and the precision of the measurements. The difference
between the means can be either specified manually (preferred) or estimated from
the data. The software can also plot a graph of the number of biologically distinct
observations vs. estimated power, examples of which are illustrated in Figure 2.3.
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Figure 2.3: Example power-curves for a number of theoretical experiments at various
measurement precisions at an alpha-level of 5%. The power is calculated for unpaired,
two-tailed t-tests between two groups of samples of equal size and equal variance. For
each curve, the variable x is defined as the fraction of the standard deviation of the
two groups compared to the difference in the means of the two groups. For example
x=0.5 corresponds to a standard deviation that is equal to half the difference in the
means, x=1.0 corresponds to a standard deviation that is equal to the difference in the
means, and x=3.0 corresponds to a standard deviation that is equal to three times the
difference in the means.
2.2.6 Experimental application
Samples
This method and the software were first used in the analysis of several different types
of biological material by Tichopad et. al. [144], in which the relative contributions of
each of the processing levels to the total variance were estimated for bovine liver, blood,
and culture samples for a number of different genes. The liver tissue was obtained from
slaughtered heifers, as were the blood samples, in addition to cultures of adherent,
growing IPI-2I cells from porcine ileum. For each sample we reverse-transcribed 500
ng of total RNA and amplified the cDNA by qPCR.
Results
The sampling plans for each of the sample types in this study were designed to include
sufficient biological and technical replication to allow the estimation of the variance
39
Chapter 2. Statistical aspects of qPCR experiment design
components by the nested ANOVA, Figure 2.4(A). Here we extend this analysis to
estimate variance components of the same data normalised to the reference gene, ActB,
in each of the three tissues, Figure 2.4(B). We use these data to compare the measured
variance structures before (Cq) and after (∆Cq) normalisation to the reference gene.
Prior to normalisation, the analysis of the liver tissue revealed substantial variation
with an average total standard deviation that, in terms of the Cq, corresponds to a
2.6-fold variation between measurements. In blood, the noise arising from sampling
and extraction was consistently small across all of the studied genes, both before and
after normalisation to the reference gene, indicating that this step is very reproducible
for such samples. The cell culture samples were found to exhibit the lowest overall
confounding variation, attributable to the clonal nature of these cultures.
In all studied genes, with the exception of the low-expressed FGF7 in liver and
IFNγ in blood, the magnitude of variance attributed to the RT step was reduced
after normalisation. Excluding FGF7 and IFNγ, the estimated standard deviations
at the RT step ranged between 0.18 - 0.46 cycles with a mean of 0.31 cycles in raw
data, and were reduced to 0.03 - 0.25 cycles with a mean of 0.17 cycles following
normalisation. The total standard deviations observed in blood and culture samples
were only marginally affected by normalisation, while the total standard deviations
of genes in liver (excluding FGF7) were dramatically reduced. The total standard
deviation in FGF7 more than doubled following normalisation due to a large increase
in the variance attributed to both the sampling and RT steps; the reason for this is
unknown and with only a single observation we cannot speculate as to the significance
of this result.
Many published reports have described the use of experimental protocols that
perform only qPCR replicates. On the basis of the variance contributions we have
estimated for the 3 studied sample types, we are able to evaluate the importance of
qPCR replicates. Again excluding the low expressed genes, FGF7 and IFNγ, we found
the standard deviations in raw data at the qPCR level to be 0.07 - 0.21 cycles, with
a mean of 0.13 cycles; similar to previous findings [141]. We conclude that a qPCR
standard deviation of 0.13 cycles is a good estimate for genes that are expressed at
reasonable levels and assayed with a protocol that yields at least some 25 template
copies per qPCR.
2.3 Concluding Remarks
The powerNest software application was specifically developed to implement the
method presented in this article; it calculates the biological and technical variance









































































Figure 2.4: The estimated variance contribution of each of the four sampling levels
to the overall variance in the measurements for several bovine tissues and genes. The
top row of plots, A, illustrate the variances of raw Cq data while the second row, B,
illustrate variances of ∆Cq data after normalising to a reference gene- ActB.
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experiment designs. Multiple datasets can be analysed simultaneously such that
an estimate of statistical power can be calculated for a specified contrast between
them. There are currently several published algorithms and software tools that
address the analysis of gene expression with data generated by qPCR experiments;
these include, among other things, different approaches to normalisation, the use of
reference genes, and clustering of multiple targets and samples [146]. In addition,
generalised software implementations of the nested-ANOVA and power calculations are
also available [147, 148]. powerNest, however, represents the first dedicated tool to
assist the researcher throughout the planning phase of an experiment and is available
online at www.powernest.net.
General results for each of the preprocessing levels in the experiments described here
highlight the importance of choosing the correct design for the specific environment of
the experiment, such as the tissues and genes to be analysed. Across all of the tissues
and genes analysed, the variance contribution from the qPCR step was only around
10% of the total and the contribution from the RT was found to exhibit about 2-times
this variability, a result that is in agreement with earlier findings [149]. Along with
the RT step, the variance of the qPCR replicates was found to be independent of the
gene being assayed. We conclude that the use of technical replicates at the qPCR level
have minimal impact on the precision of the estimated Cq value, in agreement with
previous findings [144, 17]. In almost all observations, normalisation to the reference
gene reduced the variance attributable to the RT step and the total variance was
reduced in cases where the variance structure of the reference was similar to that of
the gene of interest. The variability between sample replicates was found to be highly
tissue-dependent and inconsistent estimates of the inter-subject variation in blood and
culture tissues suggest that this variation may be gene-dependent.
It should be highlighted that in order for the technique described here to be valid
it is essential that the subjects, samples, and pre-processing procedures used for the
pilot are representative of those taken forward to the larger assay. It is obvious that
the likelihood of the pilot being representative is increased through the use of larger
numbers of biological and technical replicates; however, a sensible compromise must be
made to limit the size and cost of the pilot study. We would generally recommend that,
for the pilot to offer meaningful variance estimates, no fewer than three replicates are
used at each level. In addition, although the use of technical replicates increases the
statistical power of the assay by increasing the precision of the measurements, technical
replicates are not independent and do not increase the number of biological observations
of the given subpopulation.
When measurement is expensive and/or the individual measurements are very
precise it is preferable to add biological replicates rather than technical replicates. In
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conditions, exemplified by the bovine liver described above, where the dominant source
of variability is between measurements rather than between the biological replicates,
the use of technical replicates will be very effective in increasing precision. In general,
however, the most effective means of increasing the power and validity of qPCR
experiments is to increase the number of independent biological replicates randomly
selected from within each subpopulation.
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Preface
The content of this chapter is exactly that presented in Kitchen et al. BMC Genomics
2010, except three heatmaps, which appeared in the supplementary material, that have
been removed to improve readability. The presentation has been modified so as to
conform to the formatting guidelines for a Ph.D. thesis chapter, but the content is
unchanged from how it was presented in the original article. This original article,
formatted as it appeared in BMC Genomics, can be downloaded free of charge from
the publisher’s website.
Both the original article and this chapter were written by myself and, bar a few
recommendations by my fellow authors and reviewers, the structure and content is
my own. I was not responsible for any of the biological processing of the samples,
including patient selection, tumour biopsy, RNA preparation, and array hybridisation;
these tasks were performed by Vicky Sabine, Jane Macaskill, Lorna Renshaw, Jeremy
Thomas, Michael Dixon, and John Bartlett. I did, however, perform all of the data
analyses reported in this chapter and in the original article- with the exception of Figure
3.7 which was produced by Andrew Sims.
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Abstract
Background: Microarray technology is a popular means of producing
whole genome transcriptional profiles, however high cost and scarcity of
mRNA has led many studies to be conducted based on the analysis
of single samples. We exploit the design of the Illumina platform,
specifically multiple arrays on each chip, to evaluate intra-experiment
technical variation using repeated hybridisations of universal human
reference RNA (UHRR) and duplicate hybridisations of primary breast
tumour samples from a clinical study.
Results: A clear batch-specific bias was detected in the measured
expressions of both the UHRR and clinical samples. This bias was
found to persist following standard microarray normalisation techniques.
However, when mean-centering or empirical Bayes batch-correction
methods (ComBat) were applied to the data, inter-batch variation in
the UHRR and clinical samples were greatly reduced. Correlation
between replicate UHRR samples improved by two orders of magnitude
following batch-correction using ComBat (ranging from 0.9833–0.9991
to 0.9997–0.9999) and increased the consistency of the gene-lists from
the duplicate clinical samples, from 11.6% in quantile normalised data
to 66.4% in batch-corrected data. The use of UHRR as an inter-batch
calibrator provided a small additional benefit when used in conjunction
with ComBat, further increasing the agreement between the two gene-
lists, up to 74.1%.
Conclusion: In the interests of practicalities and cost, these results
suggest that single samples can generate reliable data, but only after
careful compensation for technical bias in the experiment. We recom-
mend that investigators appreciate the propensity for such variation in
the design stages of a microarray experiment and that the use of suitable
correction methods become routine during the statistical analysis of the
data.
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3.1 Introduction
DNA microarray technology has rapidly seduced scientists and clinicians with the
ability to simultaneously measure the expression of tens of thousands of transcripts,
enabling data-driven, holistic comparisons of groups or populations of cells, subtyping
tissues, or predicting prognosis [150, 151]. However, as with any method, sound
experimental design is essential to generate robust results from microarray experiments,
particularly given the issues of high dimensionality [152]. Sufficient care must be
taken to identify and correct for sources of experimental bias alongside a cautious
interpretation of the importance of reported differentially expressed genes [74].
Efforts to promote the routine formalisation and control of all stages of the
experimental workflow have seen success and are increasingly promoted by journals and
microarray data repositories [74]. More recent work suggests the need for the inclusion
of more detailed information concerning the statistical treatment of data in order for
results to be independently validated post-publication [153, 154]. Such standardisation
is essential to researchers wishing to re-analyse published data or combine multiple
datasets in a meta-analysis. However the utility of these standards to the individual
researcher gathering, analysing, and interpreting the data in the first instance is largely
overlooked.
Despite all efforts towards standardisation, it is still not possible to account for
all potential sources of variation in the experiment workflow; identical experiments
performed at different sites have produced significantly different results [155, 118, 156].
Inconsistencies between results generated using different microarray platforms [118,
130, 157] or generations of array [126, 158] have been highlighted and multiplicative,
systematic biases have been shown to be introduced at many stages of the experimental
process, even when using a single array platform [126].
The common practice of hybridising samples with no technical replication (i.e.
one replicate of each sample per experiment) is a result of the relatively high cost of
arrays, the perceived improvement in array manufacturing quality, and the difficulties
of obtaining sufficient amounts of high quality mRNA from some clinical samples.
This practice is fundamentally reliant on the assumption that the intra-experiment
variability is of a small enough magnitude not to undermine the power of the assay to
resolve interesting biological differences that may exist between predefined groups of
samples. There is, however, mounting evidence [118, 126, 159, 160, 161, 162, 163] to
suggest that this assumption may be flawed and that the technical variation between
replicate samples should not be ignored.
A large amount of effort has been expended in assessing the reliability, repro-
ducibility, and compatibility of results generated by a number of array platforms
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within and between laboratory sites. The microarray quality control (MAQC) project,
a US Food and Drug Administration initiative [118], explored the intra- and inter-
platform consistency of microarrays using two reference RNA samples (a universal
human reference RNA (UHRR) from Stratagene comprised of high-quality RNA from
a mixture of 10 different human cell-lines (including breast) and a human brain reference
RNA from Ambion) and primary samples processed on six microarray platforms at three
different sites. The results of the MAQC and other studies highlight the fact that,
despite the generally good consensus between results, data generated from different
platforms, in different laboratories, by different investigators can be negatively affected
by dataset-wide batch variation in the reported expression levels [118, 130, 164]. Several
methods that can remove these batch differences have been proposed, tested, and
evaluated. Batch effects have been shown to be minimised with correction methods
such as, singular value decomposition [129], distance weighted discrimination [130],
mean-centring [126], and ComBat [127].
It is slowly becoming accepted that batch effects are to be expected when combining
data generated across different labs, by different researchers, or using different platforms
[118, 130, 157, 126, 158]. There is a strong motivation to integrate multiple studies for
meta-analyses that have increased statistical power afforded by larger sample- sizes,
which can help to overcome basic limitations such as the inherent heterogeneity between
biological subjects. Combined datasets can swell to include thousands of tumours and
have been shown to lead to improved results and consensus findings [126, 165, 166, 167,
168, 169].
Some researchers are now aware of bias arising due to analysis of samples at different
sites or the use of different microarray platforms. The MAQC project [118], for example,
was a multi-site and multi-platform comparison study, while others deal exclusively with
the integration of data generated at geographically distributed locations. This study,
to the best of our knowledge, is the first to assess the propensity for introduction of
batch-processing effects at the same site and using the same protocol, making use of
the multi-array Illumina BeadChip platform. We go further than the MAQC study
by analysing both a commercial reference RNA and primary clinical material. This
approach enabled us to demonstrate that it is possible to generate robust and reliable
results, without the need for technical replication of starting RNA, but only when batch-
processing effects are identified and suitably minimised. In this study we demonstrate
compelling evidence for the existence of confounding batch-processing effects within a
single experiment, using RNA prepared in the same laboratory, arrays hybridised and
scanned at a single site, using a single protocol, and quantified on a single platform.
We investigated intra-experiment batch-processing variability on the Illumina
BeadChip [34] platform, as multiple arrays on each chip allow an investigation of
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intra- and inter-run variation. This was achieved through the hybridisation of a sample
of UHRR to a single array on each chip along with duplicate preparations of cRNA
from fresh frozen breast tumour samples that formed part of a recent clinical study
[170]. Intra-experiment variation is common in other assays, such as quantitative RT-




A qualitative measure of the performance of the BeadChips used in this study is
provided by a measurement of the fraction of probes that are consistently called to
be detected or undetected over all arrays. Analysis of detection consistency in the
UHRR data in this study was comparable with the MAQC results [118] with 60–70%
probes consistently called all-detected, and 80–90% genes consistently called as either
all-detected or all- undetected, across all arrays in each run (data not shown). The
coefficient of variation (CV) between and within the runs of the experiment was also
consistent with the findings of the MAQC study, with a mean CV in quantile normalised
data of around 7.5% (see Figure 3.1). The Illumina arrays used throughout the MAQC
study were the Human-6 (48K v1.0) BeadChips, which differ from the Human-8 (24K
v2.0) BeadChips used in this study in terms of the number of features represented.
The Human-6 (v1.0) chips contain twice the number of probesets available on Human-
8 (v2.0), however a large percentage of these additional probesets have been found to
be unreliable [171] and are all contained within a completely separate strip on the chip
leading to normalisation issues [160]. The high level of agreement in the observed CV
and detection calls suggest any differences between the array versions at the probe-level
are small.
3.2.2 Inter- and intra-run variation of the replicate UHRR samples
A clear batch-specific effect was observed in the raw data when the correlations of
identical UHRR samples were assessed over all available pairs across the five runs
processed on different days as illustrated in Figure 3.2. Generally, the level of correlation
was high (>97%), however several clusters of samples were observed that corresponded
to the batch in which the arrays were processed. In particular the samples in run
2 appeared to be very tightly correlated with each other but poorly correlated with
samples in run 4 (Figure 3.3A). Quantile normalisation was found to have only a























1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5
Figure 3.1: Coefficient of variation amongst replicate UHRR samples. From the left,
the first four segments contain five box-plots illustrating the CV within each of the
five runs; the four segments containing raw (white), quantile-normalised (dark-blue),
mean-centred (lighter-blue), and ComBat-corrected (pale-blue) data respectively. All
data were detection-filtered prior to analysis. The right-most segment shows the
experiment-wide CV of the UHRR (coloured as the previous segments) calculated with
no consideration of the individual runs.
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as that between runs 2 and 4, were conserved (Figure 3.3B). Only on application of
specialised batch-correction methods, such as mean-centring (Figure 3.3C) and ComBat
[127] (Figure 3.3D), were these run-specific disparities shown to be substantially
reduced. The correlations (calculated using Pearsons product-moment) for quantile
normalised data ranged from 0.9833–0.9991, whereas following a ComBat correction
this was increased to 0.9997–0.9999.
The probe-wise standard deviations of the raw expressions were found to be
consistently small across the UHRR arrays (mean = 0.28). Using the nested analysis
of variance described in methods, 60% (mean value) of the variability was due to that
between runs and less than 40% to that within each run. The magnitude of the variation
was marginally increased by detection-filtering (mean = 0.31), which would be expected
due to the preferential filtering of probes with low signal. The application of quantile
normalisation had a positive effect, decreasing the standard deviation to half that of the
raw data. However both after detection filtering and quantile normalisation the relative
contributions of the inter- and intra-run components to the total standard deviation
remained approximately unchanged. Of a selection of other normalisation methods,
loess, and cubic-spline performed similarly to quantile and all of these methods out-
performed simple median normalisation (Figure 3.4). In all cases a further correction
step is required after normalisation to correct for the batch effect.
Both mean-centring and ComBat reduced inter-run variation to such an extent
that it could no longer be accurately detected by the nested-Anova method (Figure
3.5). The only observable difference between the two methods was that the ComBat
corrected data also showed a slight reduction in the intra-run component of variation
(Figure 3.5). The sequence in which the data were quantile-normalised and batch-
corrected appeared to produce only marginal differences in the resulting variance
components; as a result, all remaining corrections using mean-centring and ComBat
were performed after quantile normalisation for consistency and to comply with the
statistical assumptions of the latter [161].
The differences in measured expression between all combinations of pairs of UHRR
samples that straddled the five runs (128 pairs) were calculated for raw, quantile-
normalised, mean-centred, and ComBat corrected data (Figure 3.6A). The distribution
of differences in the raw data did not resemble the expected form of a gaussian
centred at the origin; instead it was skewed towards the positive (mean = 0.199).
This was largely corrected after quantile normalisation and subsequent application of
mean-centring and ComBat further narrowed the distribution reflecting the previously
observed improvement in correlation. Similar improvements were observed in the
differences between samples that were processed in the same run (25 pairs, Figure
3.6B). A full illustration of the intra-run pairwise differences can be found in Fig 3.7.
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Figure 3.2: Layout of samples on the Illumina BeadChips and flowchart of the analysis
approach. A: Illustration of the positions of samples on the 18 BeadChips, processed
in five batches (also referred to as ‘runs’) corresponding to the five different days on
which the samples were hybridised and scanned. UHRR samples are labelled as C1-18.
Duplicate breast tumour clinical samples are labelled ‘a’ and ‘b’. The pre- and post-
treatment biopsy samples are identified by a triangle to the left and right of the sample
IDs, respectively. B: Flowchart of analysis methods
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Figure 3.3: Intra and inter-run variation in UHRR samples: Pearson-correlations.
Pairwise UHRR Pearson-correlation heatmaps highlight the batch differences,
particularly between run 2 and run 4. Red cells correspond to ∼97% correlation
and white to 100% correlation. Batches and sample numbers are consistent with the
colouring and labelling in Figure 1. All data were detection filtered, as described in
methods. A = raw data; B = normalised; C = quantile normalised, plus mean-centring;































































Figure 3.4: Coefficient of variation amongst replicate UHRR samples. This plot shows
the experiment-wide CV of the UHRR samples. The left-most of the four main sections
shows the CV of the raw (detection filtered) data, to the right of this is the CV after four
popular normalisation algorithms; quantile, loess, cubic-spline (qspline), and median.
The final two segments show the CV after batch-correcting each normalised dataset
using either mean-centring or ComBat.
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Figure 3.5: Intra and inter-run variation in UHRR samples: Nested-ANOVA. The
results of a nested-ANOVA, quantifying the probe-wise components of variation
corresponding to the within (blue) and between (green) batch variance. The model
and calculation used are as described in methods. Effects on these standard deviations
after detection-filtering (DF), quantile-normalisation (QN), mean-centring (MC), and

















































































































































































































































































































































































Figure 3.6: Distribution of the differences between replicate pairs of intra- and inter run
intensity measurements. All possible combinations of differences between replicate pairs
of UHRR controls and clinical samples were compared across the five runs. Axis labels
represent the difference between duplicate samples (δ) on the x-axis, against frequency
(ν) on the y-axis. Values on the left of each distribution represent the standard
deviation and values on the right represent the mean of the measured differences.
The four columns illustrate the effect of normalisation or batch correction on these
differences. The four rows of plots illustrate both inter- and intra-run differences
for both UHRR and tumour samples; row A contains inter-run differences calculated
between the 128 pairs of UHRR samples; row B corresponds to intra-run differences
between the 25 pairs of UHRR; row C is the inter-run differences in the 56 pairs of
tumour samples; and row D contains data for the intra-run differences in 7 pairs of
tumour samples in Run 5.
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Figure 3.7: UHRR inter-run pairwise differences. Pairwise differences between each
of the five runs calculated using UHRR samples for raw, quantile-normalised, mean-
centred, and ComBat-corrected data.
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3.2.3 Duplicate clinical breast-tumour samples
The sixty-three duplicate clinical samples provided a means to assess inter- and intra-
run variation using samples more representative of those commonly analysed using
microarray technology. The differences in the measured expressions between each
of the duplicate pairs of the clinical samples that straddled the five runs (56 pairs)
were calculated for raw, quantile-normalised, mean-centred, and ComBat corrected
data (Figure 3.6C). As with the UHRR samples, moderate differences were observed
between the raw expressions of duplicate hybridisations and quantile normalisation was
found to reduce, but not eliminate, the differences between the duplicate samples. The
distributions are similar to UHRR samples, although the raw data showed a slight
negative skew that was again successively improved following quantile-normalisation,
mean-centring, and ComBat, respectively. For completeness, intra-run distribution of
differences between the duplicate samples was assessed for the seven pairs of samples
in run five (Figure 3.6D).
Pearson’s product-moments were calculated to assess the correlation between the
duplicate samples. As with the UHRR the clinical samples were generally very highly
correlated (>98%), although the samples on BeadChips 13/15 and 14/16 were found to
be less similar than the others (Figure 3.8); this is consistent with the effect observed in
run 4 using the UHRR. Batch correction by either mean-centring or ComBat increased
the correlation for all samples except for two arrays on BeadChips 1/3 in the first run
and all arrays on BeadChips 17/18 in the final run.
3.2.4 Comparing duplicate tumour samples as a repeated dataset to
assess reproducibility of gene-lists
Of the 63 duplicate, paired clinical samples obtained from matched-biopsies before and
after treatment with the mTOR inhibitor RAD001, 42 were of sufficient quality to be
used in an analysis to reveal differentially expressed genes [170]. Using these samples we
further assessed the impact of the intra-experiment variation in terms of the differences
between lists of differentially expressed genes reported by each half of the duplicate
samples. The hybridisation plan for the 21 pairs of pre- and post-treatment samples in
each duplicate-group is illustrated in Figure 3.2; in the figure, triangles to the left of
the sample represent pre-treatment samples and triangles to the right represent post-
treatment samples. The first hybridisation of each duplicate sample is represented by
a trailing ‘a’ and the second represented by a trailing ‘b’.
The ‘A’ and ‘B’ duplicate sample groups, containing the ‘a’ and ‘b’ hybridisations of
each sample, respectively, were considered as two completely independent datasets (as
they were processed on completely separate BeadChips) in order to assess the extent
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Figure 3.8: Intra and Inter-run comparisons of clinical duplicates. Mean Pearson-
correlations between replicate pairs of tumour samples (A and B) on different chips
and runs. Colours denote the four different data types; raw, quantile normalised
(QN), quantile normalised then mean centred (QN+MC), and quantile normalised then
ComBat corrected (QN+CB). Expressions were generally highly correlated except in
the chips straddling runs 4 and 5. ComBat is able to correct for a significant amount
of this difference. Error bars represent the standard error.
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to which run-specific processing bias can influence the identification of differentially
expressed genes. These datasets were independently filtered by detection calls, quantile-
normalised, and, where stated, batch corrected by mean-centering or ComBat before
generating lists of differentially expressed genes. Two BioConductor packages, limma
and siggenes, were used to perform the statistical analyses (see methods).
Using the same stringency in the assessment of differential expression (fold-change
±1.5, adjusted p-value of 0.01) and using quantile normalised data, many more probes
were found to be differentially expressed between pre- and post-treatment samples
in sample group A (192) than in group B (30). Following batch correction with
ComBat the number of differentially expressed genes identified in the two groups was
more consistent (260 and 211) and the overlap, in terms of probes reported in both
groups, increased from just 11.6% to 66.4%, however the use of mean-centred data only
increased the overlap marginally to 15.2% (Table 3.1; Figures 3.9 and 3.10)
A B A&B overlap consensus(%)
limma QN 192 30 23 11.6
MC 225 222 59 15.2
CB 260 211 188 66.4
SAM QN 214 40 30 13.4
MC 240 238 65 15.7
CB 265 218 193 66.6
limma + UHRR QN 205 31 24 11.3
MC 8 92 7 7.5
CB 144 119 112 74.2
SAM + UHRR QN 224 42 32 13.7
MC 17 100 12 11.4
CB 149 125 117 74.5
Table 3.1: Summary of comparing the duplicate tumour samples as a repeated dataset
(A and B) to assess the reproducibility of gene-lists. Differentially expressed genes were
identified using limma and SAM as described in the text with quantile-normalisation
(QN), mean-centring (MC), and ComBat (CB). The UHRR was used as an inter-batch
calibrator.
Similar results were seen with less stringent criteria (fold-change ±1.2), which
consequently led to larger numbers of probes, but similar proportions of overlapping
probes were reported (data not shown). The analysis was repeated using significance
analysis of microarrays (SAM ) at a predicted false discovery rate of 5% and generated
very similar results to those obtained using limma, increasing the overlap between
groups of samples from just 13.4% in quantile-normalised data to 66.6% following
ComBat batch-correction. See Table 3.1 for a full summary of these results. The
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Figure 3.9: Differentially expressed genes with duplicates treated as separate datasets.
Heatmaps of genes found to be differentially expressed in each of the A and B replicate
datasets of samples and the overlap after quantile normalisation (top) and ComBat
batch-correction (bottom). The batch in which each sample was present is denoted
by bar beneath the dendrogram, in which the run-colours are consistent with those in
Figure 3.2, and the sample-type is illustrated by the blue bar (light=post-treatment,
dark=pre-treatment). The numbers of probes differentially expressed in both A and B
(‘A&B’) or ‘A’ only and ‘B’ only are shown in brackets. Sample clustering (by complete
linkage) in each heatmap was determined by only those probes in the ‘A&B’ group.
63

























































































































































































































































Figure 3.10: Numbers of genes reported to be differentially expressed after standard
analysis (quantile normalisation) (left), after a standard analysis with mean-centring
(middle), and after a standard analysis augmented with the ComBat batch correction
(right). A and B refer to the results from independent analyses of the duplicate sample
groups while C refers to the results from the pooled duplicate samples. The rows of
Venn diagrams illustrate the results with (i) limma, (ii) SAM, (iii) limma using UHRR,
and (iv) SAM using UHRR.
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heatmaps in Figure 3.9 also highlight how all the pairs of duplicate samples cluster
together following ComBat correction and the clustering is far less affected by
processing runs. The dependency between the choice of ComBat, mean-centring, or
quantile normalisation on the number of genes identified as differentially expressed in
each replicate group was very strong in both the limma and SAM analyses (χ2(2)
p-value << 0.001).
In addition to these independent analyses, the A and B groups were combined
to create a third group of samples, ‘C’. This group was analysed for differential
expression in the same way and the results summarised in terms of the number of
genes reported in any one, or any combination, of the three lists. The percentage of
genes consistently reported by limma as differentially expressed in all three groups after
ComBat correction was 41.3% compared to 11.2% after quantile normalisation alone
and 12.0% after mean-centering (Figure 3.10). The percentage of genes identified in the
pooled group C compared with those consistently reported in all three groups increased
from 44.2% after quantile normalisation to 90.1% after ComBat. Again, very similar
results were observed using SAM (Figure 3.10).
These analyses were repeated using the UHRR as inter-batch calibrator, designating
it as a covariate in both the mean-centring and ComBat corrections. The inclusion of
UHRR during quantile normalisation produced only a small difference in the number of
differentially expressed genes identified in each of the three sample groups. However, the
inclusion of the UHRR as a covariate in the mean-centring and ComBat corrections gave
very different results. In both methods there was a large reduction in the total number
of genes reported in each list, in terms of the consensus between the A and B groups,
the agreement dropped to 7.5% following mean-centring, but increased to 74.1% after
correction by ComBat (Table 3.1 and Figure 3.10). The dependency between choice
of batch correction method and number of genes reported in either replicate group
was stronger when UHRR was included in the correction in both the limma and SAM
analyses (χ2(2) p-value <<< 0.001).
3.3 Discussion
Batch-processing effects in microarray experiments are commonly encountered when
combining datasets from different studies, different labs, or different technologies. In
this study we have demonstrated that batch effects can arise within a single study, at
a single lab, using a single technology and that these can have a significant impact on
reported gene-lists.
The magnitude of the variation in the observed expression of replicate samples
derived from the UHRR in this study is consistent with that reported in other studies
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assessing the quality of microarray data, such as the MAQC [118]. We have also shown
that the correlation of replicate UHRR samples is similar to that between duplicate
pairs of samples derived from clinical breast-tissue biopsies and that this correlation is
generally high. How- ever, when duplicate groups of clinical samples were independently
analysed to identify differentially expressed genes the consistency of the resulting gene-
lists was found to be very poor. The predicted false discovery rate of 5% using SAM
was far lower than the observed proportion of genes that failed to be consistently
reported over the replicate analyses (∼87% after quantile normalisation, ∼30% after
ComBat correction). Whilst these two values are not directly equivalent, our results
suggest that the predicted FDR may imply greater consistency than would be mea-
sured if duplicate samples are available. Specialised corrections for run-bias were more
successful in reducing the magnitude of variability attributed to the inter-run batch
effect in both UHRR and clinical samples. The reliability of results generated from the
duplicate clinical samples was also greatly increased following batch-correction with a
much greater proportion of genes consistently reported as differentially expressed in
both sets of samples.
3.3.1 Use of single samples
There are many stages of sample-processing prior to conducting any gene-expression
experiment and each is vulnerable to the introduction of systematic processing errors
[126]. Opportunities to quantify this variation, prior to the microarray data analysis
itself, are extremely limited and generally the only available option is an assessment
of RNA quality. Other methods of quantifying gene expression, that are equally
susceptible to the introduction of processing error, rely on the use of technical replicates
to minimise confounding variation and maximise statistical resolution to the biological
processes under investigation [144]. In this respect the routine practice of analysing
each expression array sample as a singleton, regardless of the amount of RNA loaded,
is an unusual scientific approach. Whilst BeadChip technology has a degree of built-
in replication (approximately 30 randomly positioned beads, to which are attached
∼700,000 identical copies of a gene-specific probe [34]), this is no substitute for
biological replicates, especially when a large degree of the observed error can be
attributed to noise at the sample level, rather than at the probe level.
In the context of primary breast tumour samples, which have been repeatedly shown
to have highly heterogeneous mRNA expression profiles, there is much greater variation
between the RNA profiles from different individuals than within tumours [172]; either
when comparing different tumour sections, biopsies and the tumour or FFPE and frozen
[173], which effectively characterises the ‘intrinsic profile’ of subtype classification. On
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this basis and the grounds of cost and scarcity of primary material it could be argued
that replicates are unnecessary. However a lack of replicates limits the investigator in
terms of their ability to assess whether the observed variation is of biological or technical
origin and the extent to which it influences the resulting gene-lists. In this respect both
biological and technical replicates are desirable to allow generated data to be screened
for bias and batch-correction applied where appropriate. This is particularly important
in the clinical setting if samples for large trials are processed in multiple labs.
Using the duplicate-experiment approach we were able to demonstrate that single
samples can generate reliable data, particularly when batch correction is performed to
minimise processing bias. However the genes reported to be differentially expressed in
the pooled duplicate samples in group C were more robust in terms of their agreement
with those identified in groups A and B, especially following batch-correction.
3.3.2 Use of UHRR controls
In addition to the technical replicates commonly used in other assays, in cases where
the execution of the assay is split into several runs, it is very common for an inter-
run calibrator to be used to quantify the variation introduced by the splitting of the
experiment and to normalise for it. Despite the UHRR samples used in this study
showing very similar variation and correlation to that previously reported, we found
that the samples were of limited utility as predictors of the batch variation amongst
the clinical samples. However the replicate UHRR samples were found to slightly
improve the consensus between the results of the duplicate experiments when used in
conjunction with the ComBat correction.
Although the UHRR has been reported to be useful as a standard for microarray
experiments and suitable for monitoring the performance of genome-wide expression
platforms [118, 156, 174], it has also been reported to not be a suitable representative as
a normal sample for colon epithelial RNA [174]; similarly, the UHRR does not contain
breast tumour RNA (only that from a breast cancer cell line among a pool). A more
reliable control sample with which to improve the batch-correction might be provided
by an mRNA sample more representative of that under investigation; in this case, a
pool of tumour RNA rather than the UHRR. We found that the pre-treatment samples
were good predictors of the batch variation amongst the post-treatment samples and
so would likely make a better control (for normalisation) than the UHRR.
3.3.3 Experimental design
There is no reason to believe that the batch-processing effects observed here are limited
to the Illumina BeadChip platform. Many previous investigations of other platforms
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have postulated potential factors responsible for the introduction of processing errors
in microarray experiments [126, 6, 120, 15]. Other experiments at our facility using the
more recent Illumina Human HT-12 and Mouse Ref-8 BeadChips exhibit similar batch
effects to those in this study; samples are observed to cluster preferentially with others
processed in the same run, rather than by the biological differences between them, even
after quantile normalisation (data not shown). Specialised batch-corrections appear to
remove the bias, however without replicates such as those described in the current
study, this cannot be fully evaluated.
Regardless of the platform chosen, it is clear that compensation for processing
variation is beneficial and can only be achieved by incorporating the design of the
experiment into the downstream data analyses. If all pre-treatment samples had been
processed in one batch and all post-treatment samples in a second batch, it would not
be possible to rule out confounding differences between treatment and batch processing.
‘Real’ differences due to the common variable of interest may have been partially or
completely obscured by the batch effect. Design oversights of this type are beginning to
be highlighted [153] and demonstrate the need to record the batches or processing runs
in which data is generated. Some raw files contain metadata, such as the date in which
they were generated, embedded within them. Acknowledgement and identification of
the propensity for processing variation can be used to maximise the efficacy of batch-
correction methods through a more informed design of the hybridisation-plan that
includes, for example, randomisation and/or blocking of samples.
Our results support the notion that analysis of gene expression data should begin
with an evaluation of batch effects. If the possibility of batch effects has been
anticipated and confounding factors separated, then it should be possible to remove
the bias to generate more robust results. As with other studies, ours is limited by the
samples that were used in the evaluation of processing variation. We would have liked to
test the applicability of our findings in other published datasets, however we were unable
to find comparable datasets that include technical replicates and details of hybridisation
‘batches’ in the existing data repositories. In terms of cost and practicalities it is
understandable why most researchers do not perform replicates in clinical studies, our
results indeed suggest they may not be necessary; however providing a hybridisation
plan along with the raw data, would make the processing of data more transparent.
3.4 Conclusions
In summary, intra-experiment bias can distort the findings of gene expression studies.
Replicate samples were found to be beneficial in both the identification and reduction
of processing bias and lead to increased consensus in reported gene-lists, especially
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following specialised batch-corrections. We conclude that single samples can generate
reliable data, although an appreciation for sources of intra-experiment variation during
the design of the experiment is required to maximise the efficacy of specialised
corrections in order to minimise susceptibility to potentially confounding intra-
experiment batch-effects. Finally, based on the discrepancy between the lists of
differentially expressed genes in each group of duplicate tumour samples, the observed
rate of falsely-reported genes was consistently and significantly larger than that
predicted by SAM. Therefore, based on the results of this study, a healthy degree of
skepticism is advised when interpreting published results of microarray experiments
that do not include validation by technical replication or, preferably, by another
technique such as qPCR. In the absence of large numbers of biological replicates, it is
our opinion that technical replication should be encouraged in order to provide robust,
reliable, and credible expression-profiles.
3.5 Methods
3.5.1 Samples
In order to compare the consistency of gene expression profiles between and within
processing runs a single sample of Universal Human Reference RNA (UHRR; Strata-
gene, Stockport, United Kingdom) was added to eighteen Illumina HumanRef-8 v2
Expression BeadChips. The remaining seven arrays on each chip were used to
analyse the response to an mTOR inhibitor, Everolimus, in pre-operatively treated
post-menopausal women with oestrogen receptor-positive breast cancer. From each
extraction 100 ng RNA was amplified and biotinylated using an Illumina TotalPrep
RNA Amplification Kit (Ambion) and quantified on a Bioanalyser 2100. 750 ng cRNA
per sample was hybridised to Illumina HumanRef-8 v2 Expression BeadChips (Illumina,
Cambridge, United Kingdom) using Whole-Genome Expression Direct Hybridisation
kit (Illumina) and scanned with a BeadStation 500GX (Illumina). Full details of the
sample biopsies taken at diagnosis and at surgery were as previously described [170].
The duplication of the clinical samples was performed after labelling and labelled
samples were stored as per the manufacturers recommendations.
All raw gene expression files, clinical annotation and R scripts used to perform the
analysis are publicly available from the caBIG supported Edinburgh Clinical Research
Facility Data Repository https://catissuesuite.ecmc.ed.ac.uk/caarray.
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3.5.2 Statistical methods
A summary work flow of the analysis approach is given in Figure 3.2. Gene expression
changes were compared before and after RAD001 treatment and between responders
and non-responders using Bioconductor [175] algorithms implemented in the statistical
programming language, R [176]. Illumina probe profile expression data were normalised
using quantile normalisation and corrected for batch processing effects using mean-
centring [126] and ComBat [127]. Unless otherwise stated, the UHRR and breast
tumour samples were normalised separately and the UHRR samples were not included
as a covariate in the mean-centring or ComBat corrections. Genes differentially
expressed between pre- and post-treatment samples were identified using limma [177]
and SAM [67]. For the analysis using the limma package, genes were defined as
being differentially expressed after satisfying a minimum fold-change of ±1.5 and a
maximum, Benjamini-Hochberg adjusted, p-value of 0.01. For the SAM analysis (using
the siggenes package), the differentially expressed genes were selected at a maximum
predicted false discovery rate of 5% and the same minimum fold-change of ±1.5. Paired
statistical tests were performed in both the limma and the SAM analyses. Hierarchical
clustering of samples and probes for the creation of all heatmaps was performed using
complete linkage and similarities calculated according to the method described in [178].
Data were filtered, where specified, using the detection confidence reported by
Illumina’s BeadStudio software- determined for each bead based on the expressions of
internal control probes, local background intensity, and the uniformity of the reported
intensity of the bead. The filtering was performed prior to normalisation such that
probes with a detection confidence less than or equal to 80% in more than 25% of the
samples were removed from further analysis.
We applied a linear additive model to UHRR expression data on the log-scale to
estimate the inter- and intra-batch variance contributions. These contributions are
assumed to be independent and randomly drawn from log-normal distributions. As
all factors meet in unique combinations a nested, or hierarchical, variance model is
individually applied for each gene such that the model of the measured expression, Xij ,
of each probe is defined as
Xij = µ+Ai + εij (i = 1, ..., b; j = 1, ..., n) (3.1)
where µ is the geometric-mean expression of the gene from the UHRR population,
Ai is the random effect attributed to the i
th batch, and εij is the random measurement
error attributed to the jth array in the ith batch. Finally, b is the total number of batches
and n the number of replicate samples in the corresponding batch. The variance of any
given observation, Xij , is σ
2
A+σ
2; these components represent the inter-batch and intra-
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batch variance respectively. The estimation of σ2A and σ
2 is performed independently
for each gene as stated in [145].
Batch correction
The main difference between standard array normalisation and batch-correction is that
the latter does not make the assumption that all probes are affected equally by batch-
effects and, as such, performs individual adjustments on each probe across all samples.
Mean-centring, as used in the context of this chapter, is effectively N separate
operations, where N is the number of probes/genes, in which each operation involves
finding the mean expressions of samples within each of the batches and adjusting these
sample’s expressions such that these means share a common value. In the analyses
described here, a bespoke method was created to perform the adjustments making use
of the ‘rowMeans’ function in R and any batch in which there were observations of
only one of the tumour sample-types (e.g. the batch containing only pre-treatment
samples) were excluded from the adjustment. This procedure is not dissimilar to a
single iteration of the ‘median polish’ algorithm in which a model of the row and
column median-averages is found by iteratively finding and subtracting the median
of the rows/columns from the data; these median values are recorded as row/column
effects and, along with the sum of these effects, are then considered an estimate of
large-scale variation in the data.
The ComBat approach, as discussed in detail in [127], is a little more involved than
the mean-centring method but can be summarised in three stages:
1. Data standardisation and global parameter estimation
First, using a method similar to autoscaling, the data over all genes are standard-
ised so that they all have similar mean and variance. This step compensates for
the different expressions and variations of the various probes/genes that would
otherwise bias the batch effect estimates. Next the mean and variances of all
samples in each batch, over all probes/genes, are estimated using a linear model
and these parameters constitute the first prior-distribution.
2. Local parameter estimation
Independently for each gene, the sample mean and variance is estimated for each
batch and are used to estimate the parameters of the additive and multiplicative
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Using the parameter estimates for these two prior distributions along with Bayes
theorem, posterior distributions for each of the additive and multiplicative noise
distributions are calculated; final values of these batch effect parameters are
estimated as the expected values of the posterior distributions. This empirical
Bayes procedure allows information from all genes to be used to estimate batch
effects for each gene, providing more stable estimates than the standard sample
mean and sample variance.
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Preface
This chapter follows directly from the array experiment performed in the last chapter.
Here is presented an analysis of a bespoke array dataset, using a more modern iteration
of the Illumina BeadChip technology, in addition to two previously published sources
of data; all of which complement and extend the data and the analyses presented in
the previous chapter, as will be discussed.
The content of this chapter is also presented, in a condensed form, in Kitchen et al.
BMC Genomics 2011 (submitted).
Both the submitted article and this chapter were written by myself and, bar a few
recommendations by my fellow authors and reviewers, the structure and content is my
own. As was also the case in the previous chapters, I was not responsible for any of the
biological processing of the samples, including patient selection, tumour biopsy, RNA
preparation, sample-pooling, and array hybridisation; these tasks were performed by
Vicky Sabine, Michael Dixon, and John Bartlett. I did, however, perform all of the
data analyses reported in this chapter and in the submitted article- with direction by
Andrew Sims and Arthur Simen.
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Abstract
Background: Systematic processing errors are extremely common in
microarray experiments. When samples are analysed by the same
technician, at the same time, and using the same technology, com-
pensating for most obvious sources of technical variation is relatively
straightforward. However in experiments such as those used to classify
samples for clinical diagnostics, or any experiment in which the main
effect under investigation is confounded with sources of systematic
error, reliably resolving the effects is a non-trivial task. To better
understand the importance of various factors in experimental-design,
we assessed Illumina and Affymetrix datasets for technical variation
between replicate sample-hybridisations.
Results: Variances estimated at the inter-experiment level between
our HT-12 and Ref-8 BeadChips were more than twice as large (on
average) in our study than the inter-lab variation in the microarray
quality control (MAQC) dataset. Batch correction using established
methods was very effective in removing systematic error attributed
to the inter-experiment, -run, and -chip levels. Controls of both
universal human reference RNA (UHRR) and pools of RNA derived
from ‘analysis’ samples modelled technical variation well, with high
correlations to duplicate pairs of tumour samples although the pools
were significantly (on average approximately 4%) more highly correlated
than the UHRRs over all probes. A lack of differential expression
in the new tumour samples due to biological variation and relatively
small numbers restricted more comprehensive analyses of the UHRR and
pool as calibrators during batch correction. On correlating probe-wise
standard deviation (SD) estimates with probe GC content, we found
low-GC probes were significantly more variable to batch effects than
probes with higher-GC content. This low-GC, high-SD correlation was
significant in both our data and the MAQC Illumina dataset, but was
not resolved on analysing a large set of biological replicates.
Conclusion: The primary source of systematic error in any given
microarray experiment is unpredictable, however pools of sample RNA
and commercial controls such as UHRR are effective in modelling the
variation. We found that the pooled samples outperformed UHRR,
better emulating the effects of systematic error, and would almost
75
Chapter 4. Key sources of systematic noise in microarray data
certainly act as a more effective calibration sample during batch-
correction. Probes with low GC-content are more vulnerable to
systematic error but, although highly statistically significant amongst
technical replicate samples, the magnitude of this variation is relatively
small and is masked by biological variation. Blocking of samples
from each sample-group both within experiment-runs and within each
BeadChip are important to protect against technical noise in Illumina
data and detailed meta-data should therefore be preserved for each array
that includes the date and time of each hybridisation/scan. Diagnostic
procedures such as PCA or SVA should be routinely performed prior to





Increased adoption of high-throughput, whole-genome gene expression analysis tech-
nologies has led to an increased focus on the reliability of the experimental mea-
surements they produce. Several recent articles have provided substantial evidence
of systematic effects influencing data from many technologies including microarray,
second generation RNA-sequencing, and mass-spectrometric methods [119, 179]. Of
these very different methods, the majority of evidence for such systematic effects is
derived from microarray data due to their popularity, low cost, and relative ease by
which large datasets can be generated [6, 150, 180].
Complete confounding of batches of array scans (even in the same laboratory, but
at different times) with studied populations can be disastrous to the reputation of
reported results. For example, a study by Spielman et al. [122] reported 26% of all genes
differentially expressed between samples from European and Asian human populations.
Re-analysis of these data however revealed that the arrays for each population were
processed separately, between 1-3 years apart, and that after application of a standard
batch-correction method [181] no genes remained significantly differentially expressed.
This is a rather extreme example of a very common issue of vulnerability to confounding
experiment noise in microarray study design. Several studies have attempted to assess
reliability and consistency of array measurements and estimate potential sources of
confounding experimental noise in an attempt to reduce these vulnerabilities [153, 159].
The microarray quality control (MAQC) project was set up to explore inter-platform
and inter-laboratory consistency of microarray-derived gene expression datasets using
two reference RNA samples [118], as well as consistency of differential expression
estimates [182]. Both of these studies reported generally good consensus between
replicate samples across technologies and laboratories. However the latter study found
that filters used to determine collections of ‘significant’ probes/genes were less effective
when based on the reported significance of the individual statistical tests compared to
a filter based on the magnitude of the differential expression [183].
Analyses involving multiple laboratories, technologies, and staff are of interest
when dealing with large collaborative investigations and in large meta-analyses, where
multiple sources of existing data are collated with the intention of increasing the
statistical power to detect subtle differences in expression. Direct comparison and
integration of gene expression data through meta-analyses is a highly attractive option
and resources such as NCBI GEO [184] and EBI Array Express [185] make the process
of discovering potentially complementary datasets easier than ever. Unfortunately
appraising the quality of publicly available data remains a non-trivial task and, even
when the submission guidelines are followed correctly, it can be difficult to identify
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technical effects that may lead to systematic bias in the data that can potentially
compromise downstream statistical analyses.
Another, perhaps more common, situation requiring awareness of systematic batch
variation is the use of arrays for clinical diagnostics, in which genome-wide expression
patterns are mined to classify patient samples to one or more predefined disease
phenotypes. It is generally the case that such applications have two distinct stages in
which a training sample-set is used to build and tune a classification algorithm, before
this system is used to classify or diagnose samples of unknown phenotype. These two
stages are, in the clinical context, rarely performed at the same time or even using
the same technology. It is therefore imperative that the technical variation between
technologies, experiments, and runs is sufficiently small, or able to be reduced, such
that unknown samples can be successfully and reliably classified.
We previously reported compelling evidence for the existence of confounding batch-
processing effects within a single experiment, using RNA prepared in the same
laboratory, arrays hybridised and scanned at a single site, using a single protocol,
and quantified on a single platform [186]. In this moderate-scale experiment run on
18 Illumina Ref-8 BeadChips over the course of five days, replicate hybridisations of
a Universal Human Reference RNA (UHRR) and duplicate hybridisations from fresh
frozen pre- and post-treatment breast tumour samples [170]. The replicate UHRR
samples (one per chip) detected a batch effect that was reflected in the duplicate pairs of
tumour RNA and, following variance analysis, it was revealed that the processing batch
(corresponding to the day on which the chips were processed at the core facility) was the
main source of technical variation in the measured expressions. Importantly, although
this variation was small, it had a profound effect on the internal consistency of duplicate
analyses of differential expression in that only ∼10% of genes were consistently reported
as significantly differentially expressed. This was only remedied following specific batch-
correction using mean-centring, and further improved using ComBat [127] method,
increasing the consistency to ∼70%.
4.1.1 Motivation and analysis plan
Given previously reported variation in various array technologies [70, 126, 186, 187,
188, 189], we wished to quantify the relative error introduced at various stages in the
experimental process prior to array scanning; including the choice of array-version and
study design, relevant in clinical diagnostics applications or replication studies. In
addition, we wanted to assess different types of control sample in terms of their ability
to model some of these systematic effects and we also considered specific properties of











































































































































































































































































































































































































































































Figure 4.1: A: Illustration of our Illumina Ref-8 (experiment 1) and HT-12 (experiments
2 & 3) BeadChips, processed in eight batches (also referred to as ‘runs’) corresponding
to the different days on which the samples were hybridised and scanned. UHRR samples
are labelled as C1-25. Replicate breast tumour clinical samples are identified with a
suffix of ‘a’ through ‘d’. The pre- and post-treatment biopsy samples are identified by a
triangle to the left and right of the sample IDs, respectively. B: Schematic comparison of
the sample pre-processing used in the generation of our Ref-8/HT-12 data, the MAQC
Illumina/Affymetrix data, and the Paterson Affymetrix data.
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In this study we generated two new datasets using Illumina HT-12 BeadChips (see
Figure 4.1A for hybridisation plan), re-analysed the Illumina and Affymetrix MAQC
datasets [118], and re-analysed a comprehensive set of technical-replicate Affymetrix
arrays produced at the Paterson Institute within the University of Manchester, UK,
and described previously [126]. A schematic diagram of our Illumina study design, the
MAQC study design, and the Paterson study design is provided in Figure 4.1B.
1. Relative levels of technical variation in Illumina and Affymetrix
microarrays
As in the first experiment using Ref-8 BeadChips, ‘experiment 1’, we hybridised to
the new HT-12 chips an aliquot of freshly extracted UHRR that was split and frozen
after amplification and labelling. On two of these arrays we also included a sample
of the ‘original’ UHRR used in experiment 1 for consistency (see Figure 4.1A and
methods). The Ref-8 (v2) and HT-12 (v3) chips share a common sample-preparation
procedure, provided by Illumina, and a large number (17,542) of common probes, for
which the exact same 50-nucleotide sequence is conserved, enabling a simple and direct
comparison of expressions reported by these probes.
Using this combined Ref-8 and HT-12 dataset, in conjunction with the MAQC
datasets and the previously published Affymetrix dataset, we report an assessment of
various sources of technical variation introduced during experiment design and sample-
preparation in terms of the impact on expression measurements.
2. Utility of pooled ‘analysis samples’ as batch-calibrators, comparison with
UHRR
In the previous analysis of Ref-8 chips, we observed that the consistency of genes
reported as differentially expressed was slightly improved when the UHRR control
samples were included as a calibrator during the normalisation of the batch effect. We
speculated that pools of clinical samples, or whatever RNA source is of direct interest
to the current investigation, might perform more effectively as a batch-calibrator. This
hypothesis is based upon the assumption that some genes expressed in the samples of
interest will not be represented in the UHRR, but would be present in a pool of clinical
samples.
We report a comparison of UHRR with pooled breast-tumour RNA in terms of the
extent to which probe-level expressions are affected by batch effects and the correlation
of these differences with those observed in the duplicate clinical tumour samples. The
control sample in which probe-wise expressions are affected similarly to those of the




3. Investigation of individual probe-properties in terms of a correlation with
estimated levels of batch-variation
In the analysis of technical variation in the UHRR replicates there is greatly reduced
scope for the introduction of ‘standard’ sources of noise into the reported expressions,
such as that resulting from sampling, amplification efficiency, and labelling. Therefore
a major remaining question is over the source of the batch variation. Many articles have
reported issues with the design of microarray probes, both in terms of the quality of
their mapping to the host genome [171] and in terms of their thermodynamic properties
[190, 191].
In their original article describing the BeadArray platform, Kuhn et al. [34] provide
a brief description of the custom-built probe-design pipeline, but do not provide many
specifics, adding that the pipeline will “be described in detail elsewhere (P. Rigault, in
prep.)”. Unfortunately, there is no record of this article’s subsequent publication. The
brief details provided in [34] describe selection of appropriate genomic target regions and
ranking of potential probe-sequences based on proximity to the 3’ end of the transcript,
melting temperature, and self-complementarity.
To that end, we assessed several hybridisation-specific probe-properties in relation
to the technical variation amongst the replicate UHRR samples; including the fraction
of cytosine and guanine nucleotides (GC fraction) and the number of cytosine-guanine
dinucleotides (CpG) in the probe sequence. We also assessed the biological-replicate
clinical samples in terms of correlation of variation with properties related to sample-
prep such as the proximity of the probe to the 3’ end of the target gene and the number
of concurrently probed known transcripts.
4.2 Methods
4.2.1 Samples
All samples in each of the three Illumina BeadChip experiments described below,
were subject to the same preparation protocol: From each extraction 100ng RNA was
amplified and biotinylated using Illumina TotalPrep RNA Amplification Kit (Ambion)
and quantified on a Bioanalyser 2100. 750ng cRNA per sample was hybridised to
Illumina HumanRef-8 (v2) or Illumina HT-12 (v3) Expression BeadChips (Illumina,
Cambridge, United Kingdom) using Whole-Genome Expression Direct Hybridisation
kit (Illumina) and scanned with a BeadStation 500GX (Illumina).
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Methods for the MAQC Illumina Human-6 Expression BeadChip (v1) and Affymetrix
U133 Plus2.0 array hybridisations are provided in [118] and methods for generating the
MCF7 and MCF10A triplicate Affymetrix U133A data can be found in the original
publication [126].
All raw gene expression files and clinical annotation generated in this study are
publicly available from the caBIG supported Edinburgh Clinical Research Facility
Data Repository (https://catissuesuite.ecmc.ed.ac.uk/caarray/) and on request to the
corresponding author.
Experiment 1
Details provided in Sabine et al. and Kitchen et al. [170, 186].
Experiment 2
Four Illumina Human HT-12 (v3) BeadChips were used in this follow-up experiment, in
which the chips were processed in pairs over the course of two days (again referred to as
runs). A single UHRR replicate, from a fresh preparation, was hybridised to each chip
(sample IDs: ‘C19’ - ‘C22’; Figure 4.1). For consistency, two replicates of the original
UHRR from experiment 1 were retrieved from storage at -80oC and added to one chip on
each run (sample IDs: ‘Cz1’ and ‘Cz2’; Figure 4.1). 34 arrays over the four chips were
used to analyse eight matched primary tumour biopsies, pre- and post-treatment with
an IGFR inhibitor, hybridised in duplicate over the two runs (sample IDs: ‘101’-‘116’;
Figure 4.1). Pools of pre-treatment and post-treatment tumour RNA were created from
the clinical samples and each pool split into four aliquots and hybridised once to each
chip. As in the first experiment, all duplication/replication of clinical, reference, and
pooled samples was performed after labelling and labelled samples were stored as per
the manufacturer’s recommendations.
Experiment 3
Three Illumina Human HT-12 (v3) BeadChips were processed over the course of a
single day, to which were hybridised more UHRR samples, in two groups of replicates.
The groups correspond to different labelling protocols; the first group of samples were
obtained from the same amplification and labelling (Ambion) as the UHRR samples
used in experiment 2 (sample IDs: ‘C23’-‘C25’; Figure 4.1). The second group of
samples were labelled using the NuGen amplification kit (NuGen) (sample IDs: ‘Cn1’-
‘Cn4’; Figure 4.1). The remaining samples on these BeadChips were not analysed




Gene expression changes were compared before and after treatments and between
responders and non-responders using Bioconductor [175] algorithms implemented in the
statistical programming language, R (v.2.12.1) [176]. Illumina probe profile expression
data were normalised by quantiles and corrected for batch processing effects using
ComBat [127]. Genes differentially expressed between paired pre- and post-treatment
samples were identified using limma (v.3.6.9) [66] and SAM (v.1.28) [67]. For the
analysis using limma, genes were defined as being differentially expressed after satisfying
a minimum fold-change of ±1.5 and a maximum, Benjamini-Hochberg adjusted, p-value
of 0.01. For the SAM analysis, the differentially expressed genes were selected at a
maximum predicted false discovery rate of 5% and the same minimum fold-change of
±1.5.
All Illumina BeadChip data were filtered, where specified, using the detection
confidence reported by the BeadStudio software- determined for each bead based on the
expressions of internal control probes, local background intensity, and the uniformity
of the reported intensity of the bead. The filtering was performed prior to quantile
normalisation such that probes with a detection confidence less than or equal to 95%
in more than 20% of the samples were removed from further analysis. Affymetrix data
were filtered such that probes reported ‘absent’ in more than 20% of the samples were
removed and subjected to quantile normalisation.
We applied a linear additive model to expression data on the log-scale to estimate
the inter- and intra-batch variance contributions. These contributions are assumed to
be independent and randomly drawn from log-normal distributions. As all factors meet
in unique combinations a nested, or hierarchical, variance model is individually applied
for each gene. Models of this kind are formally defined in [192] and have previously been
used in the context of gene-expression experiment design [144, 193]. Variance estimates
in all analyses described herein were performed using an REML procedure implemented
in the nlme package in R [194, 195, 196]. In all mixed models the biological variables
such as different cell-lines in the Paterson dataset and the UHRR/UBRR dilutions in
the MAQC dataset were treated as fixed effects and all downstream sample-processing
levels treated as random effects.
Probes were re-mapped to the human genome (NCBI build 37) using Bowtie [197]
(v. 0.12.7) allowing for no mismatched bases in the alignment. Alignment annotation,
for example the position of the probe within the host gene, was provided by in-
house software and the NCBI RefSeq annotation database [198]. The 309 probes
common to both the Ref-8 and HT-12 chips that aligned the genome but fell within
intergenic regions (or those that, for whatever reason, could not be annotated using the
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RefSeq database) were considered good and retained, along with the 15,448 annotated
intragenic probes, for further analyses.
4.3 Results
4.3.1 UHRR analysis using our Ref-8 and HT-12 data
To perform reliable correlation and variance analyses simultaneously on both Illumina
chip-types, we identified and retained only the 15,757 probes with exactly conserved
sequences between Ref-8 and HT-12 that also mapped uniquely to the genome (see
methods). All data were detection-filtered and normalised together (8,948 of the
conserved probes passed the filter, see methods) before assessment by pairwise Pearson
correlation (Fig 4.2A and Fig 4.2B). Results of pairwise Spearman rank correlations
following separate filtering and normalisation of the Ref-8/HT-12 chips were very
similar (data not shown). The globally filtered/normalised data were used in all
subsequent UHRR analyses for consistency with our previous results and for a more
reliable interpretation of nested variance analyses.
It is clear from the heatmaps in Figure 4.2 that the majority of the variation between
replicate UHRR samples exists due to the three separate experiments. However,
somewhat surprisingly, the poorest correlations exist between the two experiments
involving the HT-12 chips (85.6% DF+QN between runs 6/7 and run 8) as opposed to
(90.4% between runs 1-5 and run 8). As previously reported, standard normalisation
techniques based on array-wide intensity distributions do little to improve probe-wise
correlations between replicate samples [186]. There is also an apparent band of poorer
correlation corresponding to a single HT-12 chip in run 7 (chip 22).
For consistency with the control samples hybridised to the Ref-8 chips, two replicates
of the original UHRR from experiment 1 were retrieved from storage and added to one
chip on each run in experiment 2. However, there was only a marginal improvement
in the correlation of these old UHRR samples compared to the freshly amplified and
labeled replicates (C1-18 vs. Cz1:Cz2 = 92.8% compared to C1-18 vs. C19:22 =
91.2%) although, again, the sample on chip 22 was more poorly correlated with the
UHRR samples on the Ref-8 chips than that hybridised to chip 20.
All UHRR data were subjected to batch-correction using ComBat and correction at
two levels was assessed: experiment-wise and run-wise correction. Following ComBat
correction by experiment, all pairwise correlations increased to approximately the same
level observed in the quantile-normalised Ref-8 data obtained from the first experiment
(Fig 4.2C). However, we found previously that despite high correlation between UHRR
replicates the consistency between lists of statistically significant differentially expressed
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probes from duplicate sets of samples was poor without specific batch-correction
[186]. Following ComBat correction by run, correlations in these new UHRR samples
approach those observed in the original, ComBat batch-corrected UHRR samples from
the first experiment (Fig 4.2D).
In addition to correlating UHRR expressions between sample-pairs we performed
variance estimates, for each of the 15,757 probes, at the inter-experiment, inter-run,
and inter-chip using a nested analysis of variance described in methods (Fig 4.3, main
panel). As expected, and in agreement with correlations in Figure 4.2, the experiment
was the parameter with the greatest source of measurement noise, accounting for an
average 61.7% of the total variation in reported expressions. This is likely due to
the use of a fresh round of amplification and labelling performed on the new UHRR
samples. Despite an overall reduction in the technical variation between probes, the
fraction of the total variance contributed by the each level was unaffected by quantile
normalisation. Again, it is clear that batch correction greatly reduces the technical
variation due to experiment and run. The slight effect due to the within-batch variance
moderation can be seen in the reduction in inter-chip SD after either run of ComBat.
The high inter-chip variation, compared to inter-run variation, appears to be driven by
the new samples run on the HT-12 chips as this was not observed in the standalone
analyses of the Ref-8 data in experiment 1.
A similar variance analysis was performed, for comparison, using two of the MAQC
array datasets. The MAQC Illumina Human-6 Expression BeadChip (v1) dataset, with
expressions for 47,293 probes, was subjected to the same detection-filtering criteria as
our Ref-8 and HT-12 chips and the expressions of 21,896 surviving probes were quantile
normalised prior to variance analyses. The design of the MAQC experiment only
allowed for variance components to be estimated for the inter-laboratory, inter-chip, and
inter-array levels. However, compared to the Ref-8/HT-12 inter-experiment standard
deviations, the MAQC inter-laboratory standard deviations were much smaller; less
than half as much on average (Fig 4.3, right panel). This is likely to be a result of
our use of different array-versions and widely different dates on which the arrays were
processed (about 2 years). However it is noteworthy that the majority of the variance in
the MAQC dataset was attributable to the intra-chip (inter-array) level and this is the
only dataset, for which variance analyses were performed, in which this phenomenon
holds.
The same variance analysis using the MAQC Affymetrix U133 Plus2.0 dataset
(using 23,053 probes reported as ‘present’ across at least 80% of the samples) revealed
a more familiar variance structure in which the majority of the variation is directly
attributable to systematic differences between the different laboratories performing
the experiments (Figure 4.4, left panel). The estimated standard deviations at the
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Figure 4.2: Heatmap of Pearson correlations between replicate pairs of UHRR samples
highlights the inter-experiment, inter-run, and inter-chip differences; particularly at
the inter-experiment level. Red cells correspond to ∼80% correlation and white to
100% correlation. Batches and sample numbers are consistent with the colouring and
labelling in Figure 4.1A. A: detection filtered (DF); B: DF & quantile normalised (QN);







































Figure 4.3: Comparison of variance components in our Ref-8/HT-12 data to the
MAQC dataset. Ref-8 & HT-12 combined data: Probe-wise estimates of standard
deviations (SD) corresponding to the inter-experiment (light blue), inter-run (dark
blue), and inter-chip (green) technical variance in our UHRR data. The effect on these
standard deviations following detection-filtering (DF), quantile-normalisation (QN),
ComBat batch-correction by experiment (CB(expt)), and ComBat batch-correction by
run (CB(run)) are shown.
MAQC(ILMN): Probe-wise SD-estimates corresponding to inter-laboratory (pale
blue), inter-chip (green), and inter-array (dark green) technical variances in detection-
filtered and quantile normalised UHRR/UBRR expressions from the MAQC Illumina
dataset.
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inter-laboratory level in these data are similar to the inter-experiment level in the
Ref-8/HT-12 data, as are the distributions of the coefficients of variation (standard
deviation normalised by mean expression; data not shown).
Finally, variance analysis of a previously described Affymetrix dataset of multiple
replicates of the MCF7 and MCF10A breast cell lines [126] provided a far more detailed
breakdown of the estimated biological, as well as technical, error introduced at the
various levels of sample-preparation prior to an array experiment (Figure 4.4, right
panel). The majority of the probesets show far greater inter-sample variability than
between the two cell-lines. Not obvious from this plot however, are the 4,302 probesets
for which the inter-cell-line is greater than the inter-sample standard deviation, or
the 659 probesets for which it is greater than the sum of all lower levels, potentially
indicating a fairly large amount of differential expression between the cell-lines. Inter-
sample variability, averaged over all probesets, contributed 40.6% to the total standard
deviation; compared to 13.9% due to amplification/labelling, 9.9% & 10.8% for inter
array and inter-scanner, and 15.2% at the within-scanner/residual level. This error
profile is not at all dissimilar to error estimates obtained from the various stages of
sample preparation prior to a qPCR experiment in which, when using solid tissue, the
sampling step is by far the most variable while the noise introduced during reverse-
transcription is generally low, but is sometimes larger than sampling [193].
4.3.2 Inter-batch calibrators: Comparing UHRR with pools of tu-
mour sample RNA
In addition to the repeat hybridisation of UHRR replicates, two pooled sample controls
of clinical breast-tumour RNA were run on each of the four BeadChips in experiment
2 (samples P1 through P8; Figure 4.1A). One pool was created from a mix of all seven
pre-treatment samples run in this experiment and the second pool was created using
all seven post-treatment samples (see methods).
Results of pairwise Pearson-correlations between these pooled samples identified
a large difference between chip 22 and the other three chips used in this experiment
(Fig 4.5A & 4.5B), consistent with that seen with the UHRR. No obvious differences
were observed in the correlations between the different pools composed of either pre-
or post-treatment RNA. In general, the correlations appeared similar to those observed
between replicate UHRR samples illustrated in Figure 4.2. As noted before, quantile
normalisation does little to remedy the poor correlation between chip 22 and the other
chips, but this is remedied by ComBat by treating the batches as either as runs (Fig
4.5C) or, slightly better, as separate chips (Fig 4.5D).

































Figure 4.4: Comparison of MAQC and Paterson Affymetrix variance components.
MAQC(AFFY): Probe-wise SD-estimates corresponding to inter-laboratory (pale
blue) and inter-chip (green) technical variances in detection-filtered and quantile
normalised UHRR/UBRR expressions from the MAQC Affymetrix dataset. Paterson
Affy: Probe-wise SD-estimates corresponding to several levels of technical variance
(see figure key) in detection-filtered and quantile normalised MCF7/MCF10 expressions
from the Paterson Affymetrix dataset.
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Figure 4.5: Heatmap of Pearson correlations between replicate pairs of pooled-
tumour control samples highlights the inter-run and inter-chip variation; particularly
at the inter-chip level. Red cells correspond to ∼96% correlation and white to 100%
correlation. Batches and sample numbers are consistent with the colouring and labelling
in Figure 4.1A. A: detection filtered (DF); B: DF & quantile normalised (QN); C: DF
& QN & ComBat(by run); D: DF & QN & ComBat(by chip).
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estimated by nested-anova between the new UHRR (Fig 4.6B) and pooled tumour
samples (Fig 4.6C) in experiment 2 both show a large inter-chip/intra-batch effect.
When quantile normalisation is applied, the inter-run variation is resolved, albeit at a
low level. Overall estimates of standard deviations in Fig 4.6B are larger than 4.6C
which is, in turn, larger than Fig 4.6A, however this increase is likely due to the smaller
number of replicates in the later experiment making it harder to accurately estimate
the probe-wide error-levels. The larger magnitude of variation explains the increased
inter-chip component in Figure 4.3 and it is clear from both the correlations and the
variance estimates of both the UHRR and tumour pools that the variance in this second
experiment is driven by a particular chip (chip 22), rather than a particular run as was
the case in the first experiment.
Differential expression analyses were performed on the pre- and post-treatment
tumour duplicate samples using limma and SAM (see methods). Each run within
experiment 2 was treated as a standalone duplicate sub-experiment, and as such data
were preprocessed, normalised, batch-corrected by chip, and analysed for differential
expression completely independently from each other. Run 6 corresponded to sub-
experiment 1 and run 7 to sub-experiment 2. Data from each run were independently
quantile normalised, batch-corrected by chip using only the tumour samples, batch-
corrected by chip using the tumour samples and the UHRR replicates as controls, and
batch-corrected by chip using the tumour samples and the tumour-pool replicates as
controls.
Unfortunately only 5 probes that were found significant in these tests also survived
multiple-testing correction at q<0.05, and the same 5 probes appear in every results list
regardless of normalisation or batch-correction. The number of probes satisfying p<0.05
vary between the two sub-experiments; more probes were identified as significant on
the analysis of run 6 compared to run 7. However the fraction of significant probes
consistently identified in both sub-experiments is ≈ 20% suggesting high number of false
positives making this inappropriate for further analyses. Analysis using SAM produced
the same result, with the same 5 probes consistently differentially expressed in both
replicate groups, independent of normalisation/batch-correction (data not shown).
Despite the apparent low level of biological variation between the pre- and post-
treatment samples and small number of significantly differentially expressed genes,
both the UHRR and the Pooled tumour accurately reflected the fold-changes between
duplicate tumour samples across the two runs (Fig 4.7). The plot highlights the
increased correlation of both the UHRR and the two pool controls with the individual
tumour duplicates when one of the duplicates was present on the seemingly outlying
chip 22 (second and fourth panels). In addition, the pools outperformed UHRR in
terms of modelling the specific run-induced difference in expression, measured in terms
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Figure 4.6: Variance estimates at various levels in replicate samples hybridised to
the Ref-8 and HT-12 chips used in experiments 1 and 2. Also shows the effect of
various normalisation procedures on these variance estimates; as before such procedures
include detection-filtered (DF), quantile normalised (QN), ComBat corrected by run
(CB(run)), and ComBat corrected by BeadChip (CB(chip)). A: Inter-run and inter-
chip variance estimates using UHRR replicates in experiment 1 (previously reported
in [186]). B: Inter-run and inter-chip variance estimates using UHRR replicates in
experiment 2. C: Inter-run, inter-chip, and inter-array variance estimates using pooled-
tumour replicates in experiment 2.
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of correlation with the same differences as observed between tumour duplicates across
the chips. The pre- and post-tumour pools were found to increase correlation, on
average, by 3.9% and 4.3%, respectively, compared to UHRR; one-sample t-tests based
on the difference in correlations between these pools and UHRR were both highly





















































Figure 4.7: Correlation of expression change as a result of inter-run and inter-
chip technical variation between UHRR and pooled controls with tumour duplicates.
Tumour duplicates (individually plotted) are arranged on the x-axis to be close to others
processed on the same BeadChip. UHRR and both types of pooled-control (comprised
of pre- and post-treatment tumour RNA, respectively) are correlated more strongly
with individual tumour duplicates in which one ‘half’ of the duplicate was processed on
the outlying chip 22. Pooled-controls also consistently score slightly higher correlation
than UHRR.
We performed an exhaustive comparison of the fold-change in expression due to
the different runs between the replicate pools of pre-treatment tumour RNA and each
of the fold-changes between duplicate tumour samples (Figure 4.8). These plots each
show the magnitude of the change in expression between technical replicates introduced
by the runs and show how well correlated such changes are between the Pool/tumour-
duplicates. In the figure, the pre-treatment tumour duplicate are coloured blue and
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post-treatment are green; probes that are differentially regulated, up or down, at least
two-fold due to the different runs are highlighted in each plot (red points). Note that
most of the samples with a duplicate on chip 22 are subject to a greater magnitude of
variation than samples with a duplicate on chip 21. In many cases there is a reasonably
strong agreement between absolute expression differences observed in the pool and the
individual tumour duplicates, i.e. follow a line of unit gradient passing through the
origin. However such agreement is not necessary in order for the effect to be removed
by ComBat, or alternative methods, as the absolute magnitude of the effect is explicitly
normalised during the correction procedure. Instead, it is desirable to have a strong
correlation between the control sample and the test samples for probes subject to
large differences in expression arising from technical experiment noise; it is clear that
the pooled-tumour controls (of both pre- and post-treatment samples) are consistently
more highly correlated than the UHRR (Figure 4.7).
4.3.3 Properties of the probes with respect to batch variation
In order to assess the technical systematic-variation in terms of properties of the probes
themselves and variables implicit in their mapping to the reference genome, we mapped
all probe sequences on the Ref-8 and HT-12 arrays to the human reference genome
(see methods). Several straightforward descriptive statistics were elected to serve as
measures of probe- and mapping-specific properties that could conceivably influence
probe expression. These included compositional properties such as the guanine and
cytosine nucleotide content (GC) and cytosine-guanine dinucleotide (CpG) content of
the probes, as well as mapping properties such as the position of the probe as a fraction
of the total length of the target gene, the number of (known) transcripts consecutively
probed, and the average number of exons within the probed gene; with the number of
known transcripts and number of exons acting as proxies for gene complexity and size,
respectively.
We used the analysis of run-induced fold change between duplicate tumour
samples in experiment 2 as a platform to explore potential correlations between
probe GC content on the observed variations. These samples were split into
duplicates after labelling so each half of a duplicate pair was subjected to the same
extraction/purification, the same amplification, and the same labelling; therefore any
variation between them must be a result of noise introduced during the hybridisation
and scanning of the arrays and therefore more likely due to composition of the probes,
rather than their mapping properties.
GC content is well known to be a simple and important factor in the design of
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Figure 4.8: Scatter plots of pool vs. tumour fold-change.
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melting temperature [190, 191, 199]; increased read density in regions of high GC
content from second-generation Solexa sequencing data has also been reported [200].
In terms of the distribution of all probe GC fractions over an array, one would expect,
if no specific probe-design decision had been made taking this into consideration, a
normal distribution about 0.5, i.e. we expect, on average, 50% bases to be either a
guanine or a cytosine. The distribution of GC content over our Illumina HT-12 probes
(Figure 4.9A) clearly shows that this is not the case and Illumina have specifically
designed the probes with a bias in favour of greater-than-random GC content.
In Figure 4.9B the GC-fraction distribution of the 12,042 probes used in the analysis
of run-induced fold change is plotted as a Gaussian-smoothed probability density. Also
plotted is the distribution of the subset of these probes found to be more than 2-fold up-
or down-regulated due to the batch effect in any of the 14 duplicate sample pairs. These
two distributions are very similar, suggesting that a large number of these technical
effects are random fluctuations independent of GC content. However the distribution
of any probe found to be more than 2-fold up- or down-regulated due to the batch
effect in at least 6 of the duplicate sample pairs is clearly biased towards lower GC
fractions. Results of a chi-square test based on probes with less than 50% GC content
were highly significant (χ2, pVal < 2.2 ∗ 10−16). This suggests that while the majority
of probes may be randomly affected by the batch-effect, a core number (207) of probes
with lower than average GC content are consistently affected in our experiments by
technical variation due to batch-processing of the arrays.
Taking this further, we correlated probe GC-fraction with the inter-experiment,
inter-run, and inter-chip error estimates from the UHRR replicates, again using only
the conserved probes on both the Ref-8 and HT-12 arrays. We found a highly
significant trend in which probes with lower GC fraction exhibited higher overall
technical variation. When the technical error estimate is plotted against GC content
a trend towards higher standard deviations (SD) at lower GC fractions is obvious at
both the inter-experiment and inter-run levels (Fig 4.10). Chi-square analyses showed
this low-GC/high-SD effect to be highly significant at both the inter-experiment and
inter-run level. Probes were defined to be low-GC if their GC-content is below 0.55
as approximately 50% of the conserved probes plotted had GC-content below this
level. The choice of standard deviation cutoff defining high-SD was somewhat arbitrary
and depended on the general distribution of the scatter at each level. Both the GC-
cutoff and the SD cutoffs used are highlighted in Figure 4.10. At the inter-experiment
level, Chi-square analysis showed a significant enrichment for low-GC, high-SD probes
compared to high-GC, high-SD probes (664 vs. 469; χ2 pVal = 5.3 ∗ 10−8). An
even more significant effect was observed at the inter-run level where low-GC, high-SD
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Figure 4.9: A: Histogram of GC content over our Illumina HT-12 probes. B: Gaussian-
smoothed probability density distribution (black, N=48,803). Union of probes more
than 2-fold up- or down-regulated due to the batch effect in any of the 14 duplicate
tumour-sample pairs from Figure 4.8 (green line, N=2,661). Union of probes more than
2-fold up- or down-regulated due to the batch effect in more than 5 of the duplicate
tumour pairs (red line, N=207)
< 2.2 ∗ 10−16). There was no significant enrichment at the inter-chip level.
A similar observation regarding probe GC content and expression consistency was
recently reported in a comparison of RNA preservation protocols, using matched
samples, in terms of the effect on results of downstream expression analyses [201]. To
further extend these analyses, we also compared probe GC content with our variance
estimates from the MAQC Illumina and Affymetrix datasets (Figure 4.3 and 4.4,
respectively). These MAQC datasets have a similar overall distribution of probe-GC
content, skewed in favour of higher GC fraction (data not shown), again in which
approximately 50% of probes have a GC content below 0.55. Again, GC-fraction was
plotted against standard deviation estimated at each of the inter-laboratory, inter-chip,
and inter-array levels (Figure 4.11). We performed chi-square analyses, again using the
GC-fraction cutoff of 0.55 and somewhat arbitrary standard deviation cutoffs illustrated
in Figure 4.11. At the inter-laboratory level, almost twice as many low-GC probes had
an estimated standard deviation exceeding the chosen boundary as high-GC probes
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(173 vs. 100; χ2 pVal = 9.8 ∗ 10−8). A similar, but less significant result was observed
at the inter-chip level (χ2 pVal = 2.1 ∗ 10−4).


























































Figure 4.10: Plots of probe CG-fraction against probe standard deviation estimated
at the inter-experiment (A), inter-run (B), and inter-chip (C) levels in our combined
Illumina Ref-8/HT-12 dataset. Red lines denote the cutoffs used in chi-squared analysis
at each level
In an attempt to detect whether this low-GC-high-SD effect is resolvable between
biological, as well as technical, replicates we chose a subset of pre-and post-treatment
samples from the Ref-8 dataset in experiment 1. We were careful to avoid confounding
this analysis with inter-run variation in these data and selected, from detection-filtered
and quantile normalised data, all pre-treatment biological replicates from run 3 and
all non-duplicated post-treatment biological replicates from run 5. Despite a slightly
greater number of probes with low-GC-high-SD in both the pre- and post-treatment
sample-sets, there were no significant effects reported by chi-square analysis (data not
shown).
In an attempt to detect any effects of probe-mapping properties on in our array
data, we used the same set of pre-treatment biological replicates from run 3 and
non-duplicated post-treatment biological replicates from run 5. These biologically
distinct samples, from different experimental subjects, underwent different extractions
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Figure 4.11: Plots of probe CG-fraction against probe standard deviation estimated
at the inter-laboratory (A), inter-chip (B), and inter-array (C) levels in the MAQC
Illumina dataset. Red lines denote the cutoffs used in chi-squared analysis at each level.
and therefore any biologically driven, mapping-specific artefacts could potentially be
resolved. For each probe, the standard deviation between the pre-treatment samples
and, separately, the post-treatment samples were assessed against probe position in the
target gene, number of concurrently probed transcripts, and the number of exons in
the target gene. Illustrated in Figure 4.12 is the distribution of probe-location as a
fraction of gene length among the Ref-8 probes. After adjusting for the strand of the
probe target, no significant enrichment, again assessed by chi-square, was observed for
the standard deviations of probes proximal to either the 3’ or 5’ positions, probably
due to high biological variability (data not shown). Biologically equivalent replicates,
for example several independent samples from the same tissue, might provide a means
to potentially resolve such subtle probe-mapping artefacts, however such replicates are
not present in our dataset.
To test whether the probe-mapping may correlate with replicate cRNA-synthesis,
a similar analysis was performed using the MAQC Illumina dataset. These probes
have a distribution similar to the Ref-8 arrays shown in Figure 4.12 and the analyses
again revealed no significant enrichment for estimated standard deviation due to probe
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Figure 4.12: Distribution of MAQC Illumina probes as a fraction of target gene length.
Light blue points are used for probes that mapped to the antisense DNA strand and
dark blue for the sense strand. Left plot represents the fraction of target gene length
in terms of 3’ and 5’ coordinates on each strand while the right plot is ‘normalised’
for the anti-sense strand and plots the fraction in terms of absolute position along the
DNA molecule.
position (Figure 4.3.3). It is therefore likely that such probe-mapping effects are only
able to be resolved when probes target different regions of the transcript, rather than
probes targeting the same region being affected by biological or technical variability.
4.4 Discussion
Microarrays represent a powerful means of rapidly assessing genome-wide expression
patterns for clinical applications. Unfortunately confounding technical variation and
systematic error in array technologies presents a major obstacle to their adoption
for clinical diagnostics in humans. Building on a previous investigation of technical
variation between replicate RNA samples from breast tumour biopsies, this extended
study used both Illumina and Affymetrix arrays to explore the reliability of reported
expressions across a variety of experiment designs.
Using a large set of conserved, reliably-detected probes on Illumina Ref-8 and HT-
12 BeadChips we found that the correlation between replicate UHRR hybridisations in
















































Figure 4.13: Plots of probe position against probe standard deviation estimated at the
inter-laboratory (A), inter-chip (B), and inter-array (C) levels in the MAQC Illumina
dataset. Light and dark blue points again identify probes that mapped to the antisense
and sense strands, respectively.
101
Chapter 4. Key sources of systematic noise in microarray data
than correlations previously reported using only the Ref-8 data from experiment 1.
Interestingly, we found that UHRR samples from the original experiment, which were
stored at -80oC for approximately two years, hybridised to two arrays on the new HT-12
chips correlated better with the original Ref-8 samples than did freshly prepared UHRR
replicates. This suggests that even long periods of frozen storage and additional freeze-
thaw cycles introduce less noise into experimental measurements than that inherent in
creating a new preparation of labeled cRNA, even from the same RNA source.
As in our first experiment, quantile normalisation did little to improve correlation
between the UHRR replicates across the Ref-8/HT-12 dataset. However specific
batch-correction using ComBat once again greatly improved the correlations and is a
valuable tool for removing systematic error introduced between experiments and/or
processing runs. Variance analyses using these combined data revealed the inter-
experiment level as by far the most variable source of confounding noise, however
this was confounded with different RNA preparations due to a shortage of starting
material. The inter-chip variation in the new HT-12 datasets was almost double what
it was in the Ref-8 dataset and due to this increase in inter-chip variation and high-
levels of inter-experiment variation, the inter-run variation in the combined dataset was
largely obscured. However, as we have previously seen, inter-experiment and inter-run
variances were largely eliminated following ComBat corrections.
Variance estimates using the MAQC (Illumina) dataset were similar in magnitude
to the variances obtained from just the Ref-8 data in experiment 1. This suggests
an excellent level of reliability between the three laboratories that performed these
experiments and also that the amplification and labelling of sample RNA for Illumina
analysis introduces very little noise compared to replicate RNA extractions. In contrast,
the MAQC Affymetrix dataset was found to be far more variable than their Illumina
data and was a better match to the magnitudes of variance observed in our combined
Ref-8/HT-12 dataset. The justification for the low variation in the Illumina data
is unknown, especially since the MAQC study design deliberately split the sample
replicates before cRNA synthesis- a much earlier stage in the sample-prep workflow
than our replicates (which were split after amplification and labelling). It is possible
that the small number of laboratories (three, in total) performing the MAQC Illumina
hybridisations produced highly concordant data completely by chance, while the larger
number of laboratories (six, in total) performing the Affymetrix experiments provided
a more realistic reflection of the technical variation in these data.
Analyses of the Paterson Institute and MAQC Affymetrix datasets revealed larger
overall variation in the former, probably as a result of the re-extraction of RNA from
culture providing an extra level of variance not interrogated in the MAQC experiments
however it is likely this was slightly overestimated due to the unbalanced design of the
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Paterson experiment. Overall the variance breakdown in these data are as expected,
with the dominating contributions arising from different RNA extractions (samples)
followed by that introduced during amplification and labelling.
4.4.1 Pool vs. UHRR
Several studies have found the use of replicate control samples such as UHRR to
be a useful standard in microarray experiments, suitable for monitoring expression
consistency within and across a variety of genome-wide expression platforms [202, 203,
204, 205]. However, such commercial controls are deliberately generic in terms of the
RNA they contain and deficiencies have been reported in terms of their representation
of more ‘pure’ RNA such as that derived from colon epithelial cells [206]. Similarly,
a UHRR sample is not representative of breast tumour RNA and therefore carries no
guarantee of expressing RNAs that may be variably expressed in the specific subset
of genes changed in breast tumour tissue. Therefore, in terms of compensating for
confounding technical variation, the very probes for which the correction is most
important are those that are most neglected in the UHRR controls. To that end,
we sought to compare UHRR to bespoke control samples derived from pools of
‘representative’ tumour RNA in terms of the ability of each to model the technical
noise in the expression data.
As a general observation, the pooled RNA from the tumour samples used in
experiment 2 picked up the same strong chip-effect found by the UHRR controls and,
indeed, pairwise correlations between pool replicates were very similar to the UHRR
replicates in these HT-12 data. In experiment 2 the inter-chip variation is far larger
than the inter-array and inter-run variation and it is clear from the pairwise correlations
between these control samples that chip 22 was the primary cause of this discrepancy.
However there was nothing to suggest the samples on this chip were abnormal given
the internal controls on the Illumina chips and associated quality-control analyses.
As before, array-wide quantile normalisation did not improve the agreement between
the replicate UHRR or pool controls in experiment 2, but the within-batch variance
moderation performed by ComBat successfully removed most of the effect of the
outlying chip even when correcting specifically for run-level effects. This is a very
encouraging result, as chip-level batch correction is an extremely severe manipulation
to be performing on experiment data at such a low level and, in our opinion, run-level
corrections are favourable as they are less invasive, more reliable due to greater numbers
of samples per batch, and less vulnerable to preconceived notions about differential
expression between sample groups.
Unfortunately the rather small number of samples in this experiment, combined
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with very little legitimate biological differential expression between the pre- and post-
treatment tumour biopsies in experiment 2 provided little opportunity to assess the
effect of batch correction on the consistency of reported differentially expressed probes.
However, compared to the UHRR, the pooled tumour RNA controls were shown to
more faithfully emulate the individual shift in expression between tumour technical-
duplicates as a result of variation introduced between runs and between chips. In this
case, had there been more legitimately differentially expressed probes between pre- and
post-treatment samples, the pooled RNA would almost certainly have made for a better
batch-calibrator during ComBat correction than the UHRR controls. If we had used
similar pools instead of the UHRR during batch-correction in the first experiment it
seems reasonable to speculate that the consistency between the gene-lists, reported as
significantly differentially expressed, would have been noticeably higher. A previous
study demonstrated that the composition of datasets should be relatively consistent
for meaningful integration and robust meta-analysis [126]. It seems from the current
study that different datasets should also be of a reasonable size, although comparing
identifying the minimum experiment size for combining datasets requires further work.
We also took the opportunity to assess compositional properties of the probes as
a potential explanation/surrogate for the technical effects observed in our Ref-8 and
HT-12 data. A highly significant trend in favour of low-GC content in the core set
of probes consistently affected by inter-run and inter-chip variation between sample
duplicates in experiment 2. We assumed that GC-content is likely to be a subtle effect,
resolvable only in highly similar sample replicates such as ours, in which all processing
steps prior to hybridisation were shared. However we were somewhat surprised to
find a similar, significant, enrichment for probes with low-GC and high-SD in the
MAQC Illumina dataset. This suggests that the magnitude of error introduced due to
low probe GC-content is sufficiently great that it is resolvable between the replicate
cRNA preparations assessed in the MAQC study; but less obvious than in samples
from replicate hybridisations of the same amplified, labeled cRNA used to generate our
Ref-8/HT-12 data.
Correlation of probe composition, specifically with respect to GC content, has been
reported previously in a spike-in experiment using Illumina BeadChips [51]. Here it
was found that probes with high-GC content tended to have a higher than expected
signal intensity, but probes with lower than average GC content had inflated differential
expression statistics. These findings agree with our observations, and one could suppose
that the low-GC/high-SD trend is a result of the increased signal from high-GC probe-
targets that are thus more likely to be reliably detected. Although this justification may
not be entirely relevant in this case due to the use of technical replicates and relatively
stringent detection filter to remove unreliably expressed probes. Also, analyses of
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a subset of biological replicates on our Ref-8 chips did not show any meaningfully
significant low-GC effect by chi-square analysis. Therefore the low-GC effect is more
likely to be related to thermodynamic properties of hybridisation favouring high-GC
probes/targets, a supposition that is rational given the deliberate high-GC bias in the
design of the Illumina probesets.
The proximity, with respect to the target transcript, of probes has been reported
to strongly influence the correlation of expression measurements between technologies
[71]. The analyses performed here were designed to assess whether such probe-
transcript mapping influenced expressions reported by the same platform, however no
such correlation was observed either between biological or technical replicate samples.
A more thorough analysis of the MAQC datasets would provide further insight into
any relationship between probe-location and expression between a variety of different
platforms and sample-preparation procedures. However, this is left as future work.
4.5 Conclusion
The primary source of systematic error in any given microarray experiment is
unpredictable, but can generally be attributed to RNA extraction and, to some extent,
labelling and amplification. However, pools of RNA derived from of clinical ‘analysis’
material and commercial control samples such as UHRR are effective in modelling the
variation, especially when this variation is large. However pools of RNA, relevant to
the investigation at hand, outperform UHRR in the extent to which they emulate the
effects of systematic error, acting as a more effective calibration sample during batch-
correction. Probes with low GC-content are inherently more vulnerable to systematic
error, but although highly statistically significant, the magnitude of this variation in
our data was small relative to that between biological replicates. Given the results
presented here, including those derived from external data sources, it is desirable in
a clinical context to not avoid analysis of individual test samples (to then try and
classify), but instead to run a several at the same time to get a better handle on the
experiment variation and be better equipped to compensate for it.
Moreover, sound experiment design is of critical importance to avoid confounding
systematic variation. Randomisation of samples over the different arrays on each
BeadChip, blocking of samples from each sample-group not only within each run, but
within each BeadChip are the only sure-fire methods of protecting against unwanted
technical noise in Illumina array data. In situations where this is not possible, detailed
meta-data should be preserved for each array that includes, at the very least, the date
and time of each hybridisation and scan. In either case, diagnostic procedures such as
PCA or SVA should be routinely performed prior to downstream array analyses.
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Preface
Following on from the attempts in previous chapters to provide insight into the effect
of experiment design and sample preparation on reported gene expression levels; in
this chapter I further explore the variability between two very different technologies;
microarrays and second generation RNA-sequencing (RNA-seq).
The majority of the results and data in this chapter are unpublished, however the
findings contribute to two publications currently in press [207, 208]. Again, as was
the case in previous chapters, I was not responsible for the design of the study nor
any of the biological processing of the samples, including animal handling, sample
collection, RNA preparation, sample-pooling, array hybridisation, or RNA-seq library
preparation; these tasks were performed by Kelly A. Bordner, Arthur A. Simen, and
Shrikant M. Mane. However all of the analyses and evaluation presented herein were
performed entirely by myself with some direction provided by Arthur A. Simen, Mark
B. Gerstein, and Andrew H. Sims.
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Abstract
Background: Whilst a number of investigations have been performed
to examine the reliability of gene expression measurements obtained
from matched RNA assessed by different microarray technologies,
relatively few studies have compared expressions derived from the
more recent second-generation shotgun RNA-sequencing (RNA-seq)
experiments with those obtained by microarrays. We aimed to provide a
comprehensive comparison of array and RNA-seq technologies in terms
of both the raw expression measurements and the results of differential
expression analyses at different resolutions of the genome.
Results: Comparison of different read-mapping and quantification
methods produced surprising results, with 25% of genes exhibiting
variation above the level expected by Poisson noise, probably resulting
from poor quality sequence reads. Correlations of both raw expressions
and differential expression estimates between the technologies were
relatively high and the increased sensitivity of RNA-seq, despite the poor
quality of the reads, was very clear compared to the arrays. Agreement
in the direction of change in reported fold-changes was excellent, but
absolute fold changes were not well correlated. Consistency in raw
expressions between two sets of technical replicates sequenced over two
years apart was surprisingly good, with only 7% of genes exhibiting
extra-Poisson variation despite poor overall quality of both sets of reads.
Conclusion: Despite concerns about data quality, we found that
the choice of method for mapping and quantifying the raw sequence
reads can have a large effect on the expression estimates. Overall
we found generally good agreement between RNA-seq and arrays;
integration of fold-changes reported by each technology is reasonable,
after compensating for the overestimation of changes by RNA-seq, and
the pooling of samples prior to sequencing was likely the reason for the
low power, compared to the arrays, to detect differential expression.
Gene- and exon-level analyses were approximately equivalent in terms
of comparison with arrays and also between technical & biological
replicates on RNA-seq. Analysis at the transcript-level is clearly the
most desirable method, but requires advanced and careful mapping and
quantification in order to provide reliable expression estimates.
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5.1 Introduction
Since the mid-1990s, microarrays have been the technology of choice for large-scale,
high-throughput mRNA gene expression studies. However, as discussed at length in
the preceding chapters, array-based technologies have several technical limitations that
limit the precision and accuracy of the expression measurements derived from them.
For example variable background noise, due to random and non-specific binding of
cRNA in the sample to probes on the array, is particularly disruptive for transcripts
present of low abundance and defines the lower limit of detection [209, 210]; probes
for different genes tend to differ considerably in their thermodynamic hybridisation
properties; and a limit on the upper ranges of expression due to probe saturation [87].
Finally, and perhaps most importantly, arrays are limited to the interrogation of
only those known (or speculated) genes, transcripts, and exons for which relevant probes
have been deliberately designed. This design process, and indeed the very interpretation
of array results, makes several assumptions about the structure and transcription of
the genome that is increasingly being found to be more complex and dynamic than was
previously thought [211]. Perhaps with the exception of tiling arrays [212], microarrays
are not capable of identifying, for example, novel transcript isoforms, fusion transcripts,
and pseudogenes [213]. In fact, detection of such events within the transcriptome of
the sample under analysis would serve only to obfuscate expression measurements and
complicate interpretation of the true underlying biological processes.
Sequencing-based approaches to measuring gene expression levels have the poten-
tial to overcome all of these limitations and new, ultra-high-throughput, ‘second-
generation’, sequencing techniques enable thousands of megabases of DNA to be
sequenced in a matter of hours and days [10]. Second-generation RNA-sequencing
(RNA-seq) provide, for the first time, the capability to directly sequence almost the
entire cDNA transcriptome(s) contained within a given sample, in a high-throughput
and affordable manner. It is this ability to estimate expression across the entire length
of a target transcript, rather than just within small region targeted by a probe, that
makes RNA-seq such an appealing prospect compared to existing technologies such as
arrays and qPCR [13].
There are a number of differences in the way in which the various second-generation
sequencing platforms produce short reads that fall outside the scope of this chapter,
but a comprehensive review is provided in [11]. However, as with microarrays and
qPCR, all of the various sample preparation procedures [99] required for RNA-seq are
equally liable to introduce noise into the experiment, serving to obscure legitimate and
interesting biological variation under investigation.
The fundamental measurement obtained by RNA-seq and microarray are also very
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different. Expression estimates for array probes are produced directly from their
fluorescent intensity following laser-excitation, of the dye attached to bound cDNA
(or cRNA) target sequences in the sample. Unlike arrays, the signal obtained from
RNA-seq is essentially the reads themselves and is therefore discrete, not continuous in
nature. Expressions derived from RNA-seq experiments can only be estimated following
assignment of all (or as many as possible) of the millions of short reads to the genome
or transcriptome of the organism [214]. This difference between continuous fluorescence
and discrete read-counts leads to very different statistical considerations that impact
the filtering, normalisation, and comparison of samples. For example, an array probe
can be filtered based on its fluorescent intensity vs. the local background and is filtered
after quantification, as opposed to an RNA-seq read which comes complete with per-
base quality scores and so is filtered during mapping to the reference sequence.
Despite the promised improvements in expression detection, precision, and accuracy
provided by the short-read sequencing approach, it is still a nascent technique. Many
recent articles have shown progress in attempts to understand the best methods for
assembling reads [104] (especially for identification of novel exon-boundaries [215, 108]),
quantifying expression [107] (including isoform identification), improving expression
normalisation [110] (with proper compensation for transcript length bias [112] and
highly-expressed transcripts), and analyses of differential expression [113, 117, 116].
It is little wonder then, why it is the downstream analysis that is widely seen as the
rate-limiting factor to more widespread use of the technology [214].
All of the above factors influence potential reliability of RNA-seq and agreement
with previous methods such as arrays. To address this, several studies have already
compared expression data obtained by array with RNA-seq. Bradford et al. focused
on an exon-level evaluation of RNA-seq, in a comparison with Affymetrix exon arrays
[216], finding very good agreement in the reported direction of change between cell
lines, a finding that has also been corroborated on similar arrays [217]. RNA-seq
has been compared with tiling arrays [218], in which ‘reasonable’ correlations were
observed between raw signals but that RNA-Seq outperformed the arrays in exon
boundary detection and dynamic range of expression. Finally, in an excellent article
published in 2008, Marioni et al. [109] used matched RNA on Solexa sequencing and
Affymetrix arrays, performing a quick comparison of absolute expressions between then
technologies and a more in-depth analysis of differential expression.
5.1.1 Motivation and analysis plan
A small number of previous investigations have assessed the reliability of expression
measurements obtained from matched RNA assessed by different microarray tech-
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nologies, both within the context of a single experiment [186, 189] and between
experiments, laboratories [163], and array manufacturers [182, 118]. The purpose of this
study was to compare expressions and results obtained from Illumina BeadChips and
Illumina/Solexa RNA-seq using matched RNA from mouse prefrontal-cortex (PFC).
Mouse PFC is a tissue that presents a particular challenge for accurate expression
measurements, on any platform, as it yields small amounts of RNA and differential
expression is typically small. It is therefore desirable to embrace a potentially more
sensitive technology such as RNA-seq, but it is also interesting to investigate similarities
and differences in this new method to the array-based technologies it is expected to
eventually replace. If nothing more than to assess how well probes on arrays such as
the Illumina BeadChips represent expression at the resolution of a whole-exon or, as
they are more commonly reported, a whole-gene.
Here, the effect of using different methods of mapping and quantification of
Illumina/Solexa RNA-seq reads is compared in terms of reported expressions. RNA-
seq is also compared with Illumina BeadChips in terms of both the raw expression
measurements and the results of differential expression analyses at different resolutions
of the genome. These resolutions included gene-level comparisons of RNA-seq read
counts measured over the entire length of a gene compared to array expressions
(averaged in cases where multiple probes target the same gene). Similarly for exon-level
comparison of RNA-seq reads summed over the length of all exons targeted by the array
probes. Finally at the probe-level, to assess whether RNA-seq is capable of producing




Briefly, total RNA samples were obtained from the prefrontal cortex (PFC) of healthy,
wild-type, mice at three ages: Adult (‘AD’; 6 months), middle-aged (‘MA’; 12 months),
and old-aged (‘OA’; 18 months). Two cohorts of animals were used to generate these
data, the first cohort (‘cohort 1’) contained animals obtained, pre-aged, from the US
National Institute of Aging (NIA) while the second cohort (‘cohort 2’) was comprised
of animals obtained from the Jackson Laboratories and aged in-house. All animals were
maintained and treated in accordance with procedures approved by the Yale University
Institutional Animal Care and Use Committee (protocol 2008-10975).
All RNA-seq and microarray experiments were performed at the Yale Centre for
Genome Analysis (YCGA) [219]. RNA was extracted using the Qiagen AllPrep mini
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kit, according to manufacturer’s instructions. Sample quality was verified using Agilent
2100 Bioanalyzer RNA chips and in all cases the RNA integrity number (RIN) exceeded
8.0.
For the microarray analysis, both cohorts were processed at the same time and
hybridised to Illumina MouseWG-6 BeadChips. Financial limitations initially restricted
RNA-seq analysis to being performed only using animals from cohort 1. RNA samples
from each animal in cohort 1 were split prior to cDNA synthesis, a protocol that differs
between the Illumina microarray and RNA-seq experiments. Unused RNA was stored
in RNAlater at -80oC. While all samples were run on individual Illumina arrays, due
to the high cost of sequencing, samples were pooled prior to RNA-seq analyses. Each
pool contained, equal amounts of RNA from each of five animals, of equal age, from
the same cohort. Composition of these pools is shown in Figure 5.1, where AD1−5 were



























































































Figure 5.1: Illustration of the samples from both cohorts of animals as they were
processed on Illumina BeadChips and by Illumina/Solexa RNA-seq. AD represents
adult animals, MA are middle-age, and OA are old-age. On RNA-seq, pools are denoted
by the trailing ‘p1’ to ‘p4’, where the third and fourth pools were created from animals
in the second cohort.
Due to reasons described in the Results section, the pools from cohort 1 were
recently re-analysed by RNA-seq in a second experiment (‘experiment 2’; Figure 5.1).
RNA from each of the individual animals was thawed, re-assessed for quality and re-
pooled prior to library creation. All individual samples passed the same RIN cutoff
as before. Two of the eight available lanes on the Illumina Flowcell were used for
these samples, with each lane containing a pool of each age group; this was achieved
by ‘barcoding’ each pool to allow multiplexing. Pools were created using exactly the
same constituent samples as in first experiment. Also assessed in this second RNA-seq
experiment were pooled samples from animals in cohort 2 using a single lane on the
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Flowcell.
Again, the overall design of this study is illustrated in Figure 5.1, however the




All data were generated using Illumina MouseWG-6 (v.1.1) BeadChips. Probe
expression and detection data were output from Illumina’s BeadStudio software; all
subsequent analyses was performed using Bioconductor [175] algorithms implemented
in the statistical programming language, R (v.2.12.1) [147].
All BeadChip data were filtered, where specified, using the detection confidence
reported by BeadStudio, determined for each bead based on the expressions of internal
control probes, local background intensity, and the uniformity of the reported intensity
of the bead. The filtering was performed prior to quantile normalisation such that
probes with a detection confidence less than or equal to 95% in more than 20% of the
samples were removed from further analysis. ComBat [127] batch correction was used
to compensate for the effect of cohort where specified.
Analyses for differential expression between age-groups was performed using limma
(v.3.6.9) [66] and SAM (v.1.28) [67]. For the analysis using limma, genes were defined
as being differentially expressed after satisfying a minimum fold-change of ±1.5 and a
maximum, Benjamini-Hochberg adjusted p-value of 0.01. For the SAM analysis, the
differentially expressed genes were selected at a maximum predicted false discovery rate
(FDR) of 5% and the same minimum fold-change of ±1.5.
To facilitate the comparison with data obtained by RNA-seq, all probes were
mapped to the NCBI mouse transcriptomic reference (v37) [198] using Maq (v.0.7.1)
[106], setting all nucleotide qualities to the maximum value, allowing for 0 mismatches
in the alignment, and reporting only probes with unique hits to the transcriptome.
RNA-seq
Casava (v1.0) expression counts were obtained using the output from Illumina’s
GERALD analysis module (Illumina’s Pipeline v1.5). Briefly, this module performs
the read alignment using Illumina’s ‘Efficient Large-Scale Alignment of Nucleotide
Databases’ (ELAND) algorithm to the NCBI mouse genomic reference (v37). Read
counting is performed by Casava by sorting reads with respect to their reported
alignment to the genome, summarising each read as a single integer value corresponding
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to the reported position of the first nucleotide, and summing the number of these first-
bases within each given reference region such as a gene or an exon.
In addition to Casava, raw reads were also mapped to the NCBI mouse tran-
scriptomic reference (v37) using Maq. Parameters were left at the default, allowing
for a maximum 2-base mismatch in the alignment of the seed. Reads with multiple
alignments were decided by overall mapping quality (a cumulative function of base-
quality and reference match for each base in the read) and those with the same overall
mapping-quality were assigned to one of the candidate reference locations at random.
Custom Java software was written to summarise these Maq alignments in terms of
the number of reads mapping to known genes, exons, and Illumina microarray probe-
regions. For the probe-region quantification, expressions were estimated using only
those reads overlapping the 50nt region by at least 20 bases.
Quantification of expression following Maq alignment was similar to Casava,
reporting the number of reads mapping to each region, although we defined read-
positions by their mid-point instead of their first nucleotide. It is assumed that this
reduces bias in counting exon-spanning reads, as well as providing a little leeway at
the extreme ends of the gene so as not to discard reads starting slightly before the
defined gene-start site in the reference. In addition to read-counts, normalised values
were calculated for each gene and exon that compensate for different sequence-yields
between samples and potential biases due to differences in the lengths of genes or
exons; this normalised measure of expression is the so-called ‘Reads Per Kilobase of
exon model, per Million mapped reads’ (RPKM) [107].
All downstream analyses of BeadChip data, including mapping and expression
quantification data were performed using Bioconductor packages in R. Prior to
differential expression analyses, RNA-seq count data were filtered using an iterative
approach with Fisher’s exact-tests to find the minimum number of reads, given two
libraries of different size, which are required to reach a significance of p< 0.01 if all of
these reads were recorded from a single library and none from the other. Analyses
for differential expression between age-groups was performed using edgeR (v.2.0.3)
[117] and DESeq (v.1.2.1) [116]. Both methods model count data as negative binomial
distributions and employ an empirical Bayes procedure to moderate the degree of over-
dispersion across the features. The edgeR method was used with tag-wise dispersion
and the smoothing parameter, prior.n, set to 2. For the DEseq analysis, effect size and
variance parameters were estimated from the data using default parameters. In both
cases, library sizes were defined as the total number of mapped reads in each sample.
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5.3 Results
5.3.1 RNA-seq QC and mapping
Quality control of the six lanes of RNA-seq data immediately revealed an unusual
phenomenon at bases 34 through 36 where, in the vast majority (∼80%) of the (97
million) 50bp reads, the base was called ‘N’. An example of this effect is plotted, for
one of the samples, using the FastQC toolkit (v.0.9.0; Figure 5.2). This effect was
common between all samples and it was not possible to obtain a certain diagnosis
based on the data, however failure of the hardware during these cycles is the most
probable reason (personal communication, Mark Blaxter). If, indeed, technical failure
was the cause of the poor quality bases then various subsequent issues could affect
subsequent base calls and so the decision was made to trim the ends of all reads such
that the total length of all reads for all samples was 32 nucleotides. This decision
was also motivated because of the use of the Maq toolkit, in which base-qualities are
used in the assessment of mapping-quality and so inaccurate base-qualities can lead to
inaccurate mapping quality, regardless of position within the read [106].
The trimmed reads were then mapped to the transcriptome, as described in
methods, and this Maq-mapping consistently assigned around 20% more reads than
the untrimmed reads mapped using Casava (summary provided in Table 5.1). Array
probes were mapped in exactly the same way and an annotation file containing their
mapping position, gene, exon, and position, was created. Mapped RNA-seq reads
were counted, and RPKM values calculated, using bespoke Java software (available on
request) and summarised in terms of both the standard NCBI v37 reference and the
reduced annotation provided by the mapped array probes. Therefore, for the RNA-seq
data, expression values were provided for all RefSeq genes and exons, as well as the
subset of genes and exons interrogated by the microarray probes.
5.3.2 Expression comparison: different mapping methods and techni-
cal replicates
Unlike Maq, Casava was run following the standard GERALD pipeline provided by
Illumina using untrimmed reads (see methods). To investigate the effect of the choice
of mapping method on the reported expressions we selected gene-level expressions
estimated from reads obtained from lane 1 (‘ADp1’; Figure 5.1). The gene-level
expression measures were chosen to avoid issues arising due to the presence of exon-
spanning reads that would complicate the comparison.
Although both Casava and Maq read-mapping pipelines were performed using the
same reference build, the former used the genomic sequence while the latter used the
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Figure 5.2: Distributions of base qualities reported by the sequencer (y-axis) for each
position along the read (x-axis), over all reads in sample ‘ADp1’. Whisker extremes
denote the 10% and 90% points, blue line represents the mean. Green, orange, and red
regions denote high, intermediate, and low base quality, respectively
Lane Total number Mapped reads - Maq Mapped reads - Casava
of reads # (%) # (%)
ADp1 14,870,439 9,770,087 (65.7) 7,133,764 (48.0)
MAp1 16,191,285 11,092,235 (68.5) 7,787,219 (48.1)
OAp1 16,027,933 10,842,160 (67.6) 7,550,922 (47.1)
ADp2 16,360,026 11,862,737 (72.5) 8,209,949 (50.2)
MAp2 17,244,988 12,798,551 (74.2) 8,426,676 (48.9)
OAp2 16,517,620 11,843,920 (71.7) 8,212,139 (49.7)
Total number Mapped probes - Maq
of probes # (%)
Array 45,280 35,025 (77.4)
Table 5.1: RNA-seq read- and array probe-mapping summary
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transcriptomic sequence (see methods). The two methods also used different gene
IDs and so the UCSC knownGene database [220] was used to harmonise the two
sets of expression measurements, translating accession numbers to gene symbols. For
simplicity, genes with multiple accession-numbers or gene symbols were excluded from
the comparison (leaving 15,610 genes for analysis).
A comparison of read-counts reported by each mapping method is provided in Figure
5.3. All counts were increased by a fixed value of 0.25 prior to taking the logarithm
so as not to exclude genes with no mapped reads, however the 3,171 genes with no
mapped reads in both Maq and Casava were removed from the plot to better resolve
the density gradient in the remaining points. There is a clear trend about x ∼ y
(Pearson correlation = 97.3%) between the different quantifications methods, although
a large number of genes are reported as expressed in one method, while not in the
other.
































Figure 5.3: Gene-level comparison of raw expressions estimated by Illumina’s
ELAND/Casava (x-axis) and our custom-counted Maq-aligned reads, trimmed to
include only the first 32 bases (y-axis). Genes with zero counts reported by both




To put this in context we analysed a second RNA-seq dataset, described in [208]
but not used in any further analyses in this chapter, in which three pairs of replicate
library-preparations were run on a single Solexa chip. Using Maq, we performed exactly
the same mapping as described in Methods and plotted normalised expressions (Reads
Per Kilobase of exon-model per Million mapped reads; RPKM) for each of the replicate
pairs at the gene-, exon-, and probe-level (Figure 5.4A - 5.4C, respectively). Pearson
correlations between the replicates at the gene-level was 99.6% and almost identical
at the exon-level (99.5%). Slightly less good at the probe-level (96.4%), due to the
much smaller reference region in which the reads were to be mapped, but nevertheless
a similar correlation to that between replicate arrays seen in previous chapters. Similar
distributions and correlations were obtained from analyses of count data (data not
shown). To put these correlations in context, we also analysed expressions between 18
pairs of technical replicates used in a recent publication by Blekhman et al. [111]. In
this dataset we found that the average gene-level Pearson correlations were 99.987%,
which is 30-times greater than the gene-level correlations observed in our data.
For each pair of technical duplicate samples we computed, for each gene or exon, a
p-value based on the null hypothesis that the difference between reported read counts
could be explained by random re-sampling of the reads in both samples. Significances
were obtained by two-tailed Fisher’s exact tests, in a similar manner to [109], and we
found only a small fraction of the total genes (1.03%) and exons (0.35%) exhibited
clear evidence (p < 0.01) of non-random deviation between the duplicate samples. At
the probe-level the variation was much higher, with 18.41% of the features showing
significant departure from the Poisson noise model, suggesting that analyses at this
level are too variable to be of use in assessing differential expression. Plots of observed
vs. uniform quantiles for the p-values revealed deviation from uniformity only for highly
significant (p < 0.001) genes and exons (data not shown).
Similar analyses using Fisher’s exact tests found that just over a quarter of the genes
in the Maq vs Casava read-counts comparison exhibit non-random variation, much
larger than the Poisson-noise observed between pairs of technical sample replicates.
This therefore suggests that accurately mapping reads to the genome / transcriptome
is potentially of much greater importance than running such replicates.
There are several possible reasons for this variability (shown in Figure 5.3) including
the fact that alignment by Casava and Maq employ different methods of counting
reads (read-start vs. read-centre, respectively) and possibly handle overlapping genes
differently. Perhaps the most compelling potential justification however, is that
from exactly the same input data, GERALD/Casava only mapped 7,133,764 reads,
compared to 9,770,087 reported by Maq (Table 5.1). Perhaps the trimmed reads used
in the Maq mapping allowed more to be aligned as there is less chance of failing to map
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Figure 5.4: Comparison of a pair of technical sample-duplicates at various levels of
the genome, produced from a different RNA-seq experiment, still using mouse brain
tissue, and again mapped using Maq. Red line is the result of a linear regression and
the green line is zero-intercept, unit gradient. Pearson correlations, pCor, are shown
for each comparison. A: gene-level expression comparison, B: exon-level expression
comparison, and C: probe-level expression comparison
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reads based on the poor quality / N bases observed in Figure 5.2.
5.3.3 Expression comparison: RNA-seq vs. arrays
Using the subset of RNA-seq data mapping to the same genes and exons interrogated by
the arrays, a comparison of RNA-seq expressions with array expressions reveal relatively
high concordance between the technologies, regardless of the choice of mapping method.
Array probes mapping to the same 15,610 genes used in the comparison of Maq and
Casava were plotted against the reported Casava count (Fig 5.5A), Maq counts (Fig
5.5B), and Maq RPKM (Fig 5.5C). In each plot more than half of the genes were
below the detection threshold on the array (8,700). Correlations used only those genes
detected on the arrays and those that had more than zero counts by RNA-seq.
Despite observed differences in expressions reported by different mapping methods,
at the gene-level, Maq-quantified counts were only slightly better correlated with array
expressions than the Casava counts (52.8% vs. 49.3%, respectively), however the
greatest improvement came from the use of normalised RPKM expressions (60.8%).
Very similar correlation was observed at the exon level (53.8% and 59.0% for Maq
counts/RPKM, respectively) and the trend is the same (data not shown).
Plots similar to these have been shown in several previous papers [87, 109],
however expressions derived from RNA-seq and arrays have very different distributions
(Figure 5.6) especially following the removal of unreliably detected or low expressing
probes/genes (green). Using normalised RPKM expressions does make the distribution
slightly more similar to the array, potentially explaining the improved correlation.
To overcome the limitations of the fundamentally different expression distributions
between arrays and RNA-seq, for each technology we ranked the 6,910 genes detected
by array (above the red line in Figure 5.5) such that genes with low expression had
low rank and those with high expression had high rank. Ordered by increasing RNA-
seq gene-rank, array ranks were plotted against RNA-seq ranks reported by Casava
count (Fig 5.7A), Maq counts (Fig 5.7B), and Maq RPKM (Fig 5.7C). Plotting against
the rank distributes the data evenly along the both axes and thus facilitates the
visualisation of expression heterogeneity. In all three cases it is clear that the strongest
agreement between the platforms is for the lowest and the highest expressing genes.
Also interesting is the systematic effect causing the bowing of the array points compared
to the RNA-seq ranks; such a relationship might infer a sigmoid-like trend in the
absolute expressions, however attempts to fit such a model to the data (above the array
detection threshold) in Figure 5.5 were influenced too heavily by the large number of
highly-expressing RNA-seq, low-expressing array genes and did not produce satisfying
results.
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Figure 5.5: Comparison of absolute, gene-level, expressions between RNA-seq (x-axes)
and array (y-axes). In cases where multiple probes mapped to the same gene, the
mean of their expressions was used. The red line illustrates the approximate detection-
limit of the arrays and correlations (both Pearson, ‘pCor’, and Spearman, ‘sCor’) were
calculated using only the 6,910 genes above this detection limit. Against the same array-
expression data are plotted RNA-seq expressions as reported by A: Casava counts, B:
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Figure 5.6: Expression distributions- grey bars indicate all probes/genes, green bars
are the probes/genes that remain following detection filtering. A: Array expression
distribution for all probes, B: RNA-seq (Maq) counts, and C: RNA-seq (Maq) RPKM.
5.3.4 Comparison of differential expression estimates by arrays and
RNA-seq
Given that the main strength of arrays is in the reporting of relative expression
differences between samples, rather than absolute mRNA quantification, we assessed
the array and RNA-seq datasets for differential expression between pairs of each of the
three age groups. The increased number of mapped, trimmed reads and the availability
of normalised, RPKM expression measurements at both the gene- and exon-level led to
the decision to perform the differential expression analyses using only the Maq-mapped
data.
Principal components analysis (PCA) on the detection filtered, quantile normalised
array expressions revealed a large amount of variability between biological replicates
within the three age groups (Figure 5.8A), with the first two components accounting
for around 20% of the total variance; despite the high variability there is a reasonable
separation of samples according to age. PCA and hierarchical clustering performed on
the filtered RNA-seq (gene-level RPKM) samples also revealed high variability between
the biological replicate pools, with none clustering as expected (Figure 5.8B-C). The
same effect was also observed using exon-level RPKM expressions (data not shown).
This variability was reflected in the results of differential expression analyses on the
array data using limma (see methods), which reported very few significant probes with
a FDR corrected q < 0.05. Similarly with RNA-seq, analyses using edgeR and DESeq
(see methods) reported no significant features that survived FDR adjustment at either
the gene- or exon-level.
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Figure 5.7: Array expression ranks (blue points) plotted against increasing RNA-seq
expression rank (red line) derived from: A: Casava counts, B: Maq counts, and C:












































































































Figure 5.8: A: Scatter-plot of the loadings of the first two principal-components
of filtered and normalised microarray samples show slight separation of samples
corresponding to age. Points are coloured according to animal age: green AD, blue is
MA, and red is OA. B: Scatter-plot of the loadings of the first two principal-components
of filtered and normalised RNA-seq data. C: Basic cluster-dendrogram of the filtered
and normalised RNA-seq data.
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Despite the poor yield of reliably differentially expressed features, we compared
differential expression estimates between the technologies using the reported fold-
changes between age groups. In general, a positive correlation exists between RNA-seq
and array (Fig 5.9A). Filtering genes such that only those with p < 0.05 in both the
arrays and on RNA-seq remain, the result is not particularly convincing in terms of
direct correlation between the magnitudes of the fold-change between the technologies,
but are highly similar in terms of their predicted direction of change; i.e. if arrays
report positive fold-change between age groups then, chances are, so does RNA-seq
(χ2 pVal = 1.3 ∗ 10−46; Fig 5.9B). Analyses at the exon level revealed similar results,
with the regression of all RNA-seq and array expressions yielding an almost perfect
unit gradient and zero intercept (Fig 5.9C) and, following filtering for features with
p < 0.05, again good correlation between reported direction of change (χ2 pVal =
2.7 ∗ 10−21; Fig 5.9D).
In all analyses, RNA-seq consistently reported far fewer consistent (p < 0.05) genes
and exons compared to arrays. In order to attempt to understand this disparity,
we performed gene-level RNA-seq differential expression analyses, using edgeR, on
all possible sample permutations (Figure 5.10). From these permutations it is clear
that plenty of genes are called differentially expressed whenever certain samples are
combined in the same group. Specifically, in any analyses in which lanes 2 and 3
are in the same group, more than 3,000 genes are reported to have p < 0.05 and more
than 1,000 genes have an FDR adjusted q < 0.05. This indicates that edgeR is perfectly
capable of detecting differential expression in these data, and that the FDR adjustment
works as expected. It is simply the case that biological variability between the ‘true’
age-replicate samples is too high, probably due to the pooling [221].
5.3.5 Follow-up RNA-seq experiment
Given the uncertainty in the quality of the raw reads, the poor clustering compared
to array, and the consistently more conservative estimation of significance levels from
differential expression the RNA-seq pools were re-sequenced; the design of this follow-up
experiment (‘experiment 2’) is illustrated in Figure 5.1.
There was some concern that some of the variability between biological replicates
run in the first RNA-seq experiment might have been caused by technical variability
between sequencing lanes. Although the likelihood of a lane-specific effect contributing
sufficient noise to affect the analyses of differential expression is small, in addition
to other studies, our own data (Figure 5.4) demonstrated that the variation between
technical replicates on the same chip is approximately Poisson [109, 111]. To be on
the safe side, samples were multiplexed using the Illumina ‘barcoding’ protocol such
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Figure 5.9: Log base-2 fold-changes as reported by RNA-seq (y-axes) and microarray (x-
axes). For convenience, in each plot the number of points in each quadrant is provided,
as are lines of unit gradient coloured grey. A: All genes in the only the single comparison
of MA vs. AD age groups, the blue line is the linear regression summarising bulk
distribution of points near the origin. B: Plot of genes in all three pairwise comparisons
between the age groups; MA vs. AD in blue, OA vs. MA in green, and OA vs. AD
in red. Data have been filtered such that the plot contains only genes for which the
reported p-value is less than 5% in both array and RNA-seq in any of the three contrasts.
C: Same as A, but using instead all exon-level differences between the MA and AD age
groups. D: Same as B, again using exons with reported p-value less than 5% on both
technologies in any of the three comparisons.
127



































































































































































































































































































Figure 5.10: Number of genes with p < 0.05 reported by edgeR in all possible sample
pairs. Sample IDs (1-6) correspond to the lane on which each sample was run (see
Figure 5.1; AD=1 & 4, MA=2 & 5, OA=3 & 6). Sample pairs corresponding to the
‘correct’ grouping of biological replicates are shown at the left hand side. Number of
significantly differentially expressed genes (for which p < 0.05) is illustrated by the
black bars and the number still significant following FDR adjustment (q < 0.05) shown
by the green bars.
that all six pooled-samples were run over two lanes and each lane contains one pool
from each age group. In addition to the re-sequencing of the original samples, a third
sequencing lane was used to sequence 4 pools of samples from a second cohort of aged
animals that was interrogated using arrays at the same time as the animals from the
first cohort (see Figure 5.1).
A diagnostic assessment of all samples was performed for comparison with the
quality of the reads from the first round of RNA-seq. Distribution plots of base-quality
over the length of all reads was again the most informative, revealing that the quality of
the repeat sequenced samples from cohort 1 was very poor, perhaps as a result of long
term RNA storage and numerous freeze-thaw cycles (Figure 5.11 - top). Fortunately,
the per-base quality-distributions observed in reads obtained from the new cohort 2
pooled-samples was much higher (Figure 5.11 - bottom). However a much lower total
read-yield was delivered in the new sequence samples (∼ 9 ∗ 105 reads for each sample)
and the number of reads successfully mapped with Casava ranged between 1 ∗ 105 and
8 ∗ 105, more than an order of magnitude smaller than the ∼ 8 ∗ 106 Casava-mapped
reads per sample in the first dataset (Table 5.1). All of the second RNA-seq reads
mapped using Casava (v1.3) which, by default, reported expression levels based on the
number of nucleotides mapping to a feature, allowing proper calculation of normalised
RPKM expressions.
The combined microarray data over both cohorts exhibited a noticeable batch
effect, which was effectively removed by ComBat [127] (Figure 5.12, top row). It
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Figure 5.11: Distributions of base qualities (y-axes) reported by the sequencer for each
position along the read (x-axes), over all reads in Top: sample ‘ADp1’, re-run in the
second RNA-seq experiment and Bottom: sample ‘ADp3’, a fresh pool of RNA from
the second cohort of animals. The whisker extremes, blue line, and colour-scheme is
the same as those used in Figure 5.2.
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was difficult to see any meaningful separation between age-groups, before or after
batch-correction, in either the combined cohorts or just the second cohort due to high
biological variability. RNA-seq samples from the second cohort look slightly better,
in that the two biological replicate OA samples cluster quite closely. However with
no other biological replicates in any of the other age groups, it is impossible to make
any reliable statements about the extent of biological variation in these data. Even
following RPKM normalisation, RNA-seq samples from animals of the same age do
not cluster together across the cohorts in either gene- or exon-level data (Figure 5.12,
middle and bottom rows).
Differential expression analysis on these new RNA-seq data revealed that a small
number of genes (N=38) in cohort 1 survived FDR adjustment (although no exons)
and a larger number of significant genes and exons in cohort 2 (N=101 and N=281,
respectively). Array analysis of cohort 2 samples reported no probes significant
following FDR adjustment, but a few from the ComBat-corrected combined dataset.
Comparison of replicate RNA-seq Casava quantifications
In addition to quantification by read-bases, we also performed quantification based on
read-counts for comparison with the output from Casava v1.0 in the first experiment.
Read-count expression comparison in cohort 1 between old RNA-seq run and the new
re-sequenced data perfectly follows the predicted gradient (normalised to compensate
for the large differences in the total number of mapped reads) in both gene- and exon-
level data (Figure 5.13). Correlation is better at the exon-level due to the large number
of features with no mapped reads. Given the uncertainty over base-quality and the large
difference in the total/mapped number of reads in the old compared to the new data;
the correlation is surprisingly high.
As for the technical duplicate samples used in Figure 5.4, we again computed, for
each gene and exon, p-values from two-tailed Fisher’s exact tests to explore whether
differences in counts between the old and the new RNA-seq samples could be explained
by random re-sampling. Compared to the technical duplicates run on the same chip,
we found a much larger fraction of the genes (7.47%) and exons (1.31%) exhibited clear
evidence (p < 0.01) of non-random deviation between the old and the new samples.
The latter, again, benefiting from a large number of exons for which no or very few
reads mapped in either dataset.
Comparison of the two counting modes of Casava, ‘read-start’ and ‘read-bases’,
using the newly sequenced samples shows the bias in reported expression introduced by
the former- especially when looking at exon-level data (Figure 5.14). Little difference is
observed at the gene-level, which is reasonable as few reads are expected to fall outwith
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Figure 5.12: A: Loadings of the first two principal components estimated using array
data from cohort 1 (circles) and cohort 2 (triangles) in which colours are the same as
in Figure 5.8A, data were filtered by detection and quantile normalised. B: Similar to
A, except data were batch-corrected by cohort using ComBat. C: Loadings of the first
two principal components estimated using RNA-seq data from sample pools of cohort 1
(lighter colours) and cohort 2 (darker colours) based on gene-level Maq read-counts. D:
Similar to C, except normalised gene-level RPKM expressions were used. E: Loadings
of the first two principal components estimated using RNA-seq data from sample pools
of cohort 1 (lighter colours) and cohort 2 (darker colours) based on exon-level Maq
read-counts. F: Similar to E, except normalised exon-level RPKM expressions were
used.
131
Chapter 5. Comparison of Illumina BeadChips and Solexa RNA-sequencing
Figure 5.13: A: Gene-level expressions of sample ‘ADp1’ as reported in the first (x-axis)
and second (y-axis) RNA-seq experiment runs. Casava read-start counts were used to
quantify the expression. Red line is of unit gradient, shifted to compensate for different
library sizes between the samples. B: Same as A, except expressions are summarised
at the exon-level.
annotated gene regions (Fig 5.14A). However the base-counting method generally leads
to increased expression estimates at the exon-level and, in a large number of cases,
leads to a much greater expression estimate compared to read-start position based
counts (Fig 5.14B). This could be a result of short exons, for which the majority of a
read lies within the exon, but it starts in a preceding exon and longer reads make this
problem worse. It could also be due to incorrectly annotated exons in the reference,
in which the annotation suggests the exon starts after it actually does in the sample
transcriptome.
5.4 Discussion
5.4.1 Assessment of levels of variation in these RNA-seq data
The high level of correlation observed between technical the RNA-seq replicate sample-
pairs at the gene- and exon-level agree with data obtained by others from the same
core-facility [109, 111]. This was reflected in analyses testing the departure from random
Poisson-noise between the replicates, in which a very small fraction of the total genes
and exons showed lane-to-lane variation above that expected under the random model,
but this was not the case at the probe-level.
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Figure 5.14: A: Gene-level RNA-seq expressions of sample ‘ADp1’, from the second
experiment, as reported by Casava read-start (x-axis) and read-bases (y-axis)
quantification methods. Red line is unit gradient, shifted by log2(75) to compensate
for the counting of bases rather than reads. B: Same as A, except expressions are
summarised at the exon-level.
This was the first instance in which the technical replicates were compared at
the array-probe level and the intention was to assess whether quantifying RNA-seq
expression at such a low level would enable comparisons with microarray expressions
without relying on the quality of the reference sequence annotation. It is not a surprise
that the variability between technical replicates by RNA-seq at this resolution was high
due to the much smaller window in which RNA-seq reads were mapped. This level of
analysis is therefore of limited utility due to this technical variation in read-depth.
Compared to the very strong agreement between these technical replicates, run
on the same chip and quantified using the same mapping software, the correlation
between the same raw data analysed using different mapping software was weaker.
Over a quarter of genes exhibited extra-Poisson variation between mapping methods,
compared with 1% between technical replicates quantified using the same software. The
main difference between the mapping methods, and the most likely explanation for the
expression differences, is the use of trimmed reads prior to mapping and quantification
with Maq. Therefore it is reasonable to posit that, especially when data quality is
questionable, the choice of mapping and trimming reads to remove spurious bases is
much more important than running on-chip technical replicate samples.
Correlation analyses are less suited to discrete count data, even after taking the
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logarithm, than assessing departure from the random Poisson noise model for each
feature. This is due to the effect of a large number of genes with no mapped
reads inflating the correlation estimate over the dataset. The re-sequenced samples
had poorer correlation to the original samples than that observed between mapping
methods, however the fraction of genes with extra-Poisson variance was much lower,
suggesting that even replicate library preparations (from the same RNA source)
contribute less variability than would a nave choice of mapping method.
5.4.2 RNA-seq vs arrays
It is clear from analyses performed here, and those reported by others, that RNA-seq is
more sensitive than microarrays at lower levels of expression. A large number of genes
and exons that fall below the detection limit on the arrays were found to be highly
expressed by RNA-seq, indicating the effect of the lower detection-limit of the arrays
[87]. Indeed, the strongest agreement between the two technologies is at very high and
very low levels of expression and, due to the different expression distributions output
by each technology, direct data integration at the absolute expression level is unwise.
Unfortunately, the samples used in these experiments were found to exhibit high
levels of biological variability in both the array and RNA-seq data and very few features
remained significant following FDR adjustment. BeadChips consistently identified
a greater number of probes for which the unadjusted p-values were reported to be
significant, however this is likely due to the much larger number of biological replicates
available on arrays. Both datasets are clearly underpowered to detect robust significant
differences between the ages by pairwise comparisons, however ANOVA analyses on
arrays using with all three age-groups were more successful at detecting changes in
expression between them [207]. These analyses were not presented here as at the time
of writing the RNA-seq analysis methods used were capable only of pairwise comparison
and the goal was inter-technology comparison, rather than biological discovery.
It is likely that the pooling of samples prior to RNA-seq was the main cause of
the low power. There are many factors, such as mild infections, that can affect gene-
expression in the brain but may not present a strong phenotype. Pooling increases
the chance that the cells or tissues under study contain abnormal cells from a diseased
subject [221]. If such a subject is present in the pooled sample, it is impossible to detect
it as an outlier and the increase in variability between biological replicates becomes
much more difficult to cater for. It is likely that was the case in the pooled data
obtained in these experiments.
Regardless of the effect of pooling, methods for identifying differential expression
in these RNA-seq data were determined to be effective and that FDR adjustment
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is not overly conservative in cases where there is clear evidence for a large number
of differentially expressed genes. Following permutation of the six RNA-seq samples
we suspected a potential error was made during sample preparation that caused one
of the MA samples to be switched with an OA, due to the large number of genes
found differentially expressed when the samples in lanes 2 and 3 were in the same
pseudo age-group. However, after re-sequencing these samples it is clear that the
biological variation between pooled samples was simply too high and the similarity
of sample MAp1 and OAp1 had not been mislabeled. It is a shame that the samples
were sequenced, twice, in pools rather than individually as this would have provided
more data with which to assess the biological variability- but in the interests of cost
and limited availability of starting material this was prohibited.
In the absence of robust, statistically significant results to compare between the
technologies we used the next best thing. Comparison of reported fold-changes (FC)
between the technologies illustrated a general positive trend. A large number of genes
and exons were observed with large-FC by RNA-seq and low-FC by arrays, which were
mostly populated by undetected features on the arrays. For the small number of genes
and exons with a significant p-value on both RNA-seq and array the overall agreement
between the technologies was reasonable. Fold-changes reported by arrays did not
accurately reflect those reported by RNA-seq in terms of absolute change, however the
predictive power was very strong when only the direction of change was considered.
Based on the good consistency between fold-changes, it is clear that differential
expression between array and RNA-seq are equivalent and that a combination of high
biological variability and pooled RNA-seq samples were the cause for low numbers
of statistically robust results in these data. However, several studies have compared
differential expression estimated by array to that from other methods, mostly qPCR,
and discussed the compressed fold-changes obtained by the arrays. This also seems
to be the case in our data; array fold-change estimates consistently lower, on average,
than those derived from RNA-seq data.
The read-qualities for the re-sequenced samples in cohort 1 remained poor, but
diagnostics indicated this was more likely due to degraded biological material rather
than a technical fault on the sequencer. Also, perhaps due to a combination of poor-
quality input RNA and multiplexed sequencing, the overall yield was much lower than
in the data obtained from the first round of sequencing. However, a greater fraction of
these new reads were successfully mapped with Casava, despite the overall poor read
quality suggesting that the specific problem around base 35 in the old reads was largely
responsible for the large number of discarded data. However, the correlation between
reported read-counts in the old and the new sequenced samples was surprisingly high,
but still around 7.5% of the genes and 1.3% of the exons exhibited variation that is
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larger than that expected from random shot-noise.
As with the first dataset, PCA revealed large biological variation between the
new cohort 1 samples at both the gene- and exon-level. Variation between the new
cohort two samples appeared to be less, however the lack of any meaningful numbers of
biological replicates in either cohort and small number of mapped reads make drawing
firm conclusions from these data rather perilous.
5.4.3 Discussion of level of analysis and quantification method
It is clear from the comparison of the read-bases and read-start quantification methods
within Casava that the former is much more accurate to the underlying biology and
structure of the transcriptome than the latter. As expected, the two methods had little
effect on expression estimates at the gene-level, but lead to a significant increase in the
expressions estimated at the exon-level. Even the use of read-middle quantification,
employed in our Maq-quantification pipeline, would be an improvement (at the exon-
level) on the read-start method, allowing more flexibility in terms of the accuracy of
the exon-locations as defined in the reference annotation.
Exon level comparison of RNA-seq with arrays (and within RNA-seq datasets)
is perhaps more suitable than analysis at the gene level. Absolute quantification of
RNA-seq technical replicates at the exon level is approximately equivalent, in terms
of variability, than when reads are summarised over the length of the whole gene.
Analyses at the level of individual exons is also more intuitive as these are the building
blocks of protein-coding transcripts and subtleties can be lost when performing much
less granular analyses at the gene-level. It is also possible to search for and quantify
putative novel isoforms by careful analysis at the exon-level, which is not possible at
the gene-level.
However, in terms of the relatively simplistic comparison of differential expression
reported by the two technologies, the sacrifice of granularity for generality and ease
of interpretation might favour gene-level analyses. Exon-level differential expression
is hindered by the much larger number of required comparisons (∼10 times as many
exons as there are genes) potentially falling foul of perhaps overly conservative multiple
testing corrections.
Analysis at the transcript level is the natural conclusion in the discussion of what
biological unit of measurement to use in quantifying expression. Progress has been
made in this approach and a number of software packages are available, including
ERANGE [107], tophat/cufflinks [108, 215], Scripture [222], and IQSeq (unpublished:
http://archive.gersteinlab.org/proj/rnaseq/IQSeq/). However it is worth bearing in
mind that the assignment of reads, and indeed entire exons to individual transcripts
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and the identification of novel isoforms is an extremely difficult procedure. Inclusion
of known splice-sites has been reported to improve the identification of novel isoforms
[108], presumably due to the reduction in search space following the initial mapping.
Based on evidence between the different mapping/quantification approaches used in
our data, this procedure is also highly prone to bias downstream analyses if care is not
taken during the initial read QC and alignment.
5.5 Conclusion
Overall we found good agreement between raw expressions and fold-changes reported
by RNA-seq and by arrays at both the exon- and the gene-level, however the
different distributions of raw expressions preclude direct integration of these raw
data. Integration of fold-changes reported by each technology is more promising,
after compensating for the overestimation of changes by RNA-seq, although it is not
unreasonable to assume that this agreement would increase on analysis of better-quality,
and more comprehensive, RNA-seq data. It is likely that the high biological variability
between mice, a low-powered study design, and pooling of samples prior to sequencing
were the reasons for the failure to detect differential expression in these data. Many
factors, such as mild infections, can affect gene-expression in the brain but may not
present a strong phenotype and pooling increases the chance that cells or tissues under
study contain abnormal cells from a diseased subject
Reflected in concerns about data quality, we found that the choice of method
for mapping and quantifying the raw sequence reads can have a large effect on
the expression estimates. Analyses at the gene- and exon-level were approximately
equivalent in terms of the comparison with microarrays and also between technical
& biological replicates on RNA-seq. However, transcript-level analysis is clearly the
most desirable method, as it best reflects the underlying cellular processes, but this
requires advanced mapping and quantification methods to provide reliable expressions;
care must be taken to ensure this is performed correctly, or reported expressions and
putative novel isoforms will be unreliable.
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6.1 Sample preparation and choice of technical replicates
Development of technologies and methods for the study of molecular biology is
approximately a punctuated equilibrium, in which short periods of rapid development
are followed by much longer periods of refinement in which experiment data are
gathered, analysed, and modelled. As part of the refinement process, the field learns
and experiments with best practice to get the most out of the available technology
to improve the scope, throughput, reliability, and accuracy of experimental methods.
However, strange norms are sometimes adopted by the community that are believed to
have a positive impact on accuracy or reliability of the obtained measurements, but in
fact do neither.
A prime example of one such norm is in qPCR, where it is extremely common to use
technical replicates of the qPCR step itself, typically in triplicate. Studies, including
this one (Chapter 2), using qPCR technical replicates have shown the consistency of
qPCR amplification and quantification to be highly reproducible [25] and it seems this
convention is borne from a simple desire to insure against a failed reaction. However, in
most instances we found that it is the process of sampling/extraction of nucleic material
and/or the reverse-transcription step that introduce the most variability. Splitting and
averaging technical replicates at higher levels, such as taking multiple tissue samples
from the same subject, is therefore likely to improve the consistency of measurements
between experimental subjects sharing a common phenotype and improve the statistical
power of the experiment. Taking higher-level replicates obviously provides exactly the
same protection against a failed reaction as the same number of reactions are run for
each subject.
The convention to not use technical replicates in microarray experiments is again
borne from a large number of studies comparing array expression measurements within
[223, 188] and between [118, 182] platforms that have reported good overall agreement.
However, as with qPCR, very few studies have investigated the effect of the various
stages sample preparation on the reliability of reported expression levels and those
that have reported poor consistency between different methods of amplification [73].
Chapter 3 demonstrated that batch effects can compromise the reproducibility of
reportedly significantly differentially expressed genes between conditions, but that
experiments with no technical replicates can still produce meaningful and reliable
results if the experimental design is robust to such batches and appropriate batch-
corrections are employed.
Several high-profile investigations such as MAQC [118] investigated inter-and intra-
platform consistency of microarrays. However this study was limited to analysis of
high-quality, commercial-grade reference RNAs and did not address vulnerability of the
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cDNA-prep to sampling-variability. Chapter 4 sought to evaluate the relative effects of
different sources of variation and demonstrated that the variability between biological
replicate cultures and technical replicate RNA extractions is much greater than the
technical noise introduced during downstream sample processing and array scanning.
It is therefore a credit to the methods and to the technologies themselves that the
experiment data they produce is generally so reliable. However this precision has
the negative effect of entertaining many researchers’ ignorance about biological and
sampling variation and lack of understanding about reproducibility/accuracy leading
to limited skepticism in their interpretation and reporting of results obtained from
high-throughput approaches.
Systematic variation is common in all biological experiments [119] and can have a
large influence on the interpretation of experiment data, so it is especially important
to understand its impact in ‘hypothesis generating’ experiments such as microarray,
RNA-seq, and, increasingly, qPCR. It is clear that such error is not always simply due
to imprecision of the analysis technology, but also due to variation in the preparation
of samples for analysis.
6.2 Variability of reported expressions and results
The large numbers of genes concurrently interrogated by high-throughput approaches
coupled with often small numbers of independent biological observations result in
studies that routinely have insufficient statistical power to confidently detect differential
expression [224]. There has been some frustration in several fields on the perceived
lack of reproducibility/overlap in gene-lists derived from different microarray analyses
[225, 226, 227, 228], however there often exist technical and biological differences
between studies that completely confound analyses and it is therefore not surprising
that results are in poor agreement. In-silico differences can also play a large role
in determining the reproducibility of results both between replicate studies, and re-
analyses of identical data from the same study [228]. For example, poor documentation
of statistical methods used has been cited as a common cause of poor reproducibility
in re-analyses of published data [154]. A similar conclusion was reached by the
MAQC following their stage-II analyses, in which identical data were provided to
several different teams for statistical analysis and clustering, finding that- perhaps
unsurprisingly -the proficiency of the statistician was a major factor determining the
outcome of the analyses [229].
Sources of bias, especially that introduced by the different dates and times at
which samples are processed further serve to threaten the reporting of accurate and
reproducible results [230, 231]. The combined effect of all of these sources of biological,
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technical, and computational variability is that thousands of biologically independent
observations are required to produce robust and useful results on analysis of complex
systems, especially in the clinical setting [232].
Effect of technical variation on reported expressions and results
In qPCR experiments it was shown that the effect of normalising a gene of interest
(GOI) to a reference gene with a very different variance structure actually increased
the overall variance for the GOI. This suggests the need to select a reference gene that
is not affected by the experiment factor under investigation, but does co-vary with the
GOI with respect to the variation introduced at each level of sample-prep. In terms of
the magnitude of technical variation, most originates from sampling and in solid tissue
up to 2.6-fold variation was observed between technical replicates. It is therefore fairly
clear that such variation within and between experimental subjects has high potential
to influence results of analyses for differential expression.
Data from replicate array hybridisations presented in chapter 3 showed a small
systematic effect due to the day on which the arrays were processed. All the arrays
were of perfectly reliable quality, with similarly excellent correlation (> 97%) with
those reported by MAQC. However, this small systematic variability had a large
negative effect on the consistency between results of identical analyses for differential
expression between technical replicate tumour samples. Previously published array
analyses using technical replicate samples [182] reported that comparing gene-lists
based on their reported statistical significances was less reliable than comparing them
based on reported fold-changes between treatment groups. This is an unsatisfactory
recommendation, but does support the observation that technical variation is the
limiting factor for consistency of such differential expression tests, rather than some
bulk error affecting the magnitude of the overall change between groups of samples.
A small number of studies have assessed technical replicates using RNA-seq and
found extremely low noise in the reported expressions. However we found greater
variation between different methods of quality control and mapping of the raw sequence
reads to the reference. Although not strictly technical variation as defined throughout
this thesis, differences in mapping illustrate the importance of performing careful
computational analysis, especially during the initial expression quantification. Due
to technical issues with the sequence data quality, it is not prudent to posit confident
conclusions as to the origin or effect of technical variation observed in these data, nor
from the comparison to the array data.
However, work to analyse the second set of sequenced data continues, although the
sample size and the total number of reads are very small- limiting the usefulness and
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power of such an analysis. It is also of interest to further explore the array probes that
were found to express above background, but were not represented at either the gene-
or exon-level by RNA-seq. An analysis of the compositional properties of the probes
might reveal the extent to which they suffer from non-specific hybridisation, and an
analysis of the mapping properties might reveal if some feature of the sample-prep and
library-creation prior to RNA-seq was responsible for the inconsistency between the
platforms.
6.3 Compensation for systematic technical variation
The two main considerations for obtaining a sound experiment design is where to
take replicates and how to randomise/block samples such that systematic errors are
not confounded with the biology. In terms of the former, we have shown that the
relative error introduced in each of the various levels of sample-prep are generally
predictable and will, in most cases, be smallest at the point of measurement and largest
between experimental subjects or between replicate samples/RNA-extractions. There
is the assumption that all genes are affected equally by each of these steps, however
we and others have shown this to be a false assumption [119, 126, 127]. With the
ever-decreasing cost of microarrays and technologies like Illumina’s delivering multiple
arrays on a single chip, it is reasonable that studies limited to the analysis of small
numbers of subjects might benefit greatly from the use of technical replicates at the
sampling level. Such replicates might improve statistical power by reducing within-
group biological variability between the subjects. Also, in array experiments where
the number of genes is very large, it is possible to use a method such as SVA [128]
to diagnose the source(s) of the confounding noise. In cases where large numbers of
observations are not available, such as qPCR, we have shown that relative contributions
of the various levels can be estimated from pilot data- and even possible to automatically
create optimal experiment designs.
6.4 In summary
It has been shown in chapters 3 and 4 that standard normalisation methods are
not effective at reducing or removing systematic inter-run or inter-chip variation in
microarray experiments and that more specific gene-level corrections are required to
improve the correlation of technical replicate control and tumour samples. In chapter 2,
reduction of technical variation in qPCR experiments can be achieved through targeting
of replicates to the level at which most noise is introduced, following a pilot study in
which the relative variation at each level can be estimated. Finally, in chapter 5, RNA-
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seq technical replicates were found to have remarkably strong correlation, even between
experiments performed many months apart, on different iterations of the technology,
and where the output short-read sequences were of dubious quality. However, in the case
of RNA-seq it is clear that the requirement of reliable and appropriate data analysis
is more important than ever as different methods of quality control and assignment
of the raw reads, as well as the method of quantification, can have a large impact
on consistency of results. Variability between RNA-seq and microarrays was much
larger than variability due to read-mapping, but correlations between reported direction
and, to some extent, magnitude of differential expression between sample-groups were
reasonably strong.
The analyses presented in this thesis have consistently reinforced the notion that
high-throughput, whole-genome mRNA analysis methods are fully capable of producing
highly reliable, reproducible, and accurate data. Systematic variation can threaten
this remarkable reliability but with close collaboration, researchers and analysts can
deal with these issues with relative speed and simplicity through careful and informed
experiment planning and analysis. We, and others, have consistently shown that the
incorporation of specific batch-correction methods should be a routine step in the
analysis of these high-throughput data and that targeted experiments to determine
the precise sources of non-biological variation will always be necessary to maximise
the efficacy of such corrections. Greater confidence and accuracy of the hypotheses
generated by these high-throughput techniques not only improves publishable results,
but leads to more efficient allocation and use of resources for followup confirmatory
analyses, either at the mRNA- or the protein-level.
Increasingly, as technology and methods mature, researchers are choosing to
integrate many diverse sources of whole-genome data in an attempt both to better
understand the wider biological context of their experiments and also to reduce the rate
of false-positive results produced by each individual method. This is commonly achieved
by finding and reporting only those features that are found to be significant in all, or a
large fraction of, the experiments. Despite their effectiveness in reducing the frequency
of false-positives, only increasing the accuracy and reliability of each individual
experimental method can improve the typically poor power of such integrative analysis
approaches. For example, new methods such as RNA-seq show great promise in
aiding the analysis and interpretation of proteomics data derived from tandem mass-
spectrometry; but to fully realise the power and potential that integrative, genome-wide
mRNA, proteomic, and epigenetic analyses promises, it is critical that we ensure high
confidence in the data and results obtained at each level.
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